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Abstract

IDENTIFICATION OF PHARMACOLOGICAL AND MOLECULAR MECHANISMS
INVOVED IN NICOTINE WITHDRAWAL
By Kia Janelle Jackson, B.S.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2008

Major Director: Dr. M. Imad Damaj
Associate Professor, Pharmacology and Toxicology

Tobacco dependence is the leading cause of preventable death in the United States.
Despite currently available smoking cessation therapies, there is a high rate of relapse in
smoking among those attempting to quit. While the somatic signs of nicotine withdrawal
(insomnia, increased appetite, weight gain) contribute to the continuation of smoking
behavior, it has been hypothesized that the affective signs (depression, anxiety, craving,
irritability) are greater motivators of relapse and continued tobacco use. There are few
studies that assess the molecular and receptor-mediated mechanisms of nicotine
withdrawal; therefore, our studies focus on identifying the nicotinic acetylcholine receptor

(nAChR) subtypes and post-receptor calcium-dependent mechanisms involved in nicotine
withdrawal behaviors.
Using precipitated, spontaneous, and conditioned place aversion (CPA) models, we
measured physical and affective signs of nicotine withdrawal in mice. Our data show that
major nAChR subtypes have differential roles in nicotine withdrawal. Additionally, our
results suggest a behavioral relevance for L-type calcium channels in physical nicotine
withdrawal signs, while calcium/calmodulin dependent protein kinase II (CaMKII) appears
to be involved in both physical and affective withdrawal behaviors.
Additionally, we conducted biochemical studies in the ventral tegmental area (VTA) and
nucleus accumbens (NAc) to examine the relationship between altered withdrawal
behavioral responses and calcium-dependent molecular mechanisms that contribute to
nicotine withdrawal behaviors. Our results suggest an important role for β2-containing
nAChRs in nicotine-withdrawal induced decreases in CaMKII and synapsin I function in
the NAc.
Overall, our studies implicate a critical role for the α4α6β2* nAChR subtype in the
behavioral and molecular aspects of nicotine withdrawal, thus aiding in the elucidation of
nAChR subunits and mechanisms that contribute to nicotine withdrawal behaviors. The
current studies are imperative for generating more successful smoking cessation therapies.

GENERAL INTRODUCTION
A. Tobacco and Nicotine Dependence
Tobacco dependence is the leading cause of preventable mortality in the United
States. Maintenance of smoking behavior is largely due to nicotine, the main addictive
component of tobacco (Stolerman and Jarvis, 1995; Bardo et al., 1999). Globally,
smoking-related illnesses cause over four million smoking related deaths annually.
Shockingly, every eight seconds, a human life is lost to tobacco use (Martin, 2002).
Although many aspects of nicotine contribute to smoking, such as the rewarding and
reinforcing effects, numerous studies suggest that avoidance of the negative emotional
state produced by nicotine withdrawal represents a motivational component that
promotes continued tobacco use and relapse after smoking cessation. In fact, the most
commonly reported reason for relapsing into smoking during quit attempts is the desire
to relieve the discomforts of smoking withdrawal (US Department of Health and Human
Sciences, 1988). Among adult smokers, 80% report the desire to quit completely;
however, those who attempt to quit on their own relapse within the first month and only
3% remain abstinent after six months (Hughes et al., 1992). While there are smoking
cessation therapies available, which include nicotine replacement therapies, the antidepressant bupropion (Zyban ®), and the partial nicotinic agonist varenicline (Chantix
®) (Cummings et al., 2006; Jorenby et al., 2006), the success rate of these therapies after
one year remains only about 20-25% (Gonzales et al., 2006). Indeed, severity of the
withdrawal syndrome is a better predictor of unsuccessful smoking attempts than smoke
intake or dependence (West et al., 1989). Because smoking is such a widespread health
1
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problem, it is important to understand the molecular and behavioral mechanisms of
nicotine withdrawal to generate more effective smoking cessation therapies.
Smoking cessation after chronic tobacco use produces a well characterized and
defined withdrawal syndrome. In humans, the nicotine withdrawal syndrome is
characterized by somatic signs, which include bradycardia, gastrointestinal discomfort,
and increased appetite, and affective signs, including irritability, anxiety, difficulty
concentrating, disrupted cognition, nicotine cravings, depressed mood, and other mood
disturbances (Stolerman and Shoaib, 1991; American Psychiatric Association, 1994;
Mendreck et al., 2006). Indeed, in untreated smokers, nicotine withdrawal produces
mood disturbances comparable in intensity to those seen in psychiatric outpatients
(Hughes, 2006). The negative affective symptoms can start as soon as four hours after
the last cigarette, peak in about three days, and are still measurable a month after
cessation of tobacco use (Swan et al., 1996; Ward et al., 2001; Hughes, 2007).
Animal models of drug abuse allow researchers to investigate molecular
mechanisms involved in drug abuse and potential treatments for these problems. Several
groups, including our laboratory, have reported utilization of rodent models of the
nicotine withdrawal syndrome. These animal behavioral models of nicotine withdrawal
are discussed in more detail in a later section.
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B. Molecular and Pharmacological Mechanisms of Nicotine Withdrawal
Nicotinic Receptors
A major goal in nicotine research is to gain a better understanding of the
molecular and receptor mediated mechanisms of nicotine dependence and withdrawal in
order to generate more effective smoking cessation therapies. The initial targets for
nicotine are ligand-gated ion channels called nicotinic acetylcholine receptors
(nAChRs), which have been identified throughout the central and peripheral nervous
systems, as well as at skeletal neuromuscular junctions. By mimicking the effects of the
endogenous transmitter acetylcholine (ACh), nicotine acts on a variety of nAChRs
distributed throughout these areas, having a wide range of effects on body function,
depending on the subtype composition and location. nAChRs have a pentameric
structure consisting of five membrane spanning regions around a central ion channel.
Muscle expresses five nAChR subunits which can coassemble to form two subtypes.
These are (α1)2β1 in embryonic muscle tissue, which converts to (α1)2β1 in adult
muscle tissue. Currently, twelve neuronal nAChR subunits have been identified,
including α2-α10 and β2-β4, making it possible to have much larger variety in subtype
composition in the brain and a much larger range of pharmacological effects in response
to nicotine. The high calcium (Ca2+) permeability of nAChRs in the brain and nicotine’s
ability to elicit neurotransmitter release by binding to neuronal nAChRs, suggests a
modulatory role for nAChRs in the brain (Role and Berg, 1996). Additionally, as will be
discussed in later sections, studies indicate Ca2+-dependent mechanisms and nicotine-
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induced neurotransmitter release as having an important role in nicotine dependence;
therefore, our studies will focus on nAChRs located in the brain.
In the brain, the majority of nAChRs are presynaptically located, although some
nAChR populations are found at the soma and on postsynaptic terminals (McGehee and
Role, 1995; Wonnacott, 1997). Binding of a nicotinic agonist induces a change in the
conformational state of the receptor. The receptor can exist in a sequence of
conformational states, which are interpreted in terms of the “conformational scheme” of
Katz and Thesleff (1957). These states consist of a resting state, which is inactive, yet
capable of activation, an activated state where the channel opens in response to
stimulation by a nicotinic agonist, and a desensitized state where the channel is inactive.
Upon channel opening, there is an influx of various cations into the cell, including
sodium and Ca2+. With repeated exposure to nicotine, the receptor enters the
desensitized state. A recent study revealed that β2* nAChR occupancy was ~88% after
just one cigarette, and corresponding plasma levels were shown to lead to 50%
desensitization of α4β2* nAChRs (Brody et al., 2006). Receptor desensitization after
chronic nicotine exposure also leads to a compensatory upregulation of nAChRs.
Indeed, postmortem binding studies have revealed a significant increase in the number
of nicotine and ACh binding sites in brains of smokers compared to non-smokers
(Benwell et al., 1988; Breese et al., 1997). It has been proposed that this desensitization
and upregulation of nAChRs following chronic nicotine exposure is influential in
producing withdrawal symptoms upon cessation of smoking (Benwell et al., 1988;
Balfour and Fagerstrom, 1996; Dani and Heinemann, 1996), and that maintained nAChR
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desensitization may be important for relieving nicotine withdrawal in humans (Brody et
al., 2006).
Regular smokers have an excess number of nAChRs, and maintain levels of
nicotine in the brain throughout the day that may keep many nAChRs in an inactive
desensitized state; therefore, it has been proposed that hyperactivity of synaptic
pathways due to this excess receptor number is one mechanism that may mediate
withdrawal symptoms. After many hours of abstinence, such as overnight, a smoker’s
nicotine levels fall, returning the inactivated nAChRs to a responsive state. As a result of
an excessive number of nAChRs becoming responsive, there may be abnormal
enhancement of synaptic activity in non-rewarding cholinergic pathways, which may
contribute to the discomfort associated with nicotine withdrawal that drives smoking
behavior (Dani and Heinemann, 1996). Stabilization of nAChRs in the desensitized state
with low levels of nicotine may occupy the increased pool of nAChRs and could
alleviate the hyperactivity in non-rewarding cholinergic pathways (Brody et al., 2006).
While this model explains mechanisms associated with spontaneous withdrawal, it
does not account for symptoms that occur as a result of precipitated withdrawal. It is
possible that while hyperactivity of non-rewarding pathways is one way that contributes
to the manifestation of nicotine withdrawal signs, decreased activity in rewarding
pathways may occur as a result of antagonist administration during chronic nicotine
treatment, thus precipitating withdrawal signs.
While nicotine exerts its pharmacological and physiological effects by acting on
a variety of nAChR subtypes, the main subtypes in the brain are α7* and α4β2*
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(Changeux et al.,1998), where * denotes possible assembly with other nicotinic receptor
subunits. The α4β2* nAChRs are thought to have the highest affinity for nicotine
(McGehee and Role, 1995; Picciotto et al., 1995), while α7* nAChRs are thought to
have lower affinity for nicotine (Papke and Thinschmidt, 1998). α4β2* nAChRs are
found on presynaptic dopaminergic and GABAergic neurons in the ventral tegmental
area (VTA), a brain area that is part of the mesocorticolimbic drug pathway which has
been hypothesized to be involved in mediating both the rewarding properties of drugs, as
well as the aversive behavioral state associated with nicotine withdrawal (Laviolette et
al., 2002; Laviolette et al., 2008). The α5 and 6 nAChR subunits also coassemble with
the β2 subunit in the mesocorticolimbic drug pathway on dopamine (DA) neurons and
terminals to form functional receptors (Wada et al., 1989, 1990; Le Novère and
Changeux, 1995; Le Novère et al., 1996; Klink et al., 2001). The α4α5β2 and α4α6β2
nAChR subtypes are involved in nicotine-stimulated DA release in the striatum
(Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 2005). The α6 and α5 nAChR
subunits are also expressed in brain areas that have been implicated as having a role in
nicotine dependence behaviors. Expression of 6-containing nAChRs in the brain is
largely confined to catecholaminergic nuclei, such as the VTA, substantia nigra (SN),
and locus coeruleus (LC) ( Le Novère et al., 1996; Klink et al., 2001), while the more
widely expressed α5 nAChR subunit is found in the cerebral cortex (Gerzanich et al.,
1998), cerebellum, thalamus (Flora et al.,2002) , striatum (Zoli et al.,2002),
hippocampus, SN, and VTA (Wada et al., 1990), as well as peripherally in sympathetic
and parasympathetic ganglia (De Biasi, 2002). The α3 subunit is coexpressed with α5
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and β4 nAChRs in the peripheral ganglia, and medial habenula (MHb), and
interpeduncular nucleus (IPN) (Wada et al., 1990; Zoli et al., 1995; Quick et al., 1999;
Whiteaker et al., 2002). Further, α3 nAChR subunits are also expressed in brain areas
which have been implicated as having a role in nicotine dependence behaviors, and can
also coassemble with β2 nAChRs to form functional receptors on DA neurons and
terminals (Le Novère and Changeux, 1995; Le Novère et al., 1996; Klink et al., 2001).
Studies in the upcoming chapters will focus on identifying the role of these nAChR
subunits in aspects of nicotine withdrawal.
Molecular Mechanisms of Nicotine Dependence and Withdrawal
The mesocorticolimbic drug pathway has been shown to be critically involved in
the effects of several drugs of abuse, and is comprised of projections from the VTA to
the NAc, amygdala, and prefrontal cortex. Presynaptic nAChRs are responsible for the
positive modulation of neurotransmitter release (Wonnacott, 1997). Nicotine
administration stimulates the release of most neurotransmitters throughout the brain,
including brain regions that comprise the mesocorticolimbic drug pathway (McGehee
and Role, 1995). Stimulation of neurons in the VTA via α4β2* presynaptic nAChRs
leads to enhanced DA release into the nucleus accumbens (NAc). Rapid desensitization
of α4β2* nAChRs on inhibitory GABAergic neurons reduces GABAergic inputs to DA
neurons, thus enhancing DA transmission. Additionally, stimulation of α7* nAChRs
located on excitatory glutamatergic neurons (Mansvelder and McGehee, 2002) and on
DA neurons (Pidoplichko et al., 1997) can enhance glutamate release onto DA neurons,
also enhancing DA transmission. This complex pattern of brain activation in response to
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nicotine plays a large role in the acute rewarding and reinforcing effects of nicotine,
which motivate chronic and compulsive use.
The neuroadaptations that occur as a result of chronic nicotine exposure are
thought to reflect nicotine’s influence on these neurotransmitter systems (De Biasi and
Salas, 2008). Many studies support the vital role of the neurotransmitter DA in nicotine
dependence. The nicotine induced increase in VTA DA neuron firing rate (Grenhoff et
al., 1986), and subsequent DA release in the NAc is a process thought to underlie the
addictive properties of nicotine (Ponteiri et al., 1996). Alternatively, studies report
decreased DA neuronal activity in the VTA (Liu and Jin, 2004) and decreased DA
output in the NAc after nicotine withdrawal (Hildebrand et al., 1998; Rada et al., 2001).
Indeed, it is hypothesized that this relative deficiency in DA release following cessation
of nicotine exposure accounts for many of the mood disorders, craving, and anhedonia
that persist in many smokers long after quitting (Benowitz, 2008).
Deficits in the neurotransmitter serotonin have also been suggested to play a role
in mechanisms associated with nicotine withdrawal. Clinically, the 5HT1A receptor
partial agonist buspirone shows efficacy in smoking cessation trials and may reduce
severity in abstinent smokers (Hilleman et al., 1992; Schnedier et al., 1996).
Serotonergic antidepressant treatment with the selective serotonin reuptake inhibitor
fluoxetine and a 5HT1A receptor antagonist was also shown to reverse the anhedonic
component of nicotine withdrawal in rats (Harrison et al., 2001).
As proposed for other drugs of abuse, chronic exposure to nicotine is likely to
involve modification of signaling cascades that modulate synaptic plasticity and gene
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expression (Dani et al., 2001; Nestler, 2002). There are many factors by which repeated
drug exposure could alter gene transcription in the brain, including altered transcription
rates, altered translation of mRNA into proteins, altered transcription of mature proteins
to their intracellular sites of action, and alteration of several other mechanisms involved
in gene transcription and translation (Nestler et al., 2001a). Several studies have shown
that chronic drug use leads to homeostatic changes in the brain that result in dependence
and withdrawal symptoms (Nestler and Aghajanian, 1997); however, it has been
proposed that these homeostatic changes do not explain why people relapse, even years,
after cessation of drug use. An alternative hypothesis suggests that long-term associative
memory processes, which receive input from midbrain DA neurons, are involved in
mediating relapse after long term cessation of drug use (Berke and Hyman, 2000;
Robbins and Everitt, 2002; Hyman, 2005).
Long-term potentiation (LTP) is a mechanism characterized by a strengthening
of synapses, hypothesized to play a crucial role in many forms of experience-dependent
plasticity, including various forms of learning and memory (Martin et al., 2000;
Malenka et al., 1989; Malenka and Bear, 2004). LTP could alter gene and protein
expression in neurons, leading to reorganization of neural circuitry (Hyman et al., 2006);
thus, LTP has become an important candidate mechanism involved in relapse after drug
withdrawal. Evidence suggests that LTP occurs in both the VTA and the NAc (Hyman
et al., 2006), and changes in some transcription factors involved in induction of LTP
occur in response to drugs of abuse, including nicotine. Further, the synaptic changes
that are induced by nicotine are similar to the synaptic plasticity that underlies learning
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and memory (Pidoplichko et al., 2004). One transcription factor of interest is the cAMP
response element-binding protein (CREB), best known for its role in learning and
memory, which studies have shown to be involved in mechanisms associated with
nicotine dependence, including reward (Walters et al., 2005) and withdrawal (Pandey et
al.,2001; Brunzell et al., 2003; Pluzarev and Pandey, 2004). One mechanism of CREB
activation is through phosphorylation by Ca2+-dependent proteins. A more thorough
discussion of the nicotine-induced influx of Ca2+, the subsequent activation of Ca2+dependent mechanisms, and the role of Ca2+ in nicotine dependence and withdrawal is
discussed in further detail in the next section.
C. Calcium-Dependent Mechanisms in Nicotine Dependence and Withdrawal
As a result of Ca2+ influx, presynaptic nAChRs facilitate Ca2+-dependent release
of many neurotransmitters and the activation of various downstream signaling cascades
involved in gene transcription (Wonnacott, 1997). Neuronal nAChRs can elevate
intracellular Ca2+ both directly due to the Ca2+ influx through the Ca2+ permeable
nAChR channel, and indirectly because of the ability to induce membrane depolarization
and activate voltage-gated Ca2+ channels (VGCCs), and Ca2+-induced Ca2+ release from
intracellular stores (Fig. 1A). Ca2+ influx through nAChRs mediates neurotransmitter
release through Ca2+ -dependent exocytosis of synaptic vesicles and by activating Ca2+ mediated cellular mechanisms. The nicotine-induced increase in intracellular Ca2+
initiates a cascade of second messenger events, leading to the activation of a number of
Ca2+ -dependent targets, including Ca2+ /calmodulin-dependent protein kinase II
(CaMKII), CaMKIV, and protein kinase A (PKA). This leads to activation of
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extracellular signal-regulated kinase or mitogen-activated protein kinase (ERK or
MAPK) and CREB (Fig. 1B).

12

Dajas- Bailador and Wonnacott, 2004

Figure 1. Calcium-dependent mechanisms and nicotinic receptors.
A. Neuronal nAChRs can elevate intracellular Ca2+ both directly due to the Ca2+
influx through the Ca2+ permeable channel, and indirectly because of the ability to
induce membrane depolarization and activate voltage-gated Ca2+ channels
(VGCCs), and Ca2+-induced Ca2+ release from intracellular stores. B. The nicotineinduced increase in intracellular Ca2+ initiates a cascade of second messenger
events, leading to the activation of a number of Ca2+-dependent targets, including
Ca2+/calmodulin-dependent protein kinase II (CaMKII), CaMKIV, and protein
kinase A (PKA), leading to activation of extracellular signal-regulated kinase or
mitogen-activated protein kinase (ERK or MAPK) and CREB.
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These Ca2+-dependent processes have been shown to play a role in the
molecular mechanisms of the underlying synaptic plasticity involved in drugs of abuse
such as cocaine (Nestler, 2001b). In fact, in the case of nicotine, decreased CREB
activity was detected in the NAc (Brunzell et al., 2003; Pluzarev and Pandey, 2004),
cortex, and amygdala (Pandey et al., 2001) after nicotine withdrawal, suggesting that
decreased CREB activity may be associated with the dysfunction in reward mechanisms
after nicotine withdrawal. Changes in CREB phosphorylation have also been observed
following morphine (Lane-Ladd et al., 1997), cocaine (Kano et al., 1995) and
amphetamine chronic administration (Shaw-Lutchman et al., 2003). Animals with a
decrease in CREB function do not find morphine rewarding, but find cocaine more
rewarding (Walters and Blendy, 2001). Taken together, CREB seems to play a major
role in the cellular changes that occur in the brain after acute and chronic administration
of several drugs of abuse.
There are numerous phosphorylation sites on the CREB protein that
differentially regulate its activity, including a site for CaMKII. The Ca2+-dependent
protein, CaMKII, has not been extensively evaluated in drug abuse; however, the
available studies suggest a role for CaMKII in morphine tolerance (Fan et al., 1999;
Liang et al., 2004; Tang et al., 2006) and reward (Narita et al., 2004), as well as cocaine
sensitization (Licata et al., 2004), and reinstatement (Anderson et al., 2008).
Additionally, CaMKII has been shown in vitro to reduce CREB-mediated gene
transcription (Matthews et al., 1994; Sun et al., 1994; Wu and McMurray, 2001).
However, in vivo, CaMKII was shown to increase CREB activity in the spinal cord
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(Miyabe and Miletic, 2005). Although the specific role is unclear, CaMKII appears to
have a role in modulating CREB activity.
CaMKII is the most abundant protein kinase in the brain, comprising
approximately 1-2% of total protein. Upon nicotine binding, nAChR channels open,
allowing a direct influx of Ca2+ and other ions, as well as an indirect Ca2+ influx through
Ca2+ channels. Ca2+ forms a complex with calmodulin, and this complex binds to and
activates CaMKII. Once activated, CaMKII can auto-phosphorylate and preserve 80% of
its activity, independent of Ca2+ (Schulman and Hanson, 1993). Presynaptically,
CaMKII plays a role in neurotransmitter synthesis and release (Schulman and Hanson,
1993). Tyrosine hydroxylase, the rate-limiting enzyme in DA synthesis, and synapsin I,
a vesicle protein essential for regulation of neurotransmitter release, are CaMKII
substrates. Postsynaptically, CaMKII is essential for induction of LTP (Lisman et al.,
2002). Due to its role in CREB modulation, LTP, and activation of other substrates
involved in neurotransmitter release and gene transcription, we believe that CaMKII is a
candidate protein for having a role in nicotine dependence.
The α-CaMKII mutant mouse was generated as a tool to study the role of
CaMKII in LTP (Silva et al., 1992a). It was noted that mutant mice displayed some
behaviors consistent with animals that have hippocampal lesions. For example, animals
with hippocampal lesions exhibit increased exploratory behavior and activity when
placed in an open field activity cage or Y maze (Teitelbaum and Milner, 1963; Foreman,
1983). When tested, α-CaMKII mutant mice showed increased exploratory activity in an
open field and in a Y maze (Silva et al., 1992b). Additional studies using the Morris
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water maze also revealed that α-CaMKII mutant mice, like hippocampal lesioned
animals, have impaired spatial learning, but no deficits in contextual learning (Silva et
al., 1992b). Conditional α-CaMKII mutants have also been used to study the role of αCaMKII in learning and memory. A functional mutated form of α -CaMKII was
generated in vitro, and a highly selective inhibitor for the mutated α -CaMKII was
generated (Wang et al., 2003). Mice that overexpress the mutated α -CaMKII were
generated, and it was found that the selective inhibitor could mask α -CaMKII activity in
specific brain subregions of the mutated mice on the time scale of several minutes
(Wang et al., 2003). Our studies using α-CaMKII mutant mice will be presented in
Chapter 5.
D. Behavioral Models of Nicotine Withdrawal
Animal models of nicotine withdrawal have been developed and are useful tools
for elucidating mechanisms associated with nicotine withdrawal behaviors. From these
models, studies have shown that somatic signs of nicotine withdrawal are mediated by
central and peripheral nAChRs, while affective signs are mediated solely through central
nAChR populations (Watkins et al., 2000). Rodents are first chronically exposed to
nicotine for a predetermined amount of time through osmotic mini pumps (Damaj et al.,
2003; Malin et al., 2006), chronic injections (Liu et al., 2005; Miura et al. 2006), oral
route via drinking water (Grabus et al., 2005; Liu et al., 2005), or intravenous
administration (Wilkinson and Bevins, 2008). Withdrawal may be precipitated in
chronic nicotine exposed animals with nicotinic antagonists, such as the non-selective
nAChR antagonist mecamylamine, or evaluated spontaneously by the cessation of
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chronic nicotine treatment. Physical signs in rodents are typically measured as somatic
signs (Malin et al., 1992; Hildebrand et al., 1997; Damaj et al., 2003), hyperalgesia
(Salas et al., 2004; Grabus et al., 2005), and changes in locomotor activity (Nomikos et
al., 1999; Hildebrand et al., 1999), while affective signs are typically measured as
anxiety-related behaviors (Damaj et al., 2003; Schneider et al., 2007; Stoker et al.,
2008), elevated reward thresholds (Cryan et al., 2003; Bruijnzeel and Markou, 2004;
Johnson et al., 2008), contextual fear conditioning (Davis et al., 2005), and conditioned
place aversion (CPA) (Suzuki et al., 1996; Malin et al., 2006; Jackson et al., 2008).
The somatic signs of nicotine withdrawal in rodents are indicative of signs of
irritation, as irritability is experienced by humans as part of the nicotine withdrawal
syndrome. Hyperalgesia, or increased pain sensitivity, has also been reported in some
smokers after cessation of tobacco use (Allen et al., 2000). In fact, abstinent smokers
who reported having two or more withdrawal symptoms had a higher odds ratio of
experiencing chronic pain in three or more locations compared to individuals who did
not experience withdrawal symptoms (John et al., 2008). Changes in locomotor activity
after nicotine withdrawal may reflect alterations in DA transmission. Decreases in
locomotor activity, which have been reported after nicotine withdrawal in rats,
correspond to a reduction in NAc and striatal DA content 24 hours after cessation of
chronic nicotine infusion through osmotic mini pumps (Fung et al., 1996). Indeed,
decreased DA release in the NAc has been reported after mecamylamine-precipitated
withdrawal (Hildebrand et al., 1998; Carboni et al., 2000).
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Mice undergoing nicotine withdrawal show increased anxiety-related behavior as
measured by the plus maze (Irvine et al., 2001; Damaj et al., 2003; Jackson et al., 2008)
and the light-dark box (Schneider et al., 2007; Stoker et al.,2008); thus, these models
could mimic the increase in anxiety reported in humans during nicotine abstinence.
Elevations in reward threshold measured by the intracranial self stimulation (ICSS) test
evaluate the anhedonia, or diminished interest in rewarding stimuli, associated with
nicotine withdrawal. Depression, which is highly correlated with nicotine withdrawal,
also produces anhedonia (Kenny and Markou, 2001). Contextual fear conditioning
explores the cognitive deficits observed after nicotine withdrawal (Davis et al., 2005), as
humans report difficulty concentrating and disrupted cognition after cessation of tobacco
use (Stolerman and Shoaib, 1991; American Psychiatric Association, 1994; Mendreck et
al., 2006). Nicotine withdrawal also produces deficits in contextual fear conditioning in
rodents, suggesting decreased cognition after nicotine withdrawal (Portugal et al., 2008).
The CPA paradigm measures the overall aversion, or negative mood, associated with
nicotine withdrawal (Kenny and Markou, 2001). These models have been characterized
in rodents to measure the nicotine withdrawal syndrome. Current studies strive to
establish more of these models in mice in order to use transgenic mice to understand the
nAChRs and post-receptor mechanisms associated with nicotine withdrawal.
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E. Transgenic Mice: A Complementary Approach to Pharmacological Methods
The use of genetically engineered mice, such as knockout (KO) and knockin (KI)
mice, provides a powerful tool to complement results derived from pharmacological
studies. Because our studies use only KO mice to examine nicotine withdrawal
behaviors, this section will focus on the alternatives and limitations of the use of KO
animals in behavioral studies.
The KO mouse is typically engineered using embryonic stem (ES) cells from the
129/Sv inbred mouse. The gene of interest is inactivated by replacement of coding
sequences essential for gene function with a neomycin cassette. Through homologous
recombination, the normal gene on the chromosome is replaced with the targeted
cassette, thus “knocking out” the gene function. The ES cells from the 129/Sv mouse
that contain the homologous recombination construct are injected into C57Bl/6 (B6)
mouse blastocysts, and implanted into a foster mother; thus, the pups born from this
event are composed of cells from a B6 embryo and 129/Sv stem cells. The chimeric
mice are then mated with B6 mice to transmit the KO allele, and ultimately generate KO
mice in later generations. To date, several nAChR KO mice have been generated and the
phenotypes have been characterized. These include α3 (Xu et al.,1999a), α4 (Marubio et
al., 1999; Ross et al., 2000), α5 (Salas et al., 2003), α6 (Champtiaux et al.,2002), α7
(Orr-Urtreger et al., 1997), α9 (Vetter et al., 1999), β2 (Picciotto et al., 1995), β3
(Booker et al., 1999), and β4 (Xu et al., 1999b).
Because of the overlapping expression patterns of nAChR subunits and the lack
of selective pharmacological agents to identify specific nAChR subunits, KO mice have
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proven to be useful in determining the subunit composition and physiological properties
of nAChRs in vivo, complementing results obtained from pharmacological studies, and
more recently, to test the selectivity of nicotinic receptor antibodies used for standard
immunodetection procedures (Moser et al., 2007). Additionally, these genetically
modified mice aid in elucidating the molecular and receptor-mediated mechanisms of
many pharmacological actions of nicotine-mediated behaviors and various disease states
including Alzheimer’s Disease, Parkinson’s Disease, and drug addiction. While it is
clear that the KO approach offers many possibilities that cannot be achieved through the
use of pharmacological agents, there are some important limitations to the model.
One major setback to KO studies is the occurrence of developmental
modifications that may occur as a result of gene deletion, and can interfere with
interpretation of results. It may be difficult to determine if the mouse phenotype is as a
result of the gene deletion, or simply a mutation that reflects the importance of the gene
in development. In addition, compensatory mechanisms in KO animals may raise some
difficulties in data interpretation. For example, the deletion of one nAChR subunit may
induce a compensatory increase in the expression of another subunit which can take over
function of the deleted subunit; however, the expression level of various nAChR
subunits and enzyme functions were found to be normal in various nAChR subunit KO
animals (Picciotto et al., 1995; Marubio et al., 1999; Ross et al., 2000; Champtiaux et
al., 2002). One minor discrepancy may be the genetic background of the mouse strain
used for breeding, which has a strong influence on the expression of certain phenotypes.
It was shown that the same mutation in different mouse strains can produce different
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phenotypes as a result of modifier genes, or genes that affect the phenotypic expression
of other genes (Nadeau, 2001). Most nAChR KO mice are backcrossed to the B6 strain;
however, the use of other strains for backcrossing the mutations may result in different
phenotypes. Such studies stress the importance of utilizing KO mice from the same
genetic background, and of the necessity to characterize the behavioral phenotypes of
the background strains prior to evaluating results using KO mice.
Our studies utilize the β2, α7, and α5 nAChR KO mice, and α-CaMKII
heterozygote (HT) mice. The β2 nAChR subunit was the first subunit targeted for KO
studies by Picciotto et al. (1995). In situ hybridization revealed normal mRNA levels of
the α4, α5, β4, and β3 nAChR subunits, suggesting that these subunits were not
upregulated as a result of the mutation. Studies showed that nicotine fails to stimulate
the DA system in β2 KO mice (Picciotto et al., 1998); thus, several behaviors associated
with nicotine-mediated DA release are abolished in β2 KO mice, including nicotineinduced locomotor activitation (King et al., 2004), nicotine discrimination (Shoaib et al.,
2002), nicotine self-administration (Picciotto et al., 1998), and conditioned place
preference (Walters et al., 2006), suggesting that the 2 nAChR subunit is crucial in
various features associated with nicotine dependence.
Mice null for the α7 subunit used for our studies were generated as described by
Orr-Urtreger et al. (1997). While the α7 subunit has broad expression in the brain,
studies show that α7 KO mice show normal nicotine conditioned place preference
(Walters et al., 2006), lever-pressing behavior, nicotine-induced locomotor depression,
and nicotine tolerance compared to wildtpe (WT) mice (Naylor et al., 2005), suggesting
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that α7* nAChRs are not involved in nicotine reward or tolerance based on these testing
paradigms. The α7*nAChRs, however, are involved in nicotine withdrawal-induced
hyperalgesia, as nicotine-withdrawn α7 KO do not express this response (Grabus et al.,
2005). The α5 KO mouse used in our studies was generated and characterized as
described by Salas et al. (2003). As with many other nAChR subunit KO mice, α5 KO
mice have normal neuroanatomy and normal levels of α4, α6, α7, β2, and β4 mRNA
with unchanged [125 I]- epibatidine and [125 I]α-bungarotoxin binding in the brain
compared to WT littermates. While α5 KO mice were resistant to nicotine-induced
seizures and to the hypolocomotive effects of nicotine (Salas et al., 2003), little work has
been done to characterize the pharmacological effects of nicotine in α5 KO mice. Our
experiments using these KO mice to identify nAChR subunit involvement in nicotine
withdrawal are addressed in chapters 3 and 4.
F. Dissertation Objectives
The research in this dissertation focuses on identifying the major nAChR
subtypes involved in nicotine withdrawal behaviors, and elucidating post-receptor Ca2+
dependent mechanisms that mediate withdrawal behaviors. While the positive rewarding
and reinforcing effects of nicotine motivate continued use (Kenny and Markou, 2001),
few studies assess the negative motivational component associated with nicotine
withdrawal, although the desire to relieve the discomforts of smoking withdrawal has
been reported by abstinent smokers to be the reason for relapsing into smoking during
quit attempts (US Department of Health and Human Sciences, 1988). To date, the role
of major nAChR subtypes in nicotine withdrawal is unclear, largely due to the low
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selectivity of many nAChR agonists and antagonists. Studies addressing the signaling
mechanisms involved in nicotine withdrawal behaviors are also lacking; thus, our
studies aim to identify the nAChR subtypes involved in affective and somatic nicotine
withdrawal behaviors, elucidate the role of Ca2+-dependent mechanisms involved in
nicotine withdrawal behaviors, and examine the relationship between withdrawalinduced behavioral aterations and Ca2+-dependent mechanisms that mediate nicotine
withdrawal behaviors.
Based on background information and our preliminary data, we hypothesized
that the major nAChR subtypes have differential roles in the nicotine withdrawal
syndrome. Specifically, the α4α6β2* nAChR subtype is involved in affective nicotine
withdrawal behaviors. This subtype also mediates nicotine-withdrawal induced
decreases in CaMKII function in the NAc. The decrease in CaMKII function leads to
decreased phosphorylation of CaMKII substrates, specifically synapsin I, a protein
essential for regulation of neurotransmitter release. To test our hypothesis, we began by
adapting nicotine withdrawal and CPA models for mouse studies. By adapting the
current nicotine withdrawal models for mouse studies, we had the advantage of testing
KO mice in these models to complement pharmacological data on nicotine withdrawal
studies. Using our adapted models, we addressed three specific aims.
Our first specific aim was to identify the major nAChR subtypes in affective and
somatic nicotine withdrawal behaviors. These studies were conducted using
pharmacological antagonists and mice null for specific nAChR subunits. We
hypothesized that different nAChR subtypes have differential roles in nicotine
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withdrawal. Specifically, the α4α6β2* nAChR subtype is involved in affective nicotine
withdrawal behaviors, while α5*, α7*, and α3β4* nAChRs are involved in physical
nicotine withdrawal.
The second specific aim was to examine the role and behavioral relevance of
Ca2+-dependent mechanisms, such as L-type VGCCs and CaMKII, in nicotine
withdrawal. It was suggested that the sustained elevation of Ca2+ through nAChRs is
dependent on the activation of VGCCs, largely L-type (Dajas-Bailador et al., 2002;
Dickinson et al., 2007). Thus, we used L-type VGCCs selective antagonists and an
agonist to elucidate the role of L-type VGCCs in affective and somatic nicotine
withdrawal signs. We also chose to focus on the Ca2+-dependent protein CaMKII due to
its abundance in the brain and large role in mediating several proteins involved in drugmediated behaviors. We used antagonists and CaMKII transgenic mice to examine the
role of CaMKII in nicotine withdrawal. Our preliminary studies lead us to propose that
LTCCs and CaMKII are relevant in nicotine withdrawal behaviors.
In the final specific aim, we investigated the relationship between the altered
behavioral responses in vivo and the in vitro receptor-mediated Ca2+-dependent
mechanisms involved in nicotine withdrawal. Although nAChRs in the VTA are
important for nicotine withdrawal behaviors, the subsequent neurotransmitter release
after stimulation of VTA nAChRs occurs in the NAc, and involves presynaptic nAChRs;
thus, we focused our studies on activity in the NAc after nicotine withdrawal. Using
western blot analysis, we characterized the activity and expression level of CaMKII and
synapsin I after acute nicotine exposure, and after nicotine withdrawal. Pharmacological
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and transgenic approaches were used to determine the specific subunits through which
the withdrawal-induced changes in CaMKII and synapsin I function were mediated. Our
preliminary data lead is to hypothesize that CaMKII, and consequently, synapsin I
activity, are decreased in the NAc after nicotine withdrawal. This decrease in activity is
mediated through the 4α62* nAChR subtype, and is relevant to the expression of
affective nicotine withdrawal behaviors.
Overall, this study identifies specific nAChR subtypes, post-receptor
mechanisms, and potential brain regions important in nicotine dependence and
withdrawal. Further, by showing that the decrease in CaMKII and synapsin I function,
which may contribute to the decreased DA release observed after nicotine withdrawal, is
mediated through the α4α6β2* subtype, which is a subtype crucial for expression of
affective nicotine withdrawal signs, this study stresses the importance of affective
nicotine withdrawal as a motivational component of relapse in smoking behavior. The
research in this dissertation will contribute to the understanding of the molecular and
receptor-mediated mechanisms of nicotine withdrawal, and provide new insight into
potential targets for more effective smoking cessation therapies.

CHARACTERIZATION OF A NICOTINE CONDITIONED PLACE AVERSION
MOUSE MODEL

A. Introduction
The nicotine withdrawal syndrome is characterized by both somatic and affective
signs. Because of the importance of affective nicotine withdrawal signs in nicotine
addiction, nicotine withdrawal studies which assess the receptor-mediated mechanisms
associated with this aspect of withdrawal are currently under investigation. The relative
lack of selective agonists and antagonists for the different nicotinic receptor subtypes has
lead to the generation of several α-conotoxins, which have greater selectivity for specific
nAChR subtypes, as well as transgenic mice, such as KO mice; thus, we have established
mouse models of nicotine withdrawal in order to use transgenic mice to elucidate nicotinic
receptor involvement in nicotine withdrawal.
Recently, some of the widely used affective models of nicotine withdrawal have
been characterized in mice. The ICSS model, which evaluates brain reward function as a
measure of the anhedonic component of withdrawal, has typically been evaluated in rats
(Cryan et al, 2003; Bruijnzeel and Markou, 2004); however, recent studies have
characterized the ICSS model in mice, providing the potential for measuring this affective
component of withdrawal in transgenic mice (Johnson et al., 2008). Another measure of
affective nicotine withdrawal used in the rat is the CPA model. The CPA model measures
the aversive state associated with nicotine withdrawal. It is a form of classic Pavlovian
conditioning where the animal learns to avoid a compartment that was previously paired
25
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with an aversive stimulus. Previous work using this model in the rat has shown that
nicotine withdrawal is associated with a negative affective state, and place aversion to
previously neutral environmental stimuli represents a motivational component in the
maintenance of drug use (Suzuki et al., 1996). The CPA protocol is advantageous over
more complicated affective tests such as the ICSS protocol in that there is no need for
extensive surgical procedures, and training sessions are typically shorter and less complex.
Because the model also tests the animals in an antagonist-free state, it evaluates the
important role of environmental stimuli in the maintenance of drug use. While the nicotine
CPA model has been well defined in rats, this model has not been evaluated and
characterized in mice. Indeed, the use of a mouse model would be advantageous in that it
offers the possibility of exploring the underlying mechanisms of nicotine withdrawal
through the use of genetically modified mice.
For our studies, because of the relative importance of affective withdrawal signs in
contributing to relapse, we used two nicotine withdrawal models that would allow us to
measure affective signs in mice. The plus maze model, which measures the anxiety-related
component of nicotine withdrawal, will be discussed in the next chapter. The focus of this
chapter is characterization of a nicotine CPA model in mice. In addition to these two
models measuring different affective aspects of the nicotine withdrawal syndrome
(anxiety-related behavior vs. aversion), these signs involve different brain regions, and
thus, potentially different nAChR subtypes. While the dorsal raphé nucleus is crucial in
mediating nicotine’s effects on anxiety (Cheeta et al., 2001), the aversive response involves
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the basolateral amygdala (Zanoveli et al., 2007). In the present study, we characterized a
nicotine CPA model in mice to further evaluate the affective component of nicotine
withdrawal. We determined the rate of acquisition, and the role of sex, age, and genotype
on development of aversion. We also identified the role of specific nicotinic receptor
populations through the use of various nicotinic receptor antagonists.
B. Methods
Animals
Male 129P3/J (129) and male and female B6 mice were purchased from Jackson
Laboratories. The B6 mouse is an inbred strain that has been used extensively in
pharmacological studies. Additionally, transgenic animals used in our studies were
generated using 129 embryonic stem cells, and maintained on a B6 background. The mice
were 8-10 weeks of age at the start of all studies. This is an adult age in the mouse, and
published studies utilizing mice between 8-12 weeks of age do not report major behavioral
differences to nicotine in mice in this age range. Male adult and adolescent ICR mice were
purchased from Harlan Laboratories. Adult mice were 8-10 weeks of age and weighed
approximately 20-25 g at the start of the experiment. Adolescent mice were approximately
3 weeks of age [postnatal day (PND) 21] at the start of the experiment. Animals were
maintained in an Association for Assessment and Accreditation of Laboratory Animal
Care-approved animal care facility and the studies were approved by the Institutional
Animal Care and Use Committee of Virginia Commonwealth University.
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Drugs

(-)-Nicotine hydrogen tartrate salt, mecamylamine hydrochloride, dihydro--erythroidine
(DHβE) and methyllycaconitine citrate (MLA) were purchased from Sigma-Aldrich Inc.
(St. Louis, MO, USA). Hexamethonium dichloride was purchased from Sigma /RBI
(Natick, MA). All drugs were dissolved in physiological saline (0.9% sodium chloride) at a
volume of 10 ml/kg body weight. Hexamethonium injections were administered
intraperitoneally (i.p.). All other drugs were administered subcutaneously (s.c.). Doses are
expressed as the free base of the drug.

Chronic nicotine administration

Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model
2004 (28 days) Durect Corporation, Cupertino, CA] filled with (-)-nicotine or saline
solution. The concentration of nicotine was adjusted according to animal weight and the
mini pump flow rate, resulting in 36 mg/kg/day for 14 or 28 days. Because the period of
early adolescence lasts approximately from PND 21 to 36, adult and adolescent mice used
for the age assessment were chronically infused with 48 mg/kg/day for 7 days to ensure a
sufficient level of dependence. The mini pumps were surgically implanted s.c. under sterile
conditions with sodium pentobarbital anesthesia (45 mg/kg, i.p.). An incision was made in
the back of the animal, and a pump was inserted. The wound was closed with wound clips,
and the animal was allowed to recover on a heated pad before being returned to its home
cage.
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Nicotine CPA
The mice were chronically exposed to nicotine for 7 or 14 days prior to initiation of testing
to induce dependence. Infusion continued throughout the duration of testing. The CPA
protocol was conducted over the course of four days in a biased fashion. The CPA
apparatus consisted of a three-chambered box with a white compartment, a black
compartment, and a center grey compartment. The black and white compartments also had
different floor textures to help the mice further differentiate between the two
compartments. Day 1 of CPA testing was the pre-conditioning day. The mice were placed
in the grey center compartment for a 5 minute habituation period, followed by a 15 minute
test period. During habituation, mice did not have access to the other compartments.
During the test period, mice were allowed to roam freely between compartments. The CPA
boxes were connected to a computer, which recorded the amount of time the mouse spent
in each compartment. A pre-preference score was determined for each mouse and was used
to pair the mouse with the antagonist to its initially preferred compartment. On days 2 and
3 of CPA testing, all mice received injections of saline in the morning and were
immediately confined to their non-drug-paired compartment for 30 minutes. No less than
four hours later, mice received an injection of antagonist and were immediately confined to
their drug-paired compartment for 30 minutes. Day 4 was the antagonist-free test day.
Mice moved freely between compartments as on day 1 and activity counts and time spent
on each side were recorded via photosensors using Med Associates interface and software.
Data were expressed as time spent on drug-paired side minus time spent on saline-paired
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side. A reduction in time spent in the initially preferred compartment was interpreted as
CPA.
Statistical analysis

For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA).
All studies were analyzed with one-way ANOVAs [with treatment as the between subject
factor] or two-way ANOVAs [with treatment and sex as the between subject factors] using
the Neuman-Keuls post-hoc test. p values of less than 0.05 were considered significant.
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C. Results
Acquisition of aversion in the CPA model
To determine the rate of acquisition of aversion in the CPA model, mice were subjected to
one, two, or three conditioning sessions with mecamylamine (3.5 mg/kg, s.c.) before the
drug free test day. One mecamylamine conditioning session was sufficient to produce
significant aversion in chronic nicotine infused mice. A significant aversive response was
also noted after two conditioning sessions; however, there was no significant effect after
three days of mecamylamine conditioning (Fig 2A). Next, it was important to determine
the length of the conditioning session required to develop aversion, as well as the level of
dependence necessary to precipitate an aversive response; thus, mice were placed in the
chambers for 30 or 60 minutes after mecamylamine injection, and testing was initiated
after 7 or 14 days of chronic nicotine infusion. Mice developed a significant CPA after 7
and 14 days of prior nicotine infusion, but only after a 30 minute mecamylamine
conditioning session (Fig. 2B). No significant aversion was noted after the 60 minute
conditioning session (Fig. 2B). Based on these results, for the remaining experiments, mice
were chronically exposed to nicotine for 14 days prior to initiation of testing, and subjected
to two 30 minute mecamylamine conditioning sessions to ensure development of aversion.
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Figure 2. Acquisition of aversion in the CPA model. A. Mice acquire aversion in the
CPA model after one and two conditioning sessions; however, no significant effect
was observed after three conditioning sessions. B. Aversion is precipitated in mice
chronically infused with nicotine for 7 and 14 days prior to test initiation. 30 minute
conditioning sessions are sufficient to develop aversion. The effect is lost after 60
minute conditioning sessions. Each point represents  S.E.M. of 10-12 mice per
group. * denotes p<0.05.
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Assessment of various antagonists in the CPA model
The role of various nicotinic receptors in the aversion associated with nicotine withdrawal
was evaluated using nicotinic receptor antagonists. We first wanted to determine the
involvement of central and peripheral nAChR populations in nicotine- withdrawal
aversion. Mecamylamine, a non-selective receptor antagonist that blocks both central and
peripheral nicotinic receptors, dose-dependently precipitated aversion in mice. A
significant CPA was observed with 3.5 mg/kg (s.c.) mecamylamine, but not with 1 or 2
mg/kg (Fig. 3A). Further, the highest dose of mecamylamine used for the studies did not
precipitate aversion in chronic saline infused mice, suggesting that the dose used is not
behaviorally active by itself (Fig. 3B). Hexamethonium (1 and 5 mg/kg, i.p.), a peripheral
nicotinic receptor antagonist that does not cross the blood brain barrier, did not produce
significant aversion as seen in mice treated with mecamylamine (Fig. 3C). Because the
α4β2 and α7 subtypes are major subtypes in the brain, we wanted to evaluate the role of
these receptor subtypes in nicotine withdrawal. We measured aversion after conditioning
with the β2-selective antagonist, DHE, and the α7 antagonist, MLA. DHβE dosedependently precipitated aversion at 0.5 and 2 mg/kg (s.c.), while MLA did not precipitate
aversion at 10 mg/kg (s.c.), a dose that effectively blocks 7 nicotinic receptors (Ward et
al., 1990) (Fig. 3D).
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Figure 3. Assessment of various antagonists in the CPA model. A. Mecamylamine
dose-dependently precipitates aversion in the CPA model. B. The dose of
mecamylamine used in the model, 3.5 mg/kg, does not precipitate aversion in saline
infused mice, suggesting that the dose is not behaviorally active by itself.
C. Hexamethonium (hex), a peripheral nicotinic receptor antagonist, does not
precipitate aversion in chronic nicotine infused mice. D. The 2-selective antagonist,
DHBE, but not the 7 antagonist, MLA, dose-dependently precipitates aversion in
chronic nicotine infused mice. Each point represents  S.E.M. of 10-12 mice per
group. * denotes p<0.05 vs. saline groups.
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Sex and strain assessment in the CPA model
The transgenic mice used in our studies are maintained on a B6 background and derived
from 129 embryonic stem cells. It was therefore necessary to evaluate the background
strains of our transgenic mice in order to make the most efficient interpretation of our KO
results. Additionally, because of the limited number of KO animals produced in each litter,
it is sometimes necessary to use both male and female animals for our studies; thus, we
also evaluated differences between male and female B6 mice in our CPA model. Results
show that mecamylamine (3.5 mg/kg, s.c.) precipitated aversion in male B6 and 129 mice
(Fig. 4). While there was a trend toward a more severe aversive response in B6 mice than
129 mice, the difference was not statistically significant (p= .25 for B6 vs. 129 mice)
(Fig.4). Female B6 mice were also evaluated in the nicotine CPA model. As noted,
mecamylamine (3.5mg/kg, s.c.) precipitated significant aversion in male B6 mice, but CPA
was absent in female B6 mice (Fig. 5). Based on these results, only male mice were used
for subsequent studies.
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Figure 4. CPA assessment using 129 and B6 male mice. Mecamylamine precipitates
aversion in the 129 and B6 inbred strains. Although there was a trend toward a
higher level of aversion in B6 mice, the difference was not significant (p= .25 for B6
vs. 129 group). Each point represents  S.E.M. of 12 mice per group. * denotes p <
0.05 vs. the corresponding saline group.
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Figure 5. Assessment of male and female B6 mice in the development of aversion in
the CPA model. Chronic nicotine infused male B6 mice develop aversion in the CPA
model; however, nicotine infused female B6 mice do not develop aversion in this
testing scheme. Each point represents  S.E.M. of 12 mice per group. * denotes p<0.05
vs. the corresponding saline group.
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Evaluation of age differences in the CPA model
To complete characterization of a nicotine CPA model in mice, we wanted to evaluate the
importance of age in the development of CPA. Early adolescent and adult mice were tested
in the CPA model to evaluate age effects. Mecamylamine (3.5 mg/kg, s.c.) precipitated
significant aversion in adult mice, but no significant effect was observed in adolescent
mice, suggesting that adolescents are less sensitive to the aversive effects of nicotine
withdrawal (Fig. 6). By itself, mecamylamine did not precipitate significant aversion in
adult or adolescent saline controls, suggesting that the dose used was not behaviorally
active in saline mice.
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Figure 6. Age differences in development of aversion in the CPA model.
A. Mecamylamine (3.5 mg/kg, s.c.) precipitates aversion in adult mice, but B. not in
early adolescent mice. The dose of mecamylamine used did not precipitate aversion in
saline-treated adult or adolescent mice. Each point represents  S.E.M. of 10-12 mice
per group. * denotes p<0.05 vs. control groups.
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D. Discussion
The present research aimed to characterize a nicotine CPA model in the mouse. The
adaptation of such a model for mouse studies allows us to define the underlying receptor
mechanisms of affective nicotine withdrawal through the use of genetically modified mice.
The major findings showed that mecamylamine and DHβE, but not hexamethonium or
MLA, precipitated significant aversion in the CPA model, suggesting that the aversion
associated with nicotine withdrawal is mediated by central populations of β2-containing
nAChRs. Further, we show that sex and age are contributing factors to the development of
nicotine CPA.
Acquisition of a significant CPA was observed after one and two conditioning
sessions, but surprisingly, a significant effect was lost after three conditioning sessions. It
is possible that some adaptation to the aversive stimuli occurred during the three day
consecutive conditioning, thus decreasing the degree of CPA expression on test day. In the
current study, mice were conditioned to mecamylamine for three consecutive days. Prior
nicotine CPA studies conducted in rats used one (Suzuki et al., 1996; Suzuki et al., 1999;
Ise et al., 2002; Malin et al., 2006) or four mecamylamine conditioning sessions on
alternating days (O’Dell et al., 2007). In another recent study by Guillem et al. (2007), rats
were treated for five consecutive conditioning sessions with no adaptation to the aversive
stimuli; however, this study was conducted in rats, where species differences could be a
factor. Conditioning sessions in the Guillem study were also shorter than our sessions, and
were initiated 3 days after mini pump implantation; hence, differences in the level of
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nicotine dependence are possible. Results also showed that 7 or 14 days of prior nicotine
exposure was sufficient to obtain mecamylamine-precipitated aversion after a 30 minute,
but not 60 minute conditioning session. The half-life of mecamylamine in the rodent is
approximately 1 hour (Debruyne et al., 2003); therefore, it is possible that mecamylamine’s
effects in the mouse began to diminish during the 60 minute conditioning session. In our
study, a fairly high dose of mecamylamine (3.5 mg/kg) was necessary to precipitate a
significant CPA. Significant aversion was not precipitated at 2 mg/kg mecamylamine; thus,
it is possible that the half-life dose of mecamylamine is not sufficient to precipitate
significant CPA in chronic nicotine infused mice.
Results using different antagonists suggest the involvement of central, but not
peripheral nicotinic receptor populations. While mecamylamine, a non-selective nicotinic
receptor antagonist that acts on both central and peripheral nicotinic receptor populations,
precipitated significant aversion in chronic nicotine infused mice, hexamethonium, a
peripheral nicotinic receptor antagonist that does not cross the blood brain barrier, did not
precipitate aversion at any dose tested. These results are consistent with studies which
indicate that affective nicotine withdrawal signs are mediated solely by central nicotinic
receptor populations (Watkins et al., 2000). Additionally, results suggest that the 2, but
not the 7 nicotinic receptor subunit, is involved in development of nicotine CPA. DHE,
a 2-selective antagonist, dose-dependently precipitated a significant CPA, while MLA did
not precipitate CPA at a dose that effectively blocks 7 nicotinic receptors (Ward et al.,
1990). The current results are consistent with previous studies from our lab showing that
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DHβE precipitates anxiety-related behavior in the plus maze test in nicotine-dependent
mice (Damaj et al., 2003). It is also noted that DHβE was more potent than mecamylamine
in this assessment, as DHβE was able to precipitate aversion at lower doses than
mecamylamine. Taken together, the results suggest that 2-containing nicotinic receptor
subtypes are involved in affective nicotine withdrawal behaviors and that CPA is a
centrally mediated effect. To further evaluate these conclusions, a complementary
approach using nAChR KO mice to evaluate nAChR subunit involvement in the CPA
model is presented in chapters 3 and 4.
Our evaluation using male and female B6 mice suggests that sex factors contribute
to the development of nicotine withdrawal aversion. Mecamylamine precipitated a
significant CPA in male, but not female B6 mice. Prior evaluations of female mice in
nicotine withdrawal revealed that female mice did not express an anxiety-related response,
suggesting that female mice are less sensitive to affective nicotine withdrawal (Kota et al.,
2008). Another explanation could be the influence of sex hormones. Indeed, sex hormones
can modulate the effects of nicotine and may contribute to differences in nicotine’s
responses between males and females (Damaj, 2001). Human studies also suggest that
hormonal changes during different menstrual cycle phases impact severity of the nicotine
withdrawal syndrome (Carpenter et al., 2006). In the current study, we did not control for
the estrous cycle in female mice. Consequently, it is possible that the female mice were in
different phases of the estrous cycle, thus impacting our results. Results also suggest that
genotypic factors may contribute to development of nicotine CPA. While significant
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aversion was precipitated in both male 129 and B6 mice, aversion appeared to more intense
in B6 mice, although the difference in aversion scores was not significant. These results are
consistent with results showing that physical nicotine withdrawal and anxiety-related
behavior is more intense in B6 mice than 129 mice (Damaj et al., 2003). Studies testing
additional mouse strains may be necessary to support a role for the involvement of
genotypic factors in the development of nicotine CPA.
In our final assessment, results revealed a significant contribution of age to the
development of significant aversion. Mecamylamine (3.5 mg/kg, s.c.) precipitated aversion
in chronic nicotine infused adult, but not adolescent mice. Our findings are consistent with
previous findings from Kota el al. (2007), showing that male adolescent mice are less
sensitive to the affective measures of nicotine withdrawal than male adult mice, as
adolescents do not express an anxiety-related response on the plus maze. Further, O’Dell et
al. (2007) showed that CPA was lower in chronic nicotine infused adolescent rats versus
adult rats using a biased experimental design. It is possible that adolescent rodents may be
less able than adults to associate environmental cues with aversive nicotine withdrawal
effects; however, the aforementioned study addressed this possibility using another
aversive stimulus, lithium chloride (LiCl) injections. The effect was shown to be specific to
nicotine withdrawal aversion, as there was no significant difference between adolescents
and adults in learning place aversion to LiCl (O’Dell et al., 2007). Additionally, in the
current study, two conditioning sessions were used to acquire a nicotine CPA. The
possibility that adolescent mice require more conditioning sessions to acquire a significant
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CPA cannot be ruled out; however, such an assessment was beyond the scope of the
current study.
In summary, the results of our study demonstrate that our mouse nicotine
withdrawal models are useful in assessing the pharmacological, biochemical, and genetic
mechanisms associated with a motivational component of drug dependence. Further, due to
sex and age differences that may confound our results, only male adult KO mice were used
in our nicotine withdrawal assessments. The next several chapters will utilize the CPA
model, as well as precipitated and spontaneous nicotine withdrawal models, to characterize
nAChR involvement and post-receptor mechanisms that contribute to nicotine withdrawal
behaviors.
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THE ROLE OF α46β2* NICOTINIC RECEPTORS IN NICOTINE
WITHDRAWAL
A. Introduction
The β2 nAChR subunit is a central, highly expressed subunit that coassembles with
many subunits to form functional receptors, including 4, α5, and 6 nAChRs, in the
mesocorticolimbic drug pathway on DA neurons and terminals (Wada et al., 1989, 1990;
Le Novère and Changeux, 1995; Le Novère et al., 1996; Klink et al., 2001). The α4α5β2*
and α4α6β2* nAChR subtypes are involved in nicotine-stimulated DA release in the
striatum (Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 2005). The α6 and α5
nAChR subunits are also expressed in brain areas that have been implicated as having a
role in nicotine dependence behaviors. Expression of 6-containing nAChRs in the brain
is largely confined to catecholaminergic nuclei, such as the VTA, SN, and LC ( Le Novère
et al., 1996; Klink et al., 2001 ), while the more widely expressed α5 nAChR subunit is
found in the cerebral cortex (Gerzanich et al., 1998), cerebellum, thalamus (Flora et
al.,2002) , striatum (Zoli et al.,2002), hippocampus, SN, and VTA (Wada et al., 1990), as
well as peripherally in sympathetic and parasympathetic ganglia (De Biasi, 2002).
Studies have utilized the available nicotine withdrawal models to assess nAChR
involvement in nicotine dependence behaviors, both pharmacologically, and using
transgenic animals. The 2-selective antagonist DHE was shown to precipitate anxietyrelated behavior (Damaj et al., 2003) and elevations in reward threshold in chronic nicotine
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infused rodents (Bruijnzeel and Markou, 2004), implicating a role for 2-containing
nAChRs in affective withdrawal behaviors. The 6 subunit plays a role in the locomotor
stimulating effects of nicotine (Le Novère et al., 1999), an effect suggested to be due to
enhanced mesolimbic DA transmission (Benwell and Balfour, 1992). Furthermore, studies
show that α5 KO mice are resistant to nicotine-induced seizures (Salas et al., 2003). While
the available studies provide some insight into the nAChR subtypes involved in nicotine
withdrawal, and suggest a possible role for these subunits in nicotine addictive behaviors,
evidence of a behavioral role for β2, α5, and 6 nAChRs is still lacking. Despite the
importance of affective signs in contributing to relapse, few studies address this aspect of
withdrawal. Additionally, many studies utilize nAChR antagonists, which do not have high
selectivity for specific subunits. A complementary approach would be the use of transgenic
mice for specific nicotinic receptor subunits. Indeed, the use of nAChR KO mice provides
greater specificity than would be achieved using current pharmacological agents.
In the current study, using precipitated, spontaneous, and CPA models of nicotine
withdrawal, we determined the contribution of the 2, α6, and 5 nAChR subunits in both
physical and affective signs of nicotine withdrawal using β2 and α5 nAChR KO mice and
the 6-selective nAChR antagonist -conotoxin H9A;L15A (MII[H9A;L15A]) (McIntosh
et al., 2004).
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B. Methods
Animals
Male B6 mice were obtained from Jackson Laboratories. Breeding pairs of mice lacking
the 2 subunit of the nicotinic receptor (B6 background) and WT littermates were shipped
from Institut Pasteur, Paris, France (see Picciotto et al., 1995 for information regarding
initial breeders). Mice null for the 5 nicotinic receptor subunit (B6 background) and WT
littermates were shipped from Baylor College of Medicine, Houston, Texas (see Salas et
al., 2003 for information regarding initial breeders). For all experiments, 5 KO mice
were backcrossed to at least 8-10 generations, and 2 KO mice were backcrossed at least
10-12 generations. Mutant and WT controls were obtained from crossing HT mice. This
breeding scheme controlled for any irregularities that might occur with crossing solely
mutant animals.
Drugs
(-)-Nicotine hydrogen tartrate salt and mecamylamine hydrochloride were purchased from
Sigma-Aldrich Inc. (St. Louis, MO, USA). Drugs were dissolved in physiological saline
(0.9% sodium chloride) and injected s.c. at a volume of 10 ml/kg body weight. All doses
are expressed as the free base of the drug. The 6*-selective antagonist, MII[H9A;L15A],
was synthesized as previously described in McIntosh et al. (2004). The highest dose for
MII[H9A;L15A] (30 pmol) intracerebroventricular (i.c.v.) injection was calculated based
on the functional IC50 at the α6 subunit (McIntosh et al., 2004).
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Chronic nicotine administration

Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model
2004 (28 days) Durect Corporation, Cupertino, CA] filled with saline or (-)-nicotine (36
mg/kd/day) as described in Chapter 2.
I.c.v. surgery
Mice were anesthetized with sodium pentobarbital (45 mg/kg, i.p.) on the evening prior to
testing, and a scalp incision was made to expose the bregma. Unilateral injection sites were
prepared using a 26-gauge needle with a sleeve of polyurethane (PE) tubing to control
depth of the needle at a site 2 mm rostral and 2 mm lateral to the bregma at a depth of 2
mm. Animals were sutured in such a way to enable an injection volume of 5 µl using a 26gauge needle with a sleeve of PE tubing into the lateral ventricle on the morning of testing.
The needle was held in place for 20 seconds to ensure drug delivery.
Nicotine withdrawal assessment
Mice were implanted with mini pumps containing nicotine or saline for 14 days. On the
morning of day 15, mice were injected with mecamylamine (2 mg/kg, s.c.) or saline, and
withdrawal signs were measured 10 minutes after injection. The mice were first evaluated
for 5 minutes in the plus maze test for anxiety-related behavior. The mice were then
observed for somatic signs of withdrawal for 20 minutes. Hyperalgesia was evaluated
immediately after the somatic sign observation period. The specific testing sequence was
chosen based on prior studies from the lab showing that this order of testing reduced
within-group variability and produced the most consistent results. For spontaneous
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withdrawal studies, mini pumps were removed on the morning of day 14 and testing was
initiated 18-24 hours later, on day 15.

Elevated plus maze. An elevated plus-maze, prepared with grey Plexiglas, consisted of two
open arms (23 x 6.0 cm) and two enclosed arms (23 x 6 x 15 cm in wall height) that
extended from a central platform (5.5 x 5.5 cm). It was mounted on a base raised 60 cm
above the floor. Fluorescent lights (350 lux intensity) located in the ceiling of the room
provided the only source of light to the apparatus. The animals were placed in the center of
the maze, and allowed to roam freely between the open and closed arms. The time spent in
the open and closed arms was automatically recorded by a photocell beam system. The test
lasted 5 minutes, and the apparatus was thoroughly cleaned after removal of each animal.
A decrease in the amount of time spent on the open arms was indicative of increased
anxiety-related behavior. Results were expressed as the mean  S.E.M. number of seconds
spent in the open arms. As a control, the number of times each animal crossed from one
side of the plus maze to the other was measured, noted as the total average number of arm
crosses. This was to ensure that the reduction in time spent on the open or closed arms was
not a reflection of a lack of overall activity.

Somatic signs. Mice were observed for 20 minutes in empty transparent activity cages (32 x
18 cm) for typical somatic withdrawal behaviors. Typical nicotine withdrawal signs that
were tallied included head shakes, paw tremors, body tremors, and backing. Ptosis, curls,
and jumps were also tallied collectively as “other” somatic signs. Results were expressed
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as the mean ± S.E.M. number of signs displayed by mice during the 20 minute observation
period.
Hyperalgesia. The nicotine withdrawal-induced hyperalgesia response was evaluated using
the hot plate test (Thermojust Apparatus). The hot plate is a rectangular heated surface
surrounded by plexiglass and maintained at 52°C. The device is connected to a manually
operated timer that records the amount of time the mouse spends on the heated surface
before showing signs of nociception (e.g. jumping, paw licks). The timer has an automatic
cut-off of 40 seconds to avoid tissue damage. A decreased latency on the hot plate was
counted as increased pain sensitivity (hyperalgesia). Results were expressed as the mean 
S.E.M. latency (reaction time for jumping or paw-licking) displayed by the mice.
Nicotine CPA
β2 and α5 assessment
Mecamylamine-precipitated CPA for 2 and α5 KO mice was conducted using male KO
and WT littermates as described in Chapter 2.
α6 assessment
After the mecamylamine conditioning session on the evening of day 3, i.c.v. injection sites
were prepared. On day 4, mice received i.c.v. injections of vehicle or MII[H9A;L15A]
(22.5 or 30 pmol), 5 minutes before being placed in the test chambers.
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Statistical analysis
For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA).
Studies using transgenic mice were analyzed with two-way ANOVAs [with genotype and
treatment as between subject factors] using the Neuman-Keuls post-hoc test. p values of
less than 0.05 were considered significant.
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C. Results
Evaluation of affective and physical signs of nicotine withdrawal using the precipitated
model
To assess the involvement of specific nAChR subtypes in nicotine withdrawal, a
nicotine withdrawal model was adapted to allow measurement of both physical and
affective aspects of nicotine withdrawal in one setting. Mecamylamine (2 mg/kg, s.c.)
precipitated significant nicotine withdrawal signs in mice chronically exposed to nicotine
(36 mg/kg/day) for 14 days (Fig. 7). Results show a significant reduction in the amount of
time spent on the open arms of the elevated plus maze in chronic nicotine infused mice
treated with mecamylamine when compared to control groups, indicating an anxietyrelated response in these mice (Fig. 7A). The average number of arm crosses was tallied as
a measure of locomotor activity on the plus maze. No significant difference in the number
of crosses between arms was noted between groups, suggesting that the decrease in open
arm time was not attributed to reduced activity on the plus maze (Table 1). Nicotinedependent mice also showed enhanced nicotine withdrawal somatic signs after
mecamylamine injection (Fig. 7B), as well as significant nicotine-withdrawal induced
hyperalgesia as measured by a decreased latency on the hot plate compared to saline
controls (Fig. 7C). Saline mini pump mice that received an injection of mecamylamine and
nicotine mini pump mice that received an injection of saline on test day did not differ from
saline-saline control animals, indicating that the mecamylamine dose utilized did not
produce effects on its own, and that the nicotine mini pump mice were not experiencing
nicotine withdrawal on test day.
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Figure 7. Assessment of physical and affective nicotine withdrawal signs in B6 mice
using the precipitated model. After treatment with mecamylamine (2 mg/kg, s.c.) on
test day, nicotine-dependent mice show A. anxiety-related behavior noted by a
reduction in the time spent on the open arms, B. significant somatic signs, and C.
withdrawal-induced hyperalgesia, noted by a decreased latency on the hotplate. Each
point represents the mean  S.E.M. of 8 mice per group. * denotes p < 0.05 vs. control
groups.
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Table 1: Total average number of arm crosses in the plus maze after precipitated
nicotine withdrawal.
Using the precipitated model, nicotine-dependent mice were treated with
mecamylamine (2 mg/kg, s.c.) on test day (day 15), and the total number of crosses
between open and closed arms of the plus-maze test was counted. Numbers are
presented as the total average number of arm crosses  SEM for 8 mice per group.

B6 mice

Sal-Sal

Sal-Mec

Nicotine-Sal

Nicotine-Mec

3.7  0.64

4.2  0.67

3.3  0.42

4.2  0.51
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Role of the 2 nAChR subunit in nicotine withdrawal
The 14 day – precipitated nicotine withdrawal model was used to measure the
affective and physical signs of nicotine withdrawal in chronic nicotine infused β2 KO
mice. Results in Figure 8A show that chronic nicotine infused β2 KO mice displayed a
loss of withdrawal induced anxiety-related behavior when compared to WT counterparts,
indicated by no difference in the amount of time spent on the open arms of the place maze
compared to control animals. No significant difference in the number of arm crosses
between groups was noted (Table 2). However, chronic nicotine infused β2 KO and WT
mice both displayed significantly more somatic signs than saline infused WT and KO mice
(Fig. 8B) and displayed a similar decrease in hot plate latency, indicating a significant
hyperalgesia response (Fig. 8C). Saline control β2 KO mice did not differ from WT
counterparts in any withdrawal test.
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Figure 8. The 2 nAChR subunit is involved in the affective signs, but not the physical
signs of nicotine withdrawal. When compared to WT chronic nicotine infused mice,
chronic nicotine infused 2 KO mice show A. no reduction in the time spent on the
open arms of the plus maze, indicating a loss of anxiety-related behavior, but B.
significant nicotine withdrawal somatic signs and C. a decreased hotplate latency,
indicating the presence of the hyperalgesia response. Each point represents the mean
 S.E.M. of 8 mice per group. * denotes p < 0.05 vs. saline groups and vs. nicotine KO
group for the plus maze test.
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Table 2: Total average number of arm crosses in the plus maze test after precipitated
nicotine withdrawal in β2 and α5 KO mice.
Using the precipitated model, chronic nicotine infused mice were treated with
mecamylamine (2 mg/kg, s.c.) on test day (day 15), and the total number of crosses
between open and closed arms of the plus-maze test was counted. Numbers are
presented as the total average number of arm crosses  SEM for 8 mice per group.
2 mice

5 mice

Sal-WT

Sal- KO

Mec-WT

Mec-KO

3.6  0.59

3.6  0.32

4  0.46

3.3  0.59

Sal –WT

Sal- KO

Mec-WT

Mec-KO

2.8  0.51

3  0.49

3.3  0.42

3.2  0.40
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Assessment of 2 nAChR KO mice in a spontaneous withdrawal model
It was important to demonstrate that the precipitated nicotine withdrawal behaviors
observed in transgenic mice were not an assessment of the mecamylamine-dependent
behavioral effects on specific nAChR subunits. Therefore, we used the spontaneous
withdrawal model to assess nicotine withdrawal signs in 2 KO mice 18-24 hours after
withdrawal from nicotine. Results of the spontaneous withdrawal assessment in 2 KO
mice are shown in Figure 9. As observed in the mecamylamine-precipitated model,
nicotine- withdrawn 2 KO mice displayed significant somatic signs and hyperalgesia, but
a loss of anxiety-related behavior after cessation of nicotine treatment.
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Figure 9. Assessment of nicotine withdrawal signs in 2 nAChR KO mice using the
spontaneous withdrawal model. 2 KO mice withdrawn from nicotine 18-24 hours
show A. a loss of anxiety-related behavior on the plus maze, indicated by the lack of a
reduction in the time spent on the open arms, but B. significant somatic signs, and C.
withdrawal-induced hyperalgesia, indicated by a decreased hotplate latency. Each
point represents 8 mice per group. * denotes p< 0.05 vs. saline groups.
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Role of the α5 nAChR subunit in nicotine withdrawal
The evaluation of nicotine withdrawal in α5 KO mice is shown in figure 10.
Chronic nicotine infused WT and α5 KO mice spent significantly less time on the open
arms of the elevated plus maze compared to saline infused WT and KO mice, indicating
the presence of an anxiety-related response (Fig. 10A, Table 2). Somatic sign observation
of chronic nicotine infused α5 KO mice revealed a significant reduction in paw tremors,
backing, and total somatic signs compared to chronic nicotine infused WT littermates (Fig.
10B) Both WT and α5 KO chronic nicotine infused mice displayed a decreased latency on
the hot plate, indicating a significant hyperalgesia response (Fig. 10C). There were no
significant differences between saline infused KO and WT mice for any withdrawal test.
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Figure 10. The 5 nAChR subunit plays a role in some physical aspects of nicotine
withdrawal, but not the affective signs. Nicotine-dependent 5 KO mice show A.
significant anxiety-related behavior in the plus maze test, indicated by a reduction in
time spent on the open arms, but B. display a significant reduction in total average
number of somatic signs when compared to WT counterparts. C. The nicotineinduced hyperalgesia response is still present in 5 KO mice, indicated by a decreased
hotplate latency. Each point represents the mean ± S.E.M. of 6-8 mice per group. *
denotes p < 0.05 vs. saline groups. + denotes p < 0.05 vs. saline groups and vs. WT
mec group
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Role of the α6 nAChR subunit in nicotine withdrawal
The role of 6*nAChRs in physical and affective nicotine withdrawal signs was
evaluated using a spontaneous withdrawal model. As expected, nicotine withdrawn mice,
compared to saline infused mice, spent significantly less time on the open arms of the plus
maze, indicating withdrawal-associated anxiety-like behavior, exhibited decreased latency
on the hot plate, indicating a withdrawal-induced hyperalgesia response, and displayed
indications of somatic withdrawal (Fig. 11).

Pretreatment with the highest (30 pmol) dose of MII[H9A;L15A], blocked the
expression of an anxiety-related response in nicotine-withdrawn mice. There was no
significant difference in time spent on the open arms of the plus maze between saline
infused mice and animals infused with MII[H9A;L15A] (Fig. 11A). The average number
of arm crosses was tallied as a measure of locomotor activity on the plus maze. There was
no significant difference between mice treated with vehicle and 30 pmol MII[H9A;L15A],
suggesting that the observed effects on the plus maze were not the result of a difference in
activity (veh= 2.4  0.3 vs. 30 pmol= 2.4  0.7, p=0.91).

Somatic withdrawal assessment revealed that nicotine-withdrawn mice treated with
vehicle, 22.5 or 30 pmol MII[H9A;L15A] i.c.v. displayed significantly more total somatic
signs than saline infused mice, indicating that MII[H9A;L15A] had no effect on somatic
withdrawal at any dose tested (Fig. 11B). The hot plate assessment also revealed a
significant hyperalgesia response in all nicotine-withdrawn mice compared to saline
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exposed mice, regardless of i.c.v. injection, indicating that MII[H9A;L15A] had no effects
on the nicotine withdrawal-induced hyperalgesia response at the doses tested (Fig. 11C).
Saline infused mice treated with 30 pmol MII[H9A;L15A] i.c.v. did not differ from saline
infused mice treated with vehicle i.c.v. in any behavioral test, indicating that the antagonist
at the highest dose used was not behaviorally active by itself (Fig. 11).
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Figure 11. MII[H9A;L15A] dose-dependently blocks expression of the nicotine
withdrawal-induced anxiety-related response in mice. Nicotine withdrawn mice
treated with 30 pmol MII[H9A;L15A] display A. a loss of anxiety-related response,
but B. no change in average number of somatic signs or C. hyperalgesia response.
Each point represents the mean  S.E.M. of 12 mice per group. * denotes p< 0.05 vs.
saline groups; + denotes p< .05 vs. 30 pmol MII[H9A;L15A]
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Role of the 2, 5, and 6 nAChR subunits in affective signs using the CPA model
In Chapter 2, we adapted a nicotine CPA model to further assess affective
withdrawal signs in transgenic mice. Our CPA assessment using 2 and 5 nAChR KO
mice, and the α6 selective antagonist MII[H9A;L15A], are shown in Figures 12 and 13
respectively. There was a loss of significant CPA in chronic nicotine infused 2 KO mice
(Fig. 12A). In contrast, mecamylamine precipitated CPA was present in chronic nicotine
infused 5 KO mice (Fig. 12B). In the α6 assessment, mecamylamine precipitated CPA in
chronic nicotine infused mice treated with vehicle (Fig. 13). MII[H9A;L15A], however,
dose-dependently blocked expression of aversion in nicotine-infused mice. Pre-treatment
with 30 pmol, but not 22.5 pmol MII[H9A;L15A], on test day blocked the expression of
mecamylamine-precipitated CPA in nicotine-dependent mice (Fig. 13).
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Figure 12. Assessment of the role of the 2 and 5 nAChR subunits in affective
nicotine withdrawal signs using the CPA model. A. Nicotine-dependent 2 KO mice
show a loss of significant CPA; however, B. 5 nAChR KO mice express
mecamylamine-precipitated CPA. Each point represents the mean ± S.E.M. of 8-10
mice per group. * denotes p < 0.05 vs. saline groups and vs. mec KO group in the 2
assessment.
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Figure 13. Assessment of the role of the α6 nAChR subunit in affective nicotine
withdrawal signs using the CPA model. Nicotine-infused mice treated with 30, but not
22.5 pmol MII[H9A;L15A], did not express significant CPA. The 30 pmol dose of
MII[H9A;L15A] had no effect in saline treated mice. Each point represents the mean
 S.E.M. of 12 mice per group.* denotes p< 0.05 vs. saline and 30 pmol
MII[H9A;L15A] treated groups.
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D. Discussion
The major goal of this study was to determine the role of major nAChR subtypes in
the physical and affective signs of nicotine withdrawal. Therefore, using precipitated,
spontaneous, and CPA nicotine withdrawal models to measure both physical and affective
signs of nicotine withdrawal, we found a loss of anxiety-related behavior and nicotine
withdrawal aversion, but normal physical withdrawal in β2 KO mice and in mice after pretreatment with the selective α6 antagonist, MII[H9A;L15A], suggesting that β2 and α6
containing nAChRs are involved in affective, but not physical nicotine withdrawal. Studies
with α5 KO mice revealed a reduction in somatic signs, but normal hyperalgesia and
affective withdrawal, suggesting a role for the α5 subunit in the somatic signs associated
with nicotine withdrawal.
Before proceeding with our studies using KO mice, we adapted a nicotine
withdrawal model that would allow us to measure both physical and affective nicotine
withdrawal signs in one setting. Results showed that mecamylamine precipitates anxietyrelated behavior, somatic signs, and hyperalgesia in chronic nicotine infused mice. The
half-life of mecamylamine in the rodent is approximately 1 hour (Debruyne et al., 2003).
We were able to effectively measure one affective and two physical nicotine withdrawal
signs within this one hour time frame. Our spontaneous withdrawal test using transgenic
mice also confirmed that the observed precipitated- withdrawal behavioral effects were not
an assessment of mecamylamine-dependent effects on nAChR subunits.

69
Results suggest that 2 nAChRs are involved in affective, but not physical nicotine
withdrawal. There was no reduction in somatic signs and hyperalgesia was present in
nicotine-withdrawn 2 KO mice. These data are consistent with previous studies assessing
the role of 2 nAChRs in somatic signs of nicotine withdrawal using 2 KO mice (Salas et
al., 2004; Besson et al., 2006). Both studies found that mecamylamine precipitated nicotine
withdrawal somatic signs in chronic nicotine infused 2 KO mice in a similar fashion to
what was observed in nicotine-infused WT littermates; however, neither study measured
affective signs in β2 KO mice. In the current study, we assessed two affective signs of
nicotine withdrawal in 2 KO mice and found that 2 KO mice displayed a lack of
anxiety-related behavior in the plus maze, as well as a lack of mecamylamine-precipitated
aversion in the CPA model. Our studies using transgenic mice are complemented by
previous pharmacological nicotine withdrawal studies which utilized the 2-selective
antagonist, DHβE, to precipitate anxiety-related behavior and elevations in reward
threshold, also measures of affective signs of nicotine withdrawal (Damaj et al., 2003;
Bruijnzeel and Markou, 2004). Further, in the previous chapter, our pharmacological
studies showed that DHβE dose-dependently precipitated aversion in the CPA model. Due
to the issue of compensation in transgenic animals, the complementary pharmacological
approach strengthens our interpretation of the current results. Taken together, these studies
suggest an important role for 2-containing nicotinic receptors in affective nicotine
withdrawal behaviors.
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Central administration of the selective α6 antagonist, MII[H9A;L15A], had no
effect on physical withdrawal, but dose-dependently blocked anxiety-related behavior in
the plus maze, as well as expression of aversion in the CPA model. These results indicate a
role for 6 receptors in affective, but not physical nicotine withdrawal behaviors.
Interestingly, 22.5 pmol MII[H9A;L15A] had no effect on the expression of CPA;
however, 30 pmol MII[H9A;L15A], a dose not more than half, significantly blocked the
effect. Currently the in vivo pharmacokinetics of MII[H9A;L15A] are not known; thus, it is
possible that, like nicotine, the drug has a sharp dose response curve and produces its
effects at a narrow range of concentrations. The LC, in addition to the VTA, has abundant
α6 receptor expression, and both areas have been implicated in withdrawal from drugs of
abuse. Studies show that intra-LC injections of a D1 receptor agonist attenuated morphine
withdrawal signs in rats (Dizgah et al., 2005). Further, the α6* nAChR is expressed with
the α4β2* subtype (Wada et al., 1989, 1990; Klink et al., 2001), and the current study,
along with previous studies, suggests that β2*nAChRs are critical for affective, but not
physical withdrawal (Damaj et al., 2003; Besson et al., 2006; Jackson et al., 2008). Taken
together, these results suggest a role for the α4α6β2* nAChR subtype in affective nicotine
withdrawal.
The role of the 5 nAChR subunit in nicotine withdrawal has not previously been
addressed. Assessment of the 5 subunit showed a reduction in somatic signs in chronic
nicotine infused 5 KO mice after mecamylamine treatment, while anxiety-related
behavior and hyperalgesia were still present. Additional evaluation of affective signs
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revealed the expression of mecamylamine-precipitated aversion in 5 KO mice. These
findings suggest that the 5 subunit is involved to an extent in some physical aspects of
nicotine withdrawal, but not affective nicotine withdrawal signs. It has been reported that
the 4 subunit is involved in the physical signs of nicotine withdrawal, as nicotine-infused
β4 KO mice displayed a significant reduction in somatic signs and a significant loss of
hyperalgesia in the tail-flick, but not the hot plate assessment (Salas et al., 2004). Spinal
and supraspinal nAChR populations mediate the hyperalgesia response (Schmidt et al.,
2001; Damaj et al., 2002). While the hot plate assessment involves supraspinal receptor
populations, the tail-flick test measures responses from spinal receptor populations. The 4
subunit is coexpressed with the 3 and 5 subunits in the peripheral ganglia (Salas et al.,
2004). This may explain why there was an effect for β4 in the tail-flick, but not the hot
plate assessment, as well as why the hyperalgesia response was present using the hot plate
in our α5 assessment. Somatic signs of nicotine withdrawal were also shown to be partially
mediated by peripheral nAChR populations; therefore, we propose that ganglionic 54*containing nAChR subtypes mediate somatic signs of nicotine withdrawal. This hypothesis
is evaluated further in the next chapter. Because the 5 subunit can co-assemble with both
2 and 4 nAChRs, it is likely that the role of 5 in nicotine withdrawal differs depending
on nAChR subunit composition.
As mentioned, one of the problems in interpretation of results obtained with KO
mice is whether compensatory changes in expression of other genes occur as a result of
deletion of a particular gene. Although this issue has not yet been directly explored with
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the nicotinic KO mice, it should be noted that behavioral differences observed with these
KO mice were reproduced using various nicotinic antagonists, at least for the α7 and 2
subunits, as seen in the next chapter and previous chapter respectively, as well as with
previous studies from the lab (Damaj et al., 2003). In addition, no compensatory changes of
other nicotinic subunits were reported in these particular KO strains (Orr-Urtreger et al.,
1997; Salas et al, 2004; Picciotto et al., 1995). Although we cannot completely rule out
effects on other systems, these findings argue against a role for compensatory changes and
suggest a direct role for these subunits in nicotine withdrawal.
Additionally, the issue of selectivity of nAChR agonists and antagonists has also
produced some difficulty in data interpretation. While several -conotoxins have affinity for
both 3 and 6 nAChR subunits, MII[H9A;L15A] is a much more potent at 6* than at the
3* nAChRs (McIntosh et al., 2004). In the current study, we injected 22.5-30 pmol of
peptide. Based on diffusion studies by Matta et al. (1995), the highest dose (30 pmol) would
correspond to a tissue concentration of ~ 1.2 M. At 1 M, MII[H9A;L15A] has no effect
on , or  nAChRs. The peptide is also > 2000-fold selective for
6/323 nAChRs compared to  and  nAChRs. The IC50 at  and 
nAChRs is 4.8 M and 7.8 M respectively; thus, at concentrations used, there would be
significantly less blockade of these receptor subtypes. The IC50 at  and 
nAChRs is 2.4 nM and 270 nM respectively (McIntosh et al., 2004); therefore, at the
concentrations used in our studies, selective block of 6* nAChRs is expected.
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The results of this study present a role for β2 and 6-containing nAChRs in
affective nicotine withdrawal. In addition, the present findings indicate that the α5 subunit
is not essential for affective withdrawal. Together with previous studies, these data suggest
that 62* and/ or α4α6β2*, but not α4α5β2* nAChR subtypes, are critical for affective
withdrawal. An examination of Ca2+-dependent post-receptor mechanisms that contribute
to these behavioral effects is addressed in Chapter 6.
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IDENTIFICATION OF ADDITIONAL NICOTINIC RECEPTOR SUBUNITS
INVOLVED IN NICOTINE WITHDRAWAL
A. Introduction
In the previous chapter, we began our identification of nAChR subunits involved in
nicotine withdrawal with the β2, α5, and α6 nAChRs. We began our assessment with the
β2 nAChR because it is a central, highly expressed subunit that has been implicated in
several nicotine dependence behaviors, including reward and reinforcement (Picciotto et
al., 1995; Walters et al., 2006). The α4, α5, and α6 nAChR subunits coassemble with β2
nAChRs to form functional receptors that are involved release of DA (Champtiaux et al.,
2003; Salminen et al., 2004; Lai et al., 2005), a neurotransmitter involved in behaviors
associated with nicotine dependence.
The homomeric 7 nAChR is also a major subtype found on neurons in the
mesocorticolimbic drug pathway, and has been implicated in physical withdrawal
behaviors. Pharmacologically, MLA, an 7 antagonist, was shown to precipitate mild
somatic signs (Damaj et al., 2003) and changes in locomotor activity (Nomikos et al.,
1999). Nicotine-withdrawn 7 KO mice also did not display withdrawal-induced
hyperalgesia or decreases in locomotor activity (Grabus et al., 2005). A role for β4*
nAChRs has also been suggested. It was shown that 4 KO mice do not display somatic
signs or hyperalgesia after nicotine withdrawal (Salas et al., 2004). The α3 subunit is
coexpressed with α5 and β4 nAChRs in the peripheral ganglia, MHb, and IPN (Wada et al.,
1990; Zoli et al., 1995; Quick et al., 1999; Whiteaker et al., 2002). Further, α3 nAChR
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subunits are expressed in brain areas that have been implicated as having a role in nicotine
dependence behaviors, and can coassemble with β2 nAChRs to form functional receptors
on DA neurons and terminals (Le Novère and Changeux, 1995; Le Novère et al., 1996;
Klink et al., 2001). In Chapter 3, our assessment of α5 KO mice in withdrawal revealed
that α5 KO mice display a significant reduction in somatic signs, but normal affective
withdrawal, suggesting a role for this subunit in somatic nicotine withdrawal. Recent
genetic studies suggest that a common haplotype in the CHRNA5/CHRNA3/CHRNB4
gene cluster, which codes for the α5, α3, and β4 subunits respectively, predisposes to
nicotine dependence (Berrettini et al., 2008).
Evidence of a behavioral role for α7 and α3 nAChRs in nicotine dependence is still
lacking; thus, the goal of this research was to determine the role of α7 and α3 nAChRs in
nicotine withdrawal behaviors. Using α7 KO mice, the α6/α3β2* selective antagonist αconotoxin MII (MII) , and the α3β4* selective antagonist α-conotoxin AuIB (AuIB), we
questioned 7, α3β2*, and α3β4* nAChR contributions to nicotine withdrawal using the
precipitated, spontaneous, and CPA models. Because the α3 subunit has been shown to
coassemble with both β2 and β4 nAChRs in the brain, the use of two antagonists, which
differentiate between α3β2* and α3β4* nAChR subtypes , would also allow us distinguish
between α3 coassembly with the β4 and β2 nAChR subunits in nicotine withdrawal.
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B. Methods
Animals
Male B6 mice were purchased from Jackson Laboratories. Mice lacking the 7 subunit of
the nicotinic receptor (B6 background) and WT littermates were purchased from Jackson
Laboratories (B6.129S7-charna7tm1bay, number 003232; see Orr-Urtreger et al., 1997 for
information regarding initial breeders). For all experiments 7 KO mice were backcrossed
to at least 8-10 generations and maintained on a breeding scheme as discussed in Chapter
3.

Drugs
(-)-Nicotine hydrogen tartrate salt and mecamylamine hydrochloride were purchased from
Sigma-Aldrich Inc. (St. Louis, MO, USA). The α6/α3β2*-selective antagonist MII and the
α3β4*-selective antagonist AuIB were synthesized as described in Cartier et al., 1996 and
Luo et al., 1998 respectively. The compounds were dissolved in physiological saline (0.9%
sodium chloride) and administered to each animal by i.c.v. injection. The highest doses for
MII (8 pmol) and AuIB (18 pmol) i.c.v. injections were calculated based on the functional
IC50s of each at its respective subtypes (Cartier et al., 1996; Luo et al., 1998).

Chronic nicotine administration

Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model
2004 (28 days) Durect Corporation, Cupertino, CA] filled with saline or (-)-nicotine (36
mg/kd/day) as described in Chapter 2.
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I.c.v. surgery

I.c.v. surgery and injection was performed as described in Chapter 3. Briefly, a scalp
incision was made to expose the bregma, and unilateral injection sites were prepared using
a 26-gauge needle with a sleeve of PE tubing to control depth of the needle at a site 2 mm
rostral and 2 mm lateral to the bregma at a depth of 2 mm. On the morning of testing, a
volume of 5 µl using a 26-gauge needle with a sleeve of PE tubing was injected into the
lateral ventricle and held in place for 20 seconds to ensure drug delivery.
Nicotine withdrawal assessment
Studies using α7 KO mice were conducted using the precipitated withdrawal assessment as
described in Chapter 3. In brief, α7 KO mice were treated with mecamylamine (2 mg/kg,
s.c.) on the morning of day 15, 10 minutes before testing. Studies using MII and AuIB
were conducted using the spontaneous withdrawal model as described in Chapter 3. Mice
were injected i.c.v. with vehicle, MII (2.5 or 4 pmol), or AuIB (15 or 18 pmol) on the
morning of day 15, 18-24 hours after mini pump removal, and withdrawal signs were
measured 5 minutes after injection. Spontaneous withdrawal experiments were conducted
using the same testing scheme as mentioned with precipitated studies.
Nicotine CPA
α7 assessment
Mecamylamine-precipitated CPA for α7 KO mice was conducted using male KO and WT
littermates as described in Chapter 2.
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α3β2* and α3β4* assessment
After the mecamylamine conditioning session on day 3, i.c.v. injection sites were prepared.
On day 4, mice received i.c.v. injections of vehicle, MII (2.5 or 4 pmol), or AuIB (15 or 18
pmol), 5 minutes before being placed in the test chambers.
Statistical analysis
For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA).
Studies using transgenic mice were analyzed with two-way ANOVAs [with genotype and
treatment as between subject factors] using the Neuman-Keuls post-hoc test. p values of
less than 0.05 were considered significant.
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C. Results
Role of the α7 nAChR subunit in nicotine withdrawal
The role of α7 nAChR receptors in nicotine withdrawal is shown in Figure 14.
Chronic nicotine infused WT and α7 KO mice spent significantly less time on the open
arms of the plus maze than saline infused mice, indicating the presence of an anxietyrelated response (Fig. 14A). No significant difference in the number of arm crosses
between groups was noted (Table 3). Significant withdrawal somatic signs were also
observed in chronic nicotine infused WT and α7 KO mice (Fig. 14B).

Significant

hyperalgesia was observed in chronic nicotine infused WT mice after mecamylamine
treatment; however, chronic nicotine infused α7 KO mice showed a loss of nicotinewithdrawal induced hyperalgesia, indicated by no significant decrease in hot plate latency
compared to saline controls (Fig. 14C). Saline infused KO mice did not differ from WT
counterparts in any withdrawal test.
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Figure 14. The 7 nAChR subtype is involved in some physical aspects of nicotine
withdrawal, but not the affective signs. Chronic nicotine infused 7 KO mice showed
A. a reduction in the time spent on the open arms of the plus maze, indicating an
anxiety-related response, and B. significant nicotine withdrawal somatic signs.
However, C. a loss of nicotine withdrawal-induced hyperalgesia response, as noted by
the lack of a decrease in hotplate latency, was observed in chronic nicotine infused 7
KO mice when compared to WT counterparts. Each point represents the mean 
S.E.M. of 8 mice per group. * denotes p< 0.05 vs. saline groups and vs. nicotine KO
group for the hyperalgesia test.
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Table 3: Total average number of arm crosses in the plus maze test after precipitated
nicotine withdrawal in α7 KO mice.
Using the precipitated model, chronic nicotine infused mice were treated with
mecamylamine (2 mg/kg, s.c.) on test day (day 15), and the total number of crosses
between open and closed arms of the plus-maze test was counted. Numbers are
presented as the total average number of arm crosses  SEM for 8 mice per group.
7 mice

Sal-WT

Sal- KO

Mec-WT

Mec-KO

2.7  0.42

3.5  0.48

3  0.53

2.7  0.28
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Assessment of 7 nAChR KO mice in a spontaneous withdrawal model
It was important to demonstrate that the precipitated nicotine withdrawal behaviors
observed in transgenic mice were not an assessment of the mecamylamine-dependent
behavioral effects on specific nAChR subunits. Therefore, we used the spontaneous
withdrawal model to assess nicotine withdrawal signs in 7 KO mice 18-24 hours after
withdrawal from nicotine. Spontaneous withdrawal studies using 7 KO mice were
comparable to mecamylamine-precipitated studies as shown in Figure 15. Nicotinewithdrawn 7 KO mice showed significant somatic signs and anxiety-related behavior, but
no withdrawal-induced hyperalgesia response.
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Figure 15. Assessment of nicotine withdrawal signs in 7 nAChR KO mice using the
spontaneous withdrawal model. 7 KO mice withdrawn from nicotine 18-24 hours
show A. anxiety-related behavior on the plus-maze, indicated by a reduction in the
time spent on the open arms, and B. significant somatic signs, but C. a loss of
withdrawal-induced hyperalgesia, noted by the lack of a decreased hotplate latency.
Each point represents 8 mice per group. * denotes p< 0.05 vs. saline groups.
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Role of α3β2* nAChRs in nicotine withdrawal
To evaluate the role of α3β2* nAChRs in nicotine withdrawal, we used the
α6/α3β2* selective antagonist, MII. In Chapter 3, the α6-selective antagonist,
MII[H9A;L15A], was used to evaluate the role of α6-containing nAChRs in nicotine
withdrawal. MII[H9A;L15A] is able to effectively discriminate between α3 and α6
nAChRs; thus, we used MII, which has significantly less selectivity for α6-containing
nAChRs than MII[H9A;L15A] (McIntosh et al., 2004), to separate the α6 component, and
assess the role of α3β2* nAChRs in nicotine withdrawal. Results show that MII dosedependently blocked an anxiety-related response in nicotine-withdrawn mice (Fig. 16A).
Nicotine-withdrawn mice treated with 4, but not 2.5 pmol MII, did not display a reduction
in time spent on the open arms of the plus maze as observed in nicotine-withdrawn vehicle
treated mice. The number of arm crosses was tallied and there was no significant difference
in arm crosses between vehicle and MII (4 pmol, i.c.v.) treated saline infused mice (veh=
3.1 ± 0.7; MII= 2.3 ± 0.5, p= 0.26) and no significant difference in time spent on the open
arms, suggesting that the highest does of MII was not behaviorally active by itself (Fig.
16A).
Somatic sign assessment revealed a dose-dependent attenuation of total somatic
signs after MII treatment (Fig. 16B), while MII had no effect in the hyperalgesia response
at any dose tested (Fig. 16C).
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Figure 16. MII dose-dependently blocks expression of the nicotine withdrawalinduced anxiety-related response and somatic signs in mice. Nicotine withdrawn mice
treated with 4 pmol, but not 2.5 pmol MII, display A. a loss of anxiety-related
response, B. attenuation of somatic signs, but C. a normal hyperalgesia response.
Each point represents the mean  S.E.M. of 12 mice per group. * denotes p< 0.05 vs.
saline groups; + denotes p< .05 vs. 4 pmol MII
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Role of α3β4* nAChRs in nicotine withdrawal
The α3β4*-selective antagonist AuIB was evaluated in our nicotine withdrawal
models. AuIB, purified from the venom of the “court cone”, Conus aulicus, blocks the
α3β4 receptor subtype with > 100 fold higher potency than other receptor combinations,
such as α3β2 and α4β4 (Luo et al., 1998). Nicotine-withdrawn mice treated with vehicle
i.c.v. displayed a significant anxiety-related response, and treatment with AuIB had no
effect on the anxiety-related response at any dose tested (Fig. 17A). There was no
significant difference in time spent on the open arms of the plus maze between any
nicotine-withdrawn mouse group, regardless of i.c.v. treatment. Evaluation of saline
infused mice revealed no significant difference in the amount of time spent on the open
arms and no significant difference in the number of arm crosses between vehicle or AuIB
treated mice (veh= 3.2 ± 0.4 ; AuIB= 2.7 ± 0.5, p= 0.41), suggesting that the highest dose
of AuIB (18 pmol) was not behaviorally active alone.
In the somatic sign assessment, AuIB induced a dose-dependent decrease in total
somatic signs. Nicotine-withdrawn mice treated with 15 pmol AuIB displayed a significant
reduction in somatic signs compared to vehicle treated mice, while a dose of 18 pmol AuIB
attenuated somatic signs in nicotine withdrawn mice (Fig. 17B). The hyperalgesia response
was not affected by treatment with AuIB. Nicotine-withdrawn mice treated with saline or
AuIB displayed a significant hyperalgesia response compared to saline infused animals,
and there was no significant difference between nicotine withdrawn mice that received
vehicle or AuIB (Fig. 17C).
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Figure 17. AuIB dose-dependently reduces somatic signs, but has no affect on anxietyrelated behavior or the hyperalgesia response. Nicotine withdrawn mice treated with
18 pmol MII display A. no change in anxiety-related response or C. hyperalgesia
response, but B. attenuation of total somatic signs. Each point represents the mean 
S.E.M. of 12 mice per group. * denotes p< 0.05 vs. saline groups; + denotes p< .05 vs.
saline and nicotine-vehicle groups; $ denotes p< 0.05 vs. nicotine-vehicle and 15 pmol
AuIB groups
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Role of the α7, α3β2*, and α3β4*nAChR subtypes in affective signs using the CPA
model
To further evaluate the role of the α7, α3β2*, and α3β4* nAChR subtypes in
affective nicotine withdrawal, we tested α7 KO mice and mice after treatment with α3β2*
and α3β4* in our CPA model. Our initial assessment suggested that α7* nAChRs were not
involved in the affective withdrawal response. Results show that mecamylamine (3.5
mg/kg, s.c.) precipitated aversion in α7 WT and KO mice (Fig. 18). The CPA assessment
also revealed that MII (4 pmol, i.c.v.) had no effect on expression of CPA on test day (Fig.
19A). Because our assessment in the plus maze revealed that MII blocked the anxietyrelated response, we tested a higher dose of MII to determine if we could produce an effect.
An 8 pmol dose of MII also had no effect on expression of CPA on test day (Fig. 19A).
Nicotine infused mice treated with 18 pmol AuIB expressed a significant aversion similar
to that observed in nicotine infused vehicle treated mice, indicating that expression of CPA
was not blocked by AuIB (Fig. 19B). Saline infused mice treated with AuIB (18 pmol) or
MII (8 pmol) did not significantly differ from saline infused vehicle treated mice,
suggesting, by themselves, the highest doses of AuIB and MII used for the study were not
behaviorally active.
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Figure 18. Mecamylamine precipitates aversion in nicotine-infused α7 WT and KO
mice. Nicotine-infused KO mice treated with mecamylamine (3.5 mg/kg, s.c.) did not
differ from their WT counterparts in the CPA assessment. * denotes p > 0.05 vs.
saline counterparts.
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Figure 19. The α6/α3β2* selective antagonist MII and the α3β4* antagonist AuIB
have no effect on expression of nicotine CPA. Mecamylamine precipitated CPA in
chronic nicotine-infused mice; however, neither A. 8 pmol MII nor B. 18 pmol AuIB
had an effect on expression of mecamylamine-precipitated aversion. Each point
represents the mean  S.E.M. of 12 mice per group.* denotes p< 0.05 vs. saline
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D. Discussion

These behavioral studies using pharmacological agents and genetically modified
mice suggest that 7* and α3β4* nAChRs are involved in physical nicotine withdrawal
signs, while α3β2* nAChRs are involved in the somatic signs and anxiety-related response
associated with nicotine withdrawal. Nicotine infused α7 KO mice displayed significant
anxiety-related behavior, CPA, and somatic signs after mecamylamine injection, but a loss
of the hyperalgesia response, suggesting a role for α7 in some physical, but not affective
withdrawal. I.c.v. injection of the selective α6/α3β2* antagonist, MII, blocked the
expression of anxiety-related behavior and somatic signs, but not expression of nicotine
CPA, while treatment with the α3β4* antagonist only blocked the expression of somatic
signs, suggesting that the α3β4* nAChR subtype is involved in somatic, but not affective
withdrawal signs, while the α3β2* subtype appears to be involved in nicotine withdrawalinduced somatic signs and the anxiety-related response.
Assessment of the α7 nAChR subunit using transgenic mice showed that nicotinedependent 7 KO mice expressed anxiety-related behavior, CPA, and somatic signs, but a
loss of hyperalgesia. In the previous chapter, we found that MLA did not precipitate
aversion in the CPA model in chronic nicotine infused mice, thus, complementing our
results using transgenic animals. A previous 7 nAChR KO study from our laboratory
using the oral route of chronic nicotine administration and the spontaneous nicotine
withdrawal model produced similar findings (Grabus et al., 2005). The oral route of
administration, however, yields variable amounts of nicotine intake, making it difficult to
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control the actual dose of nicotine reaching the receptor; therefore, we wanted to assess the
role of the 7 subunit using a more consistent exposure method. Taken together, these
results suggest that 7 nAChRs are involved in physical, not affective, nicotine withdrawal
signs.
The data also suggest that our two physical measures of nicotine withdrawal
(somatic signs and hyperalgesia) are mediated by different nAChR subtype populations.
While 7 KO mice showed a loss of the hyperalgesia response, these mice exhibited
somatic signs of nicotine withdrawal. The 7 nAChR subunit is expressed in the peripheral
ganglia, as well as centrally. Although hyperalgesia is measured as a physical sign in the
mouse, studies have suggested that spinal and supraspinal nAChR populations mediate the
hyperalgesia response (Schmidt et al., 2001; Damaj et al., 2002). Our hyperalgesia measure
was conducted using the hot plate, which measures supraspinal mechanisms; thus, we
cannot rule out the possibility that the nicotine withdrawal induced hyperalgesia response
is mediated by neuronal α7 nAChRs. It is also noted that MLA, the 7 antagonist,
precipitated mild somatic signs of withdrawal in WT mice (Damaj et al., 2003), while our
assessment revealed the presence of typical nicotine withdrawal somatic signs in 7 KO
mice. It was also shown, however, that MLA can antagonize 6, 3, and 3 nAChR
subunits at doses typically utilized to block 7 nAChRs (Mogg et al., 2002); thus, it is
possible that the observed behavioral responses were attributed to effects on other nAChR
subtypes.
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An i.c.v. injection of MII, the α6/α3β2* selective antagonist, dose-dependently
blocked the expression of anxiety-related behavior and somatic signs, but not expression of
CPA. One possible explanation as to why we saw an effect with MII in the plus maze, but
not the CPA assessment is that anxiety-related behavior and CPA are mediated by two
different brain regions; the dorsal raphé nucleus (Cheeta et al., 2001) and the basolateral
amygdala (Zanoveli et al., 2007) respectively; thus, it is possible that the two behaviors are
mediated by different subtypes. Furthermore, the α6 and α3 nAChR subunits share
considerable sequence homology (Le Novère and Changeux, 1995). Indeed, studies
suggest that MII may not discriminate well between α3 and α6 nAChRs (Kuryatov et al.,
2000); however, the MII analog, MII[H9A;L15A], effectively discriminates between α3
and α6 nAChR subunits (McIntosh et al., 2004). Our results from Chapter 3 showed a role
for α6-containing nAChRs in nicotine CPA and the anxiety-related response, but not
physical withdrawal. These results suggest that α6-containing nAChRs, and not α3β2*
nAChRs ,are important for nicotine CPA, while both α6 and α3β2* nAChRs are involved
in the withdrawal-induced anxiety-related response; however, because MII does not
discriminate well between α3 and α6 nAChRs, we cannot rule out the possibility that the
effects of MII in the plus maze are attributed to actions at α6β2* nAChRs. Results using
MII[H9A;L15A] showed that CPA was blocked at a dose of 30 pmol MII[H9A;L15A], but
there was no effect at the 8 pmol MII dose used in the current study. Because
MII[H9A;L15A] has higher selectivity for α6-containing receptors than MII, higher doses
of MII may be required to block α6-containing receptors, and thus, expression of CPA. MII
also dose-dependently blocked the expression of nicotine withdrawal somatic signs.
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Although results from Chapter 2 showed that β2-containing receptors are not involved in
somatic nicotine withdrawal signs, based on the current data, we cannot rule out the
possibility that the α3β2* subtype is involved in this aspect of nicotine withdrawal.
The α3β4* selective antagonist, AuIB, given centrally, also dose-dependently
attenuated somatic signs, but had no effect in the plus maze or CPA assessments. Studies
using transgenic mice revealed an attenuation of somatic signs in β4 KO mice after
mecamyalmine-precipitated withdrawal (Salas et al., 2004). Somatic withdrawal signs were
shown to be mediated by central, as well as peripheral nAChR populations by systemic and
central administration of chlorisondamine, a noncompetitive nAChR antagonist that does
not readily cross the blood brain barrier (Watkins et al., 2000). Chlorisondamine, however,
is not selective for specific nAChR subtypes. Additionally, the β4 KO mouse used in the
Salas et al. (2004) study is a general KO; thus, central and peripheral nAChR populations
cannot be differentiated. Although the α3β4* subtype is both peripherally and centrally
expressed, these studies suggest a role for central α3β4* nAChRs in somatic nicotine
withdrawal. The α3β4* subtype has limited expression in the CNS, but was shown to
dominate function in the MHb (Quick et al., 1999); therefore, α3β4* expression
specifically in the MHb may be important for somatic nicotine withdrawal.

Based on studies from the previous chapter, and the current study, our data suggests
that the α4α6β2* nAChR subtype is involved in affective nicotine withdrawal, while α7*,
α5, and α3β4* nAChRs mediate physical nicotine withdrawal. Specifically, α7* nAChRs
mediate the withdrawal induced hyperalgesia response, and the α5 and α3β4* subtypes
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play a role in somatic withdrawal. These studies also stress the importance of receptor
subunit composition in nicotine withdrawal. While β2-containing receptors were shown to
be involved in affective, but not physical withdrawal, the α3β2* subtype was implicated in
somatic nicotine withdrawal signs, and played no role in expression of nicotine CPA. The
next chapter will focus on the involvement of intracellular Ca2+-dependent mechanisms in
the nicotine withdrawal syndrome.
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THE ROLE OF CALCIUM-DEPENDENT MECHANISMS IN NICOTINE
WITHDRAWAL
A. Introduction
Activation of nAChRs leads to increases in intracellular Ca2+ via various routes. Upon
nicotine binding, there is a direct Ca2+ influx through the Ca2+ permeable nAChR. The
resulting increase in intracellular Ca2+ leads to an indirect Ca2+ influx by Ca2+ induced Ca2+
release from intracellular Ca2+ stores, and through VGCC as a result of membrane
depolarization following nAChR activation (Rathouz and Berg, 1994; Dajas-Bailador et
al., 2002). The subsequent rise in intracellular Ca2+ leads to activation of various
downstream second-messengers, including CaMKII, the most abundant Ca2+-dependent
kinase in the neuron (Deisseroth et al., 1998), and a protein involved in several essential
processes, including neurotransmitter release (Schulman and Hanson, 1993) and induction
of LTP (Lisman et al., 2002).
Studies suggest a role for L-type VGCCs and CaMKII in the effects of several
drugs of abuse. L-type VGCCs are upregulated in the cortex and limbic structures of rats
showing signs of morphine withdrawal (Antkiewicz-Michaluk et al., 1990; Zharkovsky et
al., 1993) and blockade of L- type VGCCs attenuates signs of morphine physical
dependence in rats (Michaluk et al., 1998; Vitcheva and Mitcheva, 2004; Esmaeili-Mahani
et al., 2008). L-type VGCC blockers also inhibit chronic cocaine and amphetamineinduced behavioral and neurochemical changes (Karler et al., 1993; Pierce and Kalivas,
1997; Pierce et al., 1998). Additionally, blockade of L-type VGCC or suppression of
CaMKII activity in the VTA augments acute cocaine-induced behavioral hyperactivity
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(Licata et al., 2004). Nicotine studies show that pharmacological blockade of L-type
VGCCs attenuates mecamylamine-precipitated somatic signs of nicotine withdrawal in
mice (Biala and Weglinska, 2005). Studies from our lab showed that L-type VGCC
blockers and CaMKII inhibitors block development and expression of nicotine-induced
antinociception at the spinal level (Damaj, 2005). Biochemical studies show that L-type
VGCCs, as well as α4β2* nAChRs, are upregulated in mouse cerebral cortical neurons
after 7 days chronic nicotine exposure, leading to an increased Ca2+ influx (Katsura et al.,
2002). Further, the signaling pathway that results in nicotine-induced ERK phosphorylation
in mouse primary cortical neurons involves L-type VGCCs and CaMKII (Steiner et al.,
2007). In PC12 cells, an increase in intracellular Ca2+ after stimulation of nicotinic
receptors activates CaMKII (MacNicol and Schulman, 1992), and data from our lab
shows that an acute systemic injection of nicotine is sufficient to elevate CaMKII in the
spinal cord (Damaj, 2000). Recent studies revealed that alterations in the phosphorylation
state of neuronal CaMKII occur after chronic exposure to various drugs of abuse such as
cocaine, amphetamine and morphine (Tan, 2002; Wang Z et al., 2003; Licata et al., 2004).
Although the current studies evaluating Ca2+-dependent mechanisms in nicotine
dependence provide evidence of a role for Ca2+signaling, the behavioral studies only assess
the physical aspect of nicotine withdrawal, and not the affective component, which is
suggested to be of greater motivational significance in contributing to relapse (Koob et al.,
1993; Markou et al., 1998). Additionally, there is no available behavioral correlation for
the biochemical studies, which evaluate nicotine-induced Ca2+ mechanisms in vitro; thus,
the relevance of these mechanisms to nicotine withdrawal is unclear. The goal of the
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current study was, therefore, to elucidate the behavioral relevance of L-type VGCC and
CaMKII in physical and affective nicotine withdrawal. Using our adapted spontaneous
nicotine withdrawal and CPA models, mice were treated with one of two structurally
different L-type VGCC blockers, nimodipine or verpamil, the L-type VGCC activator, (±)
Bay K8644, the CaMKII inhibitor KN93, or its inactive analog KN92, and physical and
affective withdrawal signs were measured. KN93 can also inhibit other kinases, such
CaMKIV (Enslen et al., 1994); therefore, to complement our studies of CaMKII inhibition,
we measured physical and affective nicotine withdrawal signs in nicotine-dependent
CaMKII HT mice in our mecamylamine-precipitated model.
B. Methods
Animals
Male B6, male B6.129P2-Camk2atm1Sva/J HT, and female B6129P3 mice were
purchased from Jackson Laboratories. CaMKII mutant mice were generated as described
by Silva et al., 1992a, and were backcrossed at least 16 generations. Initial attempts to
generate CaMKII KO mice were unsuccessful, as female CaMKII HT mice on a B6
background do not care for the pups, resulting in death of the entire litter. It was proposed
by Dr. A. Silva that incorporation of a mixed background would produce CaMKII HT
females that would nurse the pups; thus, in an effort to alleviate this problem, male
CaMKII HT mice were paired with female WT B6129P3 hybrid mice (Jackson
Laboratories) to produce F2 CaMKII HT mice on a mixed background. The male CaMKII
HT mice and female hybrid CaMKII HT mice would not breed; thus no KO litters were
produced. This led to the use of F2 CaMKII HT hybrids for our withdrawal studies.
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Animals were 8-10 weeks of age, were group-housed in a 21°C humidity-controlled
AAALAC-approved animal care facility with ad libitum access to food and water.
Experiments were performed during the light cycle and were approved by the Institutional
Animal Care and Use Committee of Virginia Commonwealth University.
Drugs
(-)-Nicotine hydrogen tartrate salt, mecamylamine hydrochloride, verapamil hydrochloride,
(±)Bay K8644, and KN93 were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA).
Nimodipine was purchased from Research Biochemical International (RBI) (Natick, MA).
KN92 was purchased from Seikagaku Corporation (Tokyo, Japan). Nicotine and
mecamylamine were dissolved in physiological saline (0.9% sodium chloride) and injected
s.c. at a volume of 10 ml/kg body weight. Verapamil, nimodipine, and (±)Bay K8644 were
dissolved in a vehicle solution made of 5% ethyl alcohol, 5% emulphor oil, and 90% saline
and administered by i.p. injection. KN92 and KN93 were diluted in saline and administered
by i.c.v. injection. Doses are expressed as the free base of the drug.
I.c.v. surgery
I.c.v. surgery and injection were performed as described in Chapter 3. Briefly, a scalp
incision was made to expose the bregma, and unilateral injection sites were prepared using
a 26-gauge needle with a sleeve of PE tubing to control depth of the needle at a site 2 mm
rostral and 2 mm lateral to the bregma at a depth of 2 mm. On the morning of testing, a
volume of 5 µl using a 26-gauge needle with a sleeve of PE tubing was injected into the
lateral ventricle and held in place for 20 seconds to ensure drug delivery.
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Chronic nicotine administration protocol
Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model
2004 (28 days) Durect Corporation, Cupertino, CA] filled with saline or (-)-nicotine (36
mg/kd/day) as described in Chapter 2. Due to ceiling effects with 36 mg/kg/day nicotine, in
the (±)Bay K8644 assessment, mice used for this test were infused with 24 mg/kg/day
nicotine.

Locomotor activity
Mice were injected with vehicle (i.p.) and immediately placed into individual photocell
activity cages (28 x 16.5 cm; Omnitech, Columbus, OH) for a 30 minute habituation
period. After habituation, mice were injected with vehicle or the assigned dose of
nimodipine (1- 10 mg/kg, i.p.) and immediately returned to the locomotor cages.
Interruptions of the photocell beams (two banks of eight cells each) were recorded for the
next 30 min. Data are expressed as the number of photocell interruptions.
Nicotine withdrawal assessment
Withdrawal studies were conducted using the spontaneous withdrawal assessment as
described in Chapter 3. In brief, for Ca2+ channel and pharmacological CaMKII studies,
mini pumps were removed on day 14, and testing initiated on day 15, approximately 18-24
hours after mini pump removal. Mice were injected with vehicle, nimodipine (0.25 or 1
mg/kg, i.p.), verapamil (1 mg/kg, i.p.), or (±)Bay K8644 (0.25 and 0.5 mg/kg, i.p.) 15
minutes prior to initiation of testing or with KN93 or KN92 (0.0025- 0.01 µg/µl, i.c.v.) 5
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minutes prior to testing. Mecamylamine-precipitated studies were conducted as described
in Chapter 3. For KN93 precipitated studies, mice were injected i.c.v. and testing was
initiated 5 minutes after the injection. The withdrawal testing sequence was conducted as
described in previous chapters.

Nicotine CPA

Nicotine CPA testing was conducted as described in Chapter 2. Alterations to the
procedure are described below.
Nimodipine assessment
On days 2 and 3 of CPA training, all mice received injections of saline in the morning. In
the afternoon, mice received an injection of nimodipine (1 mg/kg, i.p.) or vehicle 15
minutes prior to mecamylamine injection. Mice were placed in the assigned chamber
immediately after mecamyalmine injection for 30 minutes.
KN93 assessement
On day 4, test day, mice received i.c.v. injections of vehicle, KN93 (.01 g/l), or KN92
(.01 g/l) 5 minutes before being placed in the test chambers.
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Statistical analysis

For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA).
Data were analyzed with one-way ANOVAs with treatment as the between subject factor
or two-way ANOVAs with treatment and genotype as between subject factors for the HT
studies. Significant results were further analyzed using the Neuman-Keuls post-hoc test. p
values of less than 0.05 were considered significant.
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C. Results

Role of L-type VGCCs in physical and affective nicotine withdrawal

Before beginning our studies using L-type VGCC blockers, we wanted to determine the
appropriate doses to use for our studies that would not have effects on locomotor activity.
Preliminary data showed that nimodipine dose-dependently decreased locomotor activity in
mice. Mice treated with 3 or 10 mg/kg nimodipine displayed a significant decrease in
activity compared to vehicle treated mice (Fig. 20). There was no significant difference in
activity between vehicle treated mice or mice treated with 1 or 2 mg/kg nimodipine. Based
on this data, doses no higher than 2 mg/kg nimodipine were used for withdrawal studies.
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Figure 20. Nimodipine dose-dependently reduces locomotor activity in mice. Doses of
3 and 10 mg/kg nimodipine significantly reduced locomotor activity during the 30
minute test period; therefore, doses no higher than 2 mg/kg were used for our studies.
Data are expressed as the number of photocell interruptions ± SEM for 6 mice per
group. * denotes p < 0.05 vs. vehicle, 1 and 2 mg/kg nimodipine groups

105
As expected, nicotine-withdrawn mice pre-treated with vehicle showed a significant
decrease in the amount of time spent on the open arms of the plus maze, indicating an
anxiety-related response. Significant somatic signs and a significant decrease in hot plate
latency compared to saline controls were also observed (Figure 21). Nimodipine dosedependently reduced physical signs in nicotine-withdrawn mice. Mice treated with 1 mg/kg
nimodipine, but not 0.25 mg/kg, showed a significant decrease in total somatic signs and a
significant increase in hot plate latency, indicating a loss of the hyperalgesia response (Fig.
21B and 21C). There was no significant difference in time spent on the open arms of the
plus maze in nicotine-withdrawn mice treated with nimodipine compared to vehicle,
suggesting that nimodipine had no effect on anxiety-related behavior (Fig. 21A).
Verapamil, an L-type VGCC blocker structurally different from nimodipine, had effects
similar to nimodipine in nicotine-withdrawn mice. Verapamil (1 mg/kg, i.p.) significantly
reduced somatic signs and significantly increased hot plate latency in nicotine-withdrawn
mice; however, verapamil had no effect on anxiety-related behavior as measured by the
plus maze (Fig. 21). The Ca2+ channel blocker doses had no significant effect in saline
infused mice, indicating that, by themselves, the doses used were not behaviorally active
(Fig. 21).
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Figure 21. L-type VGCCs are involved in physical, but not affective withdrawal.
Nimodipine (1 mg/kg, i.p.) and verapamil (1 mg/kg, i.p.) B. attenuated somatic
withdrawal signs and C. attenuated the hyperalgesia response as measured by a
significant increase in hot plate latency; however, A. had no effect on anxiety-related
behavior as measured by the amount of time spent on the open arms of the plus maze.
Each point represents the mean ± SEM 8 mice per group. * denotes p < 0.05 vs. saline
controls and vs. nicotine (nic) –nimodipine (nim)/verapamil (ver) for the hot plate
assessment. + denotes p < 0.05 vs. nic –vehicle (veh). $ denotes p < 0.05 vs. saline
controls, nic- nim, 1 mg/kg and nic-min 0.25 mg/kg
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L-type VGCC blockers have been shown to inhibit α3* and 7* nAChR-mediated currents
and downstream signaling in vitro at doses typically used to block L-type VGCC (Wheeler
et al., 2006); therefore, mice were treated with the L-type VGCC activator, (±)Bay K8644,
after nicotine withdrawal to complement results observed with L-type VGCC blockers.
Because (±)Bay K8644 has significant effects on locomotor activity as measured by the
number of arm crosses on the plus maze (saline-veh: 4 ± 0.27 crosses vs. saline-BayK: 11
± 1.67 crosses), animals were not evaluated in the plus maze, as changes in locomotor
activity can confound results in this test. (±)Bay K8644 dose-dependently enhanced
somatic signs and the hyperalgesia response in nicotine-withdrawn mice. Compared to
vehicle treated nicotine-withdrawn mice, mice treated with 0.5 mg/kg (±)Bay K8644, but
not 0.25 mg/kg, exhibited significantly more somatic signs (Fig. 22A) and a significant
decrease in hot plate latency (Fig. 22B), indicating an enhanced response in both
behavioral tests.
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Figure 22. (±)Bay K8644 dose-dependently enhances physical withdrawal signs.
Nicotine-withdrawn mice treated with (±)Bay K8644 (BayK, 0.5 mg.kg, i.p.) exhibited
A. a significant increase in somatic signs and B. and a significant decrease in hot plate
latency when compared to nicotine-withdrawn vehicle (veh) treated mice. Each point
represents the mean ± SEM of 8 mice per group. * denotes p < 0.05 vs. saline controls.
+ denotes p < 0.05 vs. nicotine- veh mice
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Evaluation of L-type VGCCs using the CPA model

Results suggested that L-type VGCCs are involved in physical, but not affective
nicotine withdrawal. To further assess this effect, the aversion associated with nicotine
withdrawal was measured using the CPA model. Mice were pre-treated with nimodipine (1
mg/kg, i.p.), 15 minutes prior to mecamylamine injection during conditioning.
Mecamylamine (3.5 mg/kg, s.c.) precipitated significant CPA in chronic nicotine infused
mice compared to saline infused mice (Fig. 23). Pre-treatment with nimodipine had no
effect on development, as mice pre-treated with nimodipine expressed significant aversion
compared to saline counterparts at a dose that did not produce significant behavioral effects
in saline-infused mice (Fig. 23).
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Figure 23. L-type VGCCs are not involved in development of mecamylamineprecipitated CPA. Mecamylamine precipitates aversion in nicotine infused mice. Pretreatment with nimodipine had no effect on the development of mecamylamineprecipitated aversion. Each point represents the mean ± SEM of 12 mice per group. *
denotes p < 0.05 vs. saline group.
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Role of CaMKII in physical and affective nicotine withdrawal

To assess the role of CaMKII in nicotine withdrawal, we began with a
pharmacological assessment using KN-93, a CaMKII inhibitor. KN93 is potent, cellpermeable, and can be dissolved in water instead of DMSO, thus avoiding side effects of
this vehicle (Gao et al., 2006). As a control, we also used the inactive analog of KN93,
KN92, which does not inhibit kinase activity. KN93, however, inhibits other kinases, such
as CaMKIV (Enslen et al., 1994); therefore, to complement our pharmacological
assessment, we tested transgenic mice in our withdrawal model. While the initial goal was
to obtain CaMKII KO mice for our studies, female HT mice either did not care for the
pups, so we could not maintain live litters, or the mice did not breed; therefore, we used
CaMKII HT mice to complement our pharmacological studies.

Nicotine-withdrawn mice were treated with vehicle or a range of KN93 doses prior
to initiation of testing. KN93 dose-dependently reduced somatic signs in nicotinewithdrawn mice (Fig. 24B). Mice treated with 0.0025 g/l showed a significant reduction
in the total number of somatic signs compared to nicotine-withdrawn mice treated with
vehicle, while somatic signs were attenuated in nicotine-withdrawn mice treated with 0.005
and 0.01 g/l KN93 (Fig. 24B). In the hyperalgesia assessment, nicotine-withdrawn
vehicle treated mice displayed a significant reduction in hot plate latency compared to
saline infused animals (Fig. 24C). Treatment with KN93 had no effect on hot plate latency
at any dose tested (Fig. 24C). Interestingly, there was a significant reduction in the amount
of time spent on the open arms of the plus maze in KN93 treated nicotine-withdrawn mice
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compared to vehicle treated nicotine withdrawn mice. The highest dose of KN93 (0.01
g/l) reduced the amount of time spent on the open arms of the plus maze compared to
vehicle treated nicotine-withdrawn mice, indicating an enhanced anxiety-related response
after KN93 treatment (Fig. 24A). There was no significant difference in the number of arm
crosses between groups, suggesting that the effect was not attributed to differences in
locomotor activity (Table 4). Nicotine-withdrawn mice treated with the inactive analog,
KN92 (0.01 g/l, i.c.v.) did not differ from their vehicle treated counterparts in any
behavioral test, and the highest dose of KN93 (0.01 g/l) was not behaviorally active in
saline infused mice.
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Figure 24. KN93 attenuates somatic signs, but enhances anxiety-related behavior.
Nicotine-withdrawn mice were treated with various doses of KN93. Results show A.
KN93 dose-dependently reduces time spent on the open arms of the plus maze,
suggesting an enhanced anxiety-related response, B. a dose-dependent attenuation of
somatic signs after KN93 treatment, but C. no effect on the hyperalgesia response
after any KN93 dose tested. The highest dose of KN93 (0.01 µg/µl) did not produce
effects in saline treated mice, indicating that the dose is not behaviorally active by
itself. The inactive analog KN92 also did not produce behavioral effects in any
withdrawal assessment. Each point represents the mean ± SEM of 10 mice per group.
* denotes p < 0.05 vs. saline groups. + denotes p < 0.05 vs. nicotine-vehicle group.
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Table 4. Average number of arm crosses in the KN93 plus maze assessment

Nicotine-withdrawn mice were treated with vehicle (veh), KN93, or the inactive
analog KN92, and the total number of crosses between open and closed arms of the
plus-maze test was counted. Numbers are presented as the total average number of
arm crosses  SEM for 8 mice per group.

Treatment group

Average number of arm crosses

Saline MP- veh

2.4 ± 0.3

Saline MP- KN93, 0.01 g/l

2.5 ± 0.6

Nicotine MP- veh

2 ± 0.5

Nicotine MP- KN93, 0.0025 g/l

2.2 ± 0.6

Nicotine MP- KN93, 0.005 g/l

2 ± 0.6

Nicotine MP- KN93, 0.01 g/l

2 ± 0.3

Nicotine MP- KN92, 0.01 g/l

2.2 ± 0.4
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Results suggested that CaMKII has opposite roles in nicotine withdrawal. While there was
an attenuation of somatic signs, we observed an enhancement of the anxiety-related
response. To further examine this response, we tested the effect of KN93 in a precipitated
nicotine withdrawal model. Mini pumps were not removed on day 14, and withdrawal
signs were measured the morning of day 15 following administration of saline,
mecamylamine, or KN93. Pretreatment with mecamylamine (2mg/kg, s.c.) or KN93 (0.01
g/l, i.c.v.) precipitated a significant decrease in the open arms of the plus maze in
chronic nicotine infused mice, indicating an anxiety-related response (Fig. 25A). While
mecamylamine also precipitated a significant increase in somatic signs and a significant
decrease in hot plate latency in nicotine-infused mice, KN93 failed to precipitate physical
nicotine withdrawal signs (Fig. 25B and 25C).
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Figure 25. KN93 precipitates anxiety-related behavior, but not physical withdrawal
signs. Withdrawal was precipitated with KN93 or mecamylamine in chronic nicotine
infused mice. Mice show A. a significant decrease in the amount of time spent on the
open arms of the plus maze, indicating an anxiety-related response after KN93 and
mecamylamine treatment. B. KN93 did not precipitate somatic signs or C. a
hyperalgesia response in chronic nicotine infused mice as seen after mecamylamine
injection. Each point represents the mean ± SEM of 8 mice per group. * denotes p<
0.05 vs. saline group. + denotes p< 0.05 vs. mecamylamine group.
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While KN93 is a selective CaMKII inhibitor, it may also inhibit other CaMKs, such
as CaMKIV (Enslen et al., 1994); therefore, to complement our pharmacological approach,
we measured withdrawal signs in nicotine infused CaMKII HT mice after mecamylamine
injection. Mecamylamine precipitated an anxiety-related response in nicotine infused
CaMKII WT mice (Fig. 26A). Interestingly, saline infused CaMKII HT mice had
significantly higher plus maze baseline activity than their WT counterparts, and
mecamylamine did not precipitate an anxiety-related response in nicotine infused HTs
(Fig. 26A). There was also no significant difference between nicotine infused HT and WT
mice in either physical measure, as mecamylamine precipitated a significant increase in
somatic signs and decrease in hot plate latency in both nicotine infused HT and WT mice
(Fig. 26B and 26C).
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Figure 26. Evaluation of the role of CaMKII in nicotine withdrawal using CaMKII
HT mice. A. Saline infused CaMKII HT mice spend significantly more time on the
open arms compared to WT mice, indicating higher baseline levels on the plus maze,
while nicotine infused CaMKII HTs did not display an anxiety response. B. Nicotine
infused CaMKII HTs and WTs both exhibit significant somatic signs after
mecamylamine injection compared to saline counterparts. C. Mecamylamine
precipitates a significant hyperalgesia response in CaMKII HT and WT mice. Each
point represents the mean ± SEM of 10 mice per group. * denotes p < 0. 05 vs. saline
groups. + denotes p < 0.05 vs. WT mice
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Role of CaMKII in affective withdrawal using the CPA model

In an attempt to generate CaMKII KO mice, male CaMKII HT mice were bred with
female WT B6129P3 hybrid mice to produce F2 CaMKII HT mice on a mixed background
for our studies; therefore, we evaluated development of CPA in the hybrid background
strain. Results show that both male and female B6129 mice develop significant
mecamylamine-precipitated aversion in the CPA model (Fig. 27). For pharmacological
CaMKII studies assessing expression of CPA, vehicle, KN93, or KN92 were administered
to mice on test day, 5 minutes prior to entering the chamber. Mecamylamine (3.5 mg/kg,
s.c.) precipitated aversion in nicotine infused mice treated with vehicle i.c.v. (Fig. 28A).
KN93 (0.01 g/l, i.c.v.), but not KN92 (0.01 g/l, i.c.v.) showed a strong trend toward
enhanced expression of mecamylamine-precipitated CPA that did not reach statistical
significance (p= 0.06). The dose of KN93 used did not produce CPA in saline infused
mice. Activity counts showed no significant between group differences in activity on test
day (Table 5), suggesting that results were not attributed to differences in chamber activity.
To complement the pharmacological approach, CaMKII HT mice were evaluated using the
CPA model. Mecamylamine precipitated significant aversion in CaMKII WT and HT mice
(Fig. 28B). There was no significant difference in activity count between groups (Table 5).
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Figure 27. Assessment of male and female B6129P3 hybrid mice in the development of
aversion in the CPA model. Nicotine infused male and female B6129P3 hybrid mice
develop aversion after mecamylamine conditioning in the CPA model. Each point
represents  S.E.M. of 12 mice per group. * denotes p<0.05 vs. the corresponding
saline group

121

Figure 28. Inhibition of CaMKII enhances the aversion associated with nicotine
withdrawal. A. Nicotine infused mice treated with KN93 on test day express a strong
trend that did not reach statistical significance toward enhanced CPA compared to
nicotine-infused mice treated with vehicle (veh) or KN92 (p=0.06). B. Mecamylamine
precipitates aversion in CaMKII WT and HT mice. There was no significant
difference in the level of aversion between WT and HT mice. Each point represents
the mean ± SEM of 12 mice per group. * denotes p < 0. 05 vs. saline groups.
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Table 5. Average activity counts in the CPA model for the CaMKII assessment
Mice were treated with vehicle (veh) or KN93 (0.01g/l) i.c.v. for the
pharmacological assessment on test day. CaMKII HT and WT mice were also
evaluated in the CPA model. Activity counts were taken for each compartment in the
CPA chamber. Numbers represent the total activity counts in drug-paired
compartment on test day for each group and are presented as the average activity
count on test day (post-conditioning day) ± S.E.M. for 12 mice.
Treatment groups

Average activity countsdrug-paired compartment

Saline MP- veh

438 ± 78.1

Saline MP-KN93

369.9 ± 34.2

Nicotine MP- veh

437 ± 97.8

Nicotine MP- KN93

455.8 ± 185.1

Nicotine MP- KN92

492.9 ± 92.9

Saline CaMKII WT

624.1 ± 45

Nicotine CaMKII WT

671 ± 50.5

Nicotine CaMKII HT

692.9 ± 36.4
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D. Discussion
The main goal of this study was to investigate the role of L-type VGCCs and
CaMKII in nicotine withdrawal. The overall results suggest that Ca2+-dependent
mechanisms are involved in physical and affective nicotine withdrawal. L-type VGCC
blockers attenuated nicotine withdrawal somatic signs and the hyperalgesia response, and
(±)BayK 8644, an L-type VGCC activator, enhanced these signs. There was no effect in
the plus maze or CPA model, suggesting a role for L-type VGCCs in physical, but not
affective withdrawal. The results of the CaMKII assessment were not as clear. The
pharmacologically CaMKII assessment revealed that KN93 dose-dependently attenuated
somatic withdrawal signs, but enhanced the affective response, suggesting differential roles
for CaMKII in somatic and affective nicotine withdrawal. Surprisingly, the transgenic data
using CaMKII HT mice suggests a role opposite that of the pharmacological assessment.

The L-type VGCC blockers, nimodipine and verapamil, attenuated the expression
of nicotine withdrawal-induced somatic signs and the hyperalgesia response, but had no
effect on the anxiety-response or CPA, suggesting a role for L-type VGCCs in physical,
but not affective nicotine withdrawal. These results are consistent with a previous study by
Biala and Weglinska (2005), which treated mice with various L-type VGCC blockers after
mecamylamine-precipitated withdrawal. Despite the complementary results, in our study,
we show that the doses used in the Biala study (5 and 10 mg/kg of each L-type VGCC
blocker), significantly depress locomotor activity in mice, which could impact data
interpretation in a withdrawal study. Further, the Biala study used the mecamylamine-
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precipitated model to evaluate expression of nicotine withdrawal. It is unknown whether
the combination of mecamylamine and L-type VGCCs produces a drug interaction that
influences the results; thus, to avoid such an interaction, the current study utilized a
spontaneous nicotine withdrawal model and L-type VGCC blocker doses that do not
impact locomotor activity. L-type VGCC blockers have been shown to inhibit α3* and α7*
nAChR-mediated currents and downstream signaling in vitro at doses typically used to
block L-type VGCC (Wheeler et al., 2006); therefore, mice were also treated with the Ltype VGCC activator, (±)Bay K8644. Nicotine-withdrawn mice treated with (±)Bay K
showed enhanced somatic signs and an enhanced hyperalgesia response. Taken together,
these results suggest an important role for L-type VGCCs in physical, but not affective
nicotine withdrawal. The results may also highlight a potential role for indirect sources of
nicotine-induced Ca2+ influx. Upon nicotine binding, there is a direct Ca2+ influx through
the Ca2+ permeable nAChR. The resulting increase in intracellular Ca2+ leads to an indirect
Ca2+ influx through VGCC as a result of membrane depolarization following nAChR
activation. Because physical signs are altered by L-type VGCC pharmacological agents,
this would suggest an important role for a mechanism of Ca2+ influx that occurs as a result
of nAChR activation.
The intracellular rise in Ca2+ through nAChRs leads to activation of CaMKII. Our
data in chapter 6 shows that acute nicotine induces increases in CaMKII activity in the
VTA and NAc. Additionally, previous data reports increases in CaMKII function in PC12
cells (MacNicol and Schulman, 1992), and in the spinal cord membrane after nicotine
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treatment (Damaj, 2000). Our pharmacological data showed that the CaMKII inhibitor
KN93 dose-dependently attenuated somatic signs, but enhanced the expression of the
anxiety-related response. There was also a trend toward enhancement of CPA expression
after KN93 treatment on test day. It is possible, in the CPA model, that a floor effect
prevented the aversive response after KN93 treatment from reaching significance. Using a
lower dose of nicotine (24 mg/kg/day instead of 36 mg/kg/day) in the CPA model for
future studies may prevent this floor effect, and provide clearer results. Overall, these
results imply that CaMKII has differential roles in somatic and affective nicotine
withdrawal. While KN93 enhanced the anxiety-related response, suggesting that CaMKII
activity is decreased after nicotine withdrawal, the antagonist attenuated somatic signs,
suggesting that CaMKII is increased after nicotine withdrawal.

In Chapters 3 and 4, we found that somatic and affective nicotine withdrawal signs
are mediated by different subtypes; thus, it is possible that the opposing roles of CaMKII in
somatic and affective withdrawal could reflect the involvement of different nAChR
subtypes. It may also be possible that the effect of KN93 is attributed to blockade of
nAChRs. KN93 has been shown to reversibly block α3* and α7* nAChR-mediated
responses in vitro (Liu and Berg, 1999). Our studies in Chapter 4 implicate the α3 nAChR
subunit in somatic nicotine withdrawal; thus, it may be possible that the attenuation of
somatic signs by KN-93 is attributed to blockade of α3-containing nAChRs. It is currently
unknown if KN93 blocks α4β2* nAChRs, which was shown in Chapter 3 to be necessary
for affective nicotine withdrawal. An electrophysiological evaluation that is beyond the
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scope of our studies would be necessary to examine α4β2* nAChR responses after KN93
treatment. Additionally, KN-93 inhibits L-type VGCCs in vitro (Gao et al., 2006).
Although KN-93 had no effect on the hyperalgesia response, as was observed with L-type
VGCC blockers, we cannot rule out the possibility that the effects on somatic signs may
involve inhibition of this target.

While the pharmacological results suggested a role for CaMKII in somatic and
affective nicotine withdrawal, the assessment using CaMKII HT mice produced different
results. There was no significant difference in somatic signs or hyperalgesia response
between nicotine and saline infused CaMKII HT and WT mice after mecamylamine
treatment, suggesting that CaMKII is not involved in the development of physical nicotine
withdrawal signs. Interestingly, there was a loss of the anxiety-related response in nicotine
infused CaMKII HT mice, as there was no decrease in time spent on the open arms after
mecamylamine treatment, and no difference between CaMKII HT and WT mice in
development of a significant CPA. The difference in affective measures may be explained
by the fact that the anxiety-related behavior and aversive responses involve two different
brain regions. Although these results suggest that CaMKII is involved in the nicotine
withdrawal-induced anxiety-related response, the transgenic mouse data suggests CaMKII
function is increased after nicotine withdrawal, which is the opposite of what was observed
in the pharmacological KN93 assessment. One possible explanation for the discrepancy
between our pharmacological and transgenic data is the lack of selectivity of KN93. KN93
blocks CaMKIV activity at an IC50 of 3 µM, a concentration only 4-fold higher than the
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IC50 value for CaMKII (0.8 µM) (Hook and Means, 2001). It is therefore possible that the
observed effects are attributed to blockade of CaMKIV activity rather than CaMKII.
However, based on diffusion studies by Matta et al. (1995), the highest dose of KN93
(0.01µg/µl) would correspond to a tissue concentration of ~ 0.7 M, which is below the
IC50 value sufficient to block CaMKIV activity. Another possibility is that the comparison
of CaMKII HT mice to the pharmacological data is unclear. The CaMKII HT mice possess
50% of the CaMKII enzyme, and it is unknown whether this enzyme level is sufficient for
expression of the alterations in nicotine withdrawal observed after KN93 treatment. It is
possible that total blockade of CaMKII activity is necessary for expression of attenuated
somatic signs and an enhanced anxiety-related response. The CaMKII HT mice were also
bred on a mixed genetic background containing B6 and B6129 hybrids. Many studies
support an important role for a genetic component to nicotine dependence; thus, we cannot
rule out the possibility that the mixed genetic background contributed to the observed
phenotype in CaMKII HT mice. Our breeding attempts found that the CaMKII HT mothers
maintained on a B6 background breed and give birth to live litters, but do not care for the
pups; thus we could not obtain CaMKII KO mice for our studies. For future studies, rather
than incorporating a mixed background strain, we will attempt to foster the pups from HTs
maintained on a B6 background with WT mice to obtain KOs.
The overall results of this study suggest that different Ca2+-dependent mechanisms
are involved in physical and affective nicotine withdrawal. L-type VGCCs mediate somatic
signs and hyperalgesia, suggesting the importance of the indirect Ca2+ influx in expression
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of physical nicotine withdrawal. The role of CaMKII in nicotine withdrawal behaviors is
more complex. Pharmacological data supports a role for CaMKII in having opposing roles
in nicotine withdrawal, as an antagonist attenuates somatic signs, yet enhances affective
signs; however, the transgenic assessment did not elucidate a role for CaMKII in nicotine
withdrawal. While the current study, taken together with previous biochemical studies,
does implicate a role for CaMKII in nicotine dependence, further work is necessary to
examine the behavioral specifics of CaMKII in nicotine withdrawal. The next chapter
focuses on exploring the relationship between changes in the function of CaMKII and
synapsin I, a CaMKII substrate necessary for neurotransmitter release after nicotine
withdrawal, and in vivo nicotine withdrawal induced behavioral alterations.
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IN VITRO CHARACTERIZATION OF MOLECULAR MECHANISMS OF
NICOTINE WITHDRAWAL: A ROLE FOR CAMKII AND SYNAPSIN I
A. Introduction
In the previous chapter, we found that Ca2+ -dependent mechanisms, specifically Ltype VGCC and CaMKII, are involved in nicotine withdrawal behaviors. While L-type
VGCC blockers attenuated physical withdrawal signs, L-type VGCC activators had the
opposite effect. Further, CaMKII inhibitors attenuated somatic signs, but enhanced
anxiety-related behavior and aversion. Since these studies showed that these Ca2+dependent mechanisms are relevant to nicotine withdrawal behaviors, we wanted to
examine the relationship between the altered behavioral response in vivo, and the in vitro
Ca2+-dependent molecular mechanisms involved in nicotine withdrawal. We focused our
studies on CaMKII and its presynaptic substrate, synapsin I.
Synapsin I is a presynaptic vesicle-associated protein that is essential for
neurotransmitter release. It is phosphorylated and activated by various protein kinases,
including PKA, MAPK, cyclin-dependent protein kinases (cdks), and CaMKII, which
phosphorylates the protein at Ser-566 and Ser-603 (De Camilli et al., 1990; Hilfiker et al.,
1999). Phosphorlyation of synapsin I by CaMKII in particular causes the protein to
dissociate from the synaptic vesicle and allows the vesicle to move to and fuse with the
plasma membrane for neurotransmitter release (De Camilli et al., 1990; Greengard et al.,
1993). Indeed, experimental data indicates an important role of synapsin I phosphorylation
by CaMKII in the regulation of neurotransmitter release. It was shown that introduction of
activated CaMKII into rat synaptosomes induces release of glutamate and noradrenaline,
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and this release is reduced by CaMKII inhibitors (Nichols et al., 1990). Further, using giant
squid synapses, it was shown that CaMKII injected presynaptically facilitates
neurotransmitter release by phosphorylation of synapsin I (Llinás et al., 1991). Synapsin I
has also been suggested as a candidate for mediating molecular processes associated with
learning and memory, such as LTP. There was an increase in synapsin I concentration in
dentate gyrus slices after induction of LTP (Lynch et al., 1994). This effect was also
observed in vivo, where LTP was induced in the dentate gyrus of rats by increasing
neuronal activity, and increases in synapsin I mRNA were detected (Hicks et al., 1997).
This is of particular relevance since it has been suggested that addiction and
learning and memory share common molecular substrates and pathways, such as
intracellular signaling cascades that lead to activation of the transcription factor CREB
(Nestler, 2001b; Nestler, 2002). In fact, like CaMKII, synapsin I activity and expression
are altered by various drugs of abuse. Synapsin I mRNA was increased in the LC,
amygdala, spinal cord, and pontine central gray area after chronic morphine treatment in
rats, suggesting that increases in synapsin I in these particular brain areas, which are
important for opiate action, may be part of the molecular mechanisms underlying opiate
tolerance and withdrawal (Matus-Leibovitch et al., 1995). Further, increased synapsin I
phosphorylation and subsequent DA release were noted after amphetamine sensitization in
rats, and after chronic amphetamine treatment in rat striatal synaptosomes (Iwata et al.,
1996; Iwata et al., 1997a; Iwata et al., 1997b). Taken together, these studies indicate a role
for CaMKII and synapsin I in mechanisms associated with neurotransmitter release in drug
dependence.
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The current study focuses on investigating the changes in CaMKII and synapsin I
function after nicotine withdrawal, and provides initial results, which suggest that the
changes in function of these two proteins are relevant to nicotine withdrawal behaviors.
Using CaMKII 32 P activity assays and western blot analysis, we measured nicotineinduced changes in CaMKII and synapsin I function in the VTA and NAc. The VTA and
NAc are part of the mesocorticolimbic drug pathway, and several studies have implicated
these two brain regions as having a role in mediating behaviors associated with nicotine
dependence. Before proceeding with our withdrawal biochemical studies, we began with
an acute nicotine assessment to determine how CaMKII and synapsin I are regulated by
nicotinic receptors in the aforementioned brain regions. Although studies suggest an
important role for nAChRs in the VTA in mediating nicotine withdrawal behaviors, the
DA terminals that project from the VTA and the presynaptic nAChRs that mediate
neurotransmitter release are located in the NAc. It is proposed that the decreased DA
release following cessation of nicotine exposure is responsible for many of the mood
disorders, craving, and anhedonia that persist in many smokers long after quitting
(Benowitz, 2008). Because decreased DA release occurs in the NAc following precipitated
and spontaneous withdrawal (Hildebrand et al., 1998; Rada et al., 2001), our chronic and
withdrawal studies focus on CaMKII and synapsin I function in the NAc. To identify these
changes in protein function, we used various nAChR antagonists to examine the acute
nicotine-induced effects of nicotine in the VTA and NAc, followed by an assessment of
nicotine’s chronic effects on CaMKII and synapsin I function in the NAc. For the
withdrawal evaluation in the NAc, we precipitated withdrawal using the β2-selective
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antagonist, DHβE, and the α7 antagonist, MLA, and complemented our pharmacological
approach using coinciding nAChR KO mice. Overall, the current assessment provides
initial targets, which aid in the elucidation of post-receptor molecular mechanisms that
may contribute to nicotine withdrawal behaviors.
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B. Methods
Animals
Male B6 mice, β2 KO mice, and α7 KO mice and respective WT littermates were obtained
and bred as described in Chapters 3 and 4.
Drugs
(-)-Nicotine hydrogen tartrate salt, mecamylamine hydrochloride, DHE, and MLA were
purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Nimodipine was purchased
from Research Biochemical International (Natick, MA). Nimodipine was dissolved in a
vehicle solution made of 5% ethyl alcohol, 5% emulphor oil, and 90% saline. Drugs were
administered at a volume of 10 ml/kg body weight. Doses are expressed as the free base of
the drug.
Chronic nicotine administration protocol
Mice were implanted with Alzet osmotic mini pumps [model 2002 (14 days) or model
2004 (28 days) Durect Corporation, Cupertino, CA] filled with saline or (-)-nicotine (36
mg/kd/day) as described in Chapter 2.
Biochemical studies
Acute studies
Mice were treated with various antagonists [mecamylamine (2 mg/kg, s.c.), DHβE (2
mg/kg, s.c.), nimodipine (10 mg/kg, i.p.)] or saline prior to nicotine (2 mg/kg, s.c.)
administration. This dose of nicotine was chosen because our studies found that there was
a significant increase in CaMKII activity in the VTA and NAc after treatment with this
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dose of nicotine (Fig. 29). The VTA and NAc were dissected 10 minutes after saline,
mecamylamine, or DHβE injection, or 15 minutes after nicotine or nimodipine injection,
and placed immediately in cold extraction buffer.

Chronic studies

Mice were chronically infused with nicotine for 14 days as described in the chronic
administration protocol. The NAc was dissected on day 14 and placed immediately in cold
extraction buffer.

Withdrawal studies
Chronic nicotine and saline infused mice were injected with DHβE (2 mg/kg, s.c.) or MLA
(10mg/kg, s.c.) to precipitate withdrawal. nAChR KO mice were injected with
mecamylamine (2 mg/kg, s.c.). The NAc was dissected 10 minutes after antagonist
injection. Brain sections were placed in cold extraction buffer immediately after dissection.
CaMKII 32 P activity assay

CaMKII activity was measured using an assay kit (Upstate biotechnology, Lake Placid,
NY). Following experimental treatment, brain tissues were homogenized in Ca2+-free Tris
buffer that contains 1 mM PMSF.

Homogenates were normalized for protein

concentration. Samples were centrifuged in order to separate the membrane and the cytosol
containing-kinase. The activity of CaMKII in the membrane portion was measured.
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Standard phosphorylation reaction solutions contained 70 g protein, 10 mM MgCl2, 1
Ci of [32P]ATP, 10 mM Pipearzine-N,N’-bis(2-ethanesulfonic acid) (PIPES) (pH 7.4), 5
M CaCl2 and 5 g calmodulin. Standard reactions were performed in a shaking water
bath at 30°C. Ca2+-dependent calmodulin-protein kinase II activity was determined using
the following calculations: [(count-specific binding) x (correcting factor)]/[(specific
radioactivity)x time (10 min)]. Activity was expressed as the number of pmol

32

P

incorporated into calmodulin protein kinase II substrate peptide/min/mg of protein in the
presence (dependent reaction) or absence (independent reaction).

Western blot assay
VTA and NAc sections were homogenized in extraction buffer containing 50 mM Tris, 1
% SDS, 1 mM PMSF, 1 mM EDTA, 5 mM EGTA, 1 mM Na+ orthovanadate, 20 µg/ml
leupeptin, 10 µg/ml aprotinin, and 1 µM okadaic acid . Protein concentrations were
determined using the Bradford assay and 20 g of protein were incubated with sample
buffer and heated for 5 minutes at 95C.

Samples were then separated by SDS-

polyacrylamide gel electrophoresis on a 10% TRIS-HCL gel and subjected to
immunoblotting. α-CaMKII (1:1000; Sigma, St. Louis, MO), α-pCaMKII (1:10000; Fisher
Scientific, USA), Synapsin I (1:2000; Chemicon International, Inc, USA), or pSynapsin I
Ser 603 (an antibody specific for the site phosphorylated by CaMKII) (1:2000; Sigma, St.
Louis, MO) primary antibodies and -tubulin antibody (1:5000; Upstate, Temecula, CA)
were incubated overnight at 4C. Secondary antibodies (1:5000; LiCor Biosciences, Inc.,
Lincoln, NE) were incubated for 1 hour at room temperature. Bound antibody was detected
using the LiCor Odyssey Infrared Imaging System (LiCor Biosciences, Inc., Lincoln, NE).
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α-CaMKII bands were detected at 50 kDa, α-pCaMK II bands were detected at 52 kDa,
Synapsin I bands were detected at 80 kDa, pSynapsin I Ser 603 bands were detected at 78
kDa, and -tubulin bands were detected at 55 kDa.
Staistical analysis

For all data, statistical analyses were performed using StatView ® (SAS, Cary, NC, USA).
Data were analyzed with one-way ANOVAs with treatment as the between subject factor
or two-way ANOVAs with treatment and genotype as between subject factors. Significant
results were further analyzed using the Neuman-Keuls post-hoc test. p values of less than
0.05 were considered significant.
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C. Results
Effect of acute nicotine administration on CaMKII activity in the VTA and NAc
Before starting our withdrawal assessment, we first wanted to determine how CaMKII is
regulated after acute nicotine, as acute drug responses are an important part of the initial
cascade that occurs in response to drug exposure. CaMKII activity was measured in the
VTA and NAc after acute systemic nicotine administration (2 mg/kg, s.c.). Results show
that acute nicotine induces increases in CaMKII activity in the VTA (Fig. 29A) and NAc
(Fig. 29B).
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Figure 29. Acute nicotine induces increases in CaMKII activity in the VTA and NAc.
Mice were treated with an acute systemic injection of nicotine (2 mg/kg, s.c.), and
brain sections were dissected and prepared for analysis using a CaMKII 32 P activity
assay. Activity was expressed as the number of pmol 32P incorporated into calmodulin
protein kinase II substrate peptide/min/mg of protein in the presence (dependent) or
absence (independent) of calcium. Each point represents the mean ± S.E.M. of 5 mice
per group. * denotes p < 0.05 vs. saline group
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Next, we wanted to determine if the nicotine-induced increase in CaMKII activity was
mediated through nAChRs, and examine the involvement of L-type VGCCs, which may
suggest a role for indirect sources of nicotine-induced Ca2+ influx. Mice were treated with
the non-selective nAChR antagonist, mecamylamine (2 mg/kg, s.c.), or the L-type VGCC
blocker, nimodipine (10 mg/kg, i.p.), 10 or 15 minutes prior to nicotine administration.
Mecamylamine and nimodipine significantly blocked the acute nicotine-induced increase
in CaMKII activity in the VTA (Fig. 30), suggesting that the nicotine-induced increase in
CaMKII activity is mediated directly through nAChRs and involves indirect sources of
nicotine-induced Ca2+ influx through L-type VGCC channels. The antagonist doses used
did not produce a significant effect alone, as there was no significant difference in activity
between naïve antagonist treated mice and saline treated mice (Fig. 30).
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Figure 30. Acute nicotine induces an increase in CaMKII activity in the VTA that is
mediated directly through nAChRs and indirectly through L-type VGCCs. Mice were
treated with mecamylamine (2 mg/kg, s.c.) or nimodipine (10 mg/kg, i.p.) 10 or 15
minutes prior to an acute systemic injection of nicotine (2 mg/kg, s.c.) Brain sections
were dissected and prepared for analysis using a CaMKII 32 P activity assay. Activity
was calculated as the number of pmol 32P incorporated into calmodulin protein
kinase II substrate peptide/min/mg of protein in the presence (dependent) or absence
(independent) of Ca2+, and expressed as % deviation from baseline response. Each
point represents the mean ± S.E.M. of 5 mice per group. * denotes p < 0.05 vs. saline,
mec, and mec + nic groups
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Synapsin I activity in the VTA and NAc after acute nicotine administration
Studies in the lab revealed that the acute nicotine induced increase in CaMKII activity in
the VTA and NAc was significantly blocked by DHβE, but not MLA (Walters and Damaj,
2008, submitted). Further, the acute nicotine-induced increase in CaMKII activity was
present in α7, but not β2 KO mice (Walters and Damaj, 2008, submitted). These results
suggest that the acute nicotine-induced increases in CaMKII activity are mediated by β2containing, and not α7, nAChRs. Western blot analysis also revealed that the total CaMKII
protein level was unchanged after acute nicotine treatment (Walters and Damaj, 2008,
submitted). Synapsin I is a substrate of CaMKII that is phosphorylated by the kinase at
Ser-566 and Ser-603; thus, we wanted to see if synapsin I plays a role in the acute
pharmacological effects of nicotine. Western blot analysis revealed a significant increase in
pSynapsin I Ser 603 (p603) in the VTA (Fig. 31) and NAc (Fig. 32) after acute nicotine
administration (2 mg/kg, s.c.). The acute nicotine-induced increases in p603 in the VTA
(Fig. 31) and NAc (Fig. 32) were significantly blocked by mecamylamine, suggesting a
nAChR-mediated effect. To test the specificity of this effect, we treated mice with the β2selective antagonist, DHβE (2 mg/kg, s.c.) 10 minutes before nicotine administration.
Similar to what was observed with pCaMKII activity, results show that the acute nicotineinduced increase in p603 in the VTA (Fig. 33) and NAc (Fig. 34) were significantly
blocked by DHβE at doses that are not biochemically active alone. There was no change in
the total synapsin I protein level in either the VTA or NAc with any drug treatment (Figs.
31-34).
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VTA

Figure 31. Acute nicotine-induced increases in pSynapsin I Ser 603 (p603) in the VTA
are blocked by mecamylamine. The dose of mecamylamine (mec, 2 mg/kg, s.c.) used
was not active by itself. Results were calculated as the ratio of p603 or synapsin (SI)
and α-tubulin and expressed as the % deviation from the baseline response. Each
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline,
mec, and mec + nic groups
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NAc

Figure 32. Acute nicotine-induced increases in pSynapsin I Ser 603 (p603) in the NAc
are blocked by mecamylamine. The dose of mecamylamine (mec, 2 mg/kg, s.c.) used
was not active by itself. Results were calculated as the ratio of p603 or synapsin (SI)
and α-tubulin and expressed as the % deviation from the baseline response. Each
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline,
mec, and mec + nic groups
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VTA

Figure 33. Acute nicotine-induced increases in pSynapsin I Ser 603 (p603) in the VTA
are blocked by the β2-selective antagonist, DHβE. The dose of DHβE (2 mg/kg, s.c.)
used was not active by itself. Results were calculated as the ratio of p603 or synapsin
(SI) and α-tubulin and expressed as the % deviation from the baseline response. Each
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline,
DHβE, and DHβE + nic groups
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NAc

Figure 34. Acute nicotine-induced increases in pSynapsin I Ser 603 (p603) in the NAc
are blocked by the β2-selective antagonist, DHβE. The dose of DHβE (2 mg/kg, s.c.)
used was not active by itself. Results were calculated as the ratio of p603 or synapsin
(SI) and α-tubulin and expressed as the % deviation from the baseline response. Each
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline,
DHβE, and DHβE + nic groups
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Synapsin I activity in the NAc after chronic nicotine exposure
In order to understand the mechanisms involved in nicotine withdrawal, we first needed to
examine changes in activity after chronic nicotine exposure. Mice were chronically infused
with nicotine for 14 days. On day 14, the NAc was dissected and prepared for western blot
analysis. Results show that chronic nicotine induces a significant increase in p603
expression compared to chronically infused saline controls (Fig. 35), suggesting that
tolerance does not develop to the acute nicotine-induced increase in p603.

147

Figure 35. Chronic nicotine induces an increase in pSynapsin I Ser 603 (p603) activity
in the NAc. After 14 days of chronic nicotine exposure, there was a significant
increase in p603 expression in the NAc compared to chronic saline controls. Each
point represents the mean ± S.E.M. of 4 mice per group. * denotes p < 0.05 vs. saline
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CaMKII and Synapsin I activity in the NAc after nicotine withdrawal
Stimulation of nAChRs in the VTA leads to alterations in neurotransmitter release in the
NAc. Our data show that acute nicotine increases activity of important markers of
neurotransmitter release (CaMKII and synapsin I). Further, after nicotine withdrawal,
decreased DA release in the NAc was reported (Hildebrand et al., 1998; Rada et al., 2001),
and it has been proposed that this deficient DA release in the NAc contributes to the mood
disorders and overall negative affective state that accompanies nicotine withdrawal
(Benowitz, 2008); therefore, we focused on changes in CaMKII and synapsin I function in
the NAc after nicotine withdrawal. Based on the decreased DA release observed in the
NAc after nicotine withdrawal, we hypothesized that there would be a decrease in CaMKII
and synapsin I activity in the NAc after nicotine withdrawal. To assess changes in protein
function, mice chronically infused with nicotine or saline for 14 days were treated with the
β2-selective antagonist, DHβE (2 mg/kg, s.c.), or the α7 antagonist, MLA (10 mg/kg, s.c.),
on the morning of day 15, and brain sections were dissected 10 minutes after injection. A
spontaneous withdrawal assessment was also conducted to complement our precipitated
biochemical results. Results show that DHβE (2 mg/kg, s.c.) at a dose that precipitates
significant aversion in mice (Chapter 2) induced a significant decrease in pCaMKII and
CaMKII total protein levels in the NAc (Fig. 36). Additionally, p603 and synapsin I total
protein levels in the NAc of chronic nicotine infused mice were decreased after treatment
with DHE, coinciding with the decreased CaMKII function (Fig. 37). Conversely, MLA
did not precipitate a change in pCaMKII, CaMKII (Fig. 38), p603 or synapsin I (Fig. 39)
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function in the NAc, suggesting that α7 nAChRs are not involved in nicotine-withdrawal
induced changes in this brain region.
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Figure 36. DHβE significantly reduces pCaMKII and CaMKII activity and level in
the NAc after chronic nicotine administration. Mice chronically infused with nicotine
for 14 days were injected with DHβE ( 2 mg/kg, s.c.) on the morning of day 15 to
precipitate withdrawal. Each point represents the mean ± S.E.M. of 5 mice per group.
* denotes p < 0.05 vs. saline group
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Figure 37. DHβE significantly reduces pSynapsin I Ser 603 (p603) and Synapsin I (SI)
activity and level in the NAc after chronic nicotine administration. Mice chronically
infused with nicotine for 14 days were injected with DHβE ( 2 mg/kg, s.c.) on the
morning of day 15 to precipitate withdrawal. Each point represents the mean ±
S.E.M. of 5 mice per group. *denotes p < 0.05 vs. saline group
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Figure 38. MLA does not precipitate a change in pCaMKII or CaMKII activity or
level in the NAc. Mice chronically infused with nicotine for 14 days were injected with
MLA (10 mg/kg, s.c.) on the morning of day 15 to precipitate withdrawal. There was
no significant difference between saline and nicotine infused mice after MLA
treatment. Each point represents the mean ± S.E.M. of 5 mice per group.
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Figure 39. MLA does not precipitate a change in pSynapsin I Ser 603 (p603) or
synapsin I (SI) activity or level in the NAc. Mice chronically infused with nicotine for
14 days were injected with MLA (10 mg/kg, s.c.) on the morning of day 15 to
precipitate withdrawal. There was no significant difference between saline and
nicotine infused mice after MLA treatment. Each point represents the mean ± S.E.M.
of 5 mice per group.
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To complement our pharmacological approach using DHβE and MLA, we examined
protein function in β2 and α7 KO mice. β2 and α7 KO and WT mice were chronically
infused with saline or nicotine for 14 days. On day 15, the mice were treated with
mecamylamine (2 mg/kg, s.c.), and pCaMKII, CaMKII, p603, and synapsin I were
measured in the NAc. There was a significant decrease in pCaMKII activity in chronic
nicotine infused WT mice after mecamylamine treatment compared to saline counterparts;
however, the decrease in pCaMKII activity was absent in β2 KO mice (Fig. 40).
Additionally, the decrease in p603 activity in WT mice that was also absent in β2 KO mice
(Fig. 41). Interestingly, there was no change in total CaMKII (Fig. 40) or synapsin I
protein level (Fig. 41) in WT mice after mecamylamine treatment in any group tested.
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Figure 40. Assessment of pCaMKII and CaMKII activity and level in β2 KO mice. β2
KO and WT mice chronically infused with nicotine for 14 days were injected with
mecamylamine (mec, 2 mg/kg s.c.) on the morning of day 15 to precipitate
withdrawal. There was a significant decrease in pCaMKII activity in WT mice that
was not present in β2 KO mice. Interestingly, there was no change in total CaMKII
protein level in any group tested after mecamylamine treatment. Each point
represents the mean ± S.E.M. of 4-6 mice per group. * denotes p < 0.05 vs. saline and
β2 KO groups
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Figure 41. Assessment of pSynapsin I Ser 603 (p603) and synapsin I (SI) activity and
level in β2 KO mice. β2 KO and WT mice chronically infused with nicotine for 14
days were injected with mecamylamine (mec, 2 mg/kg s.c.) on the morning of day 15
to precipitate withdrawal. There was a significant decrease in p603 activity in WT
mice that was not present in β2 KO mice. Interestingly, there was no change in total
synapsin I protein level in any group tested after mecamylamine treatment. Each
point represents the mean ± S.E.M. of 4-6 mice per group. * denotes p < 0.05 vs.
saline and β2 KO groups
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MLA, an α7 antagonist, did not precipitate a decrease in CaMKII or synapsin I function,
suggesting that α7 nAChRs are not involved in the nicotine withdrawal-induced change in
CaMKII or synapsin I function. To complement the results of this pharmacological study,
we measured protein levels in nicotine-dependent α7 nAChR WT and KO mice after
mecamylamine treatment. The assessment in α7 KO mice revealed a significant decrease in
pCaMKII (Fig. 42) and p603 activity (Fig. 43) in both nicotine-infused α7 WT and KO
mice after mecamylamine treatment. There was no change in the total protein level for
either CaMKII or synapsin I in any group tested (Figs. 42 and 43).
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Figure 42. Assessment of pCaMKII and CaMKII function in α7 KO mice. α7 KO and
WT mice chronically infused with nicotine for 14 days were injected with
mecamylamine (mec, 2 mg/kg s.c.) on the morning of day 15 to precipitate
withdrawal. There was a significant decrease in pCaKII activity in α7 KO and WT
mice. Interestingly, there was no change in total CaMKII protein level in any group
tested after mecamylamine treatment. Each point represents the mean ± S.E.M. of 4-6
mice per group. * denotes p < 0.05 vs. saline groups
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Figure 43. Assessment of pSynapsin I Ser 603 (p603) and synapsin I function in α7
KO mice. α7 KO and WT mice chronically infused with nicotine for 14 days were
injected with mecamylamine (mec, 2 mg/kg s.c.) on the morning of day 15 to
precipitate withdrawal. There was a significant decrease in p603 activity in α7 KO
and WT mice with no change in total synapsin I protein level in any group tested
after mecamylamine treatment. Each point represents the mean ± S.E.M. of 4-6 mice
per group. * denotes p < 0.05 vs. saline groups
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D. Discussion
The goal of the biochemical studies in this chapter was to examine the relationship
between in vivo behavioral modifications and molecular mechanisms that mediate nicotine
withdrawal behaviors. The current studies suggest that β2-containing nAChRs, but not α7
nAChRs, are crucial in mediating the decreases in CaMKII and synapsin I activity in the
NAc after nicotine withdrawal. DHβE blocked the increase in synapsin I activity in the VTA
and NAc. Additionally, DHβE, but not MLA, precipitated a significant decrease in CaMKII
and synapsin I activity and protein level. These results were complemented using β2 and α7
nAChR KO, where it was shown that mecamylamine precipitated a significant decrease in
CaMKII and synapsin I function in WT and α7 KO mice, but the decrease was not present in
β2 KO mice after 14 days of chronic nicotine infusion.

We began our studies by determining the acute effect of nicotine on CaMKII and
synpasin I function, as this represents the initial cascade of events that occurs after acute
nicotine exposure. Our studies revealed that acute systemic nicotine induced increases in
CaMKII activity in the VTA and NAc. The increased activity was significantly blocked by
the non-selective nAChR antagonist, mecamylamine, as well as by the L-type VGCC
blocker nimodipine in the VTA. While these results indicate that the acute nicotine-induced
increase in CaMKII activity is mediated directly through nAChR, it also suggests an
important role for L-type VGCC, which may suggest the importance of indirect sources of
Ca2+ influx in nicotine induced CaMKII activation. It must be noted that in vitro studies
show that L-type VGCC blockers can block nAChR signaling at doses typically used to
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block L-type VGCCs (Wheeler et al., 2006); thus, these results should be interpreted with
caution, as they may reflect actions at targets other than L-type VGCC.

We also examined the CaMKII substrate, synapsin I, a vesicle associated protein
essential for neurotransmitter release, after acute nicotine. As seen with CaMKII, there was
a significant increase in synapsin I activity, but not total protein level after acute nicotine
treatment. This nicotine-induced increase in activity was significantly blocked by
mecamylamine, and by DHβE in the VTA and NAc at doses used to precipitate affective
nicotine withdrawal behaviors (Chapter 2 and 3). Previous studies from our lab also show
that acute nicotine-induced increases in CaMKII in the VTA and NAc are mediated by β2*,
but not α7* nAChRs (Walters et al., 2008, submitted). Taken together, these results imply
that acute nicotine-induced increases in CaMKII and synapsin I activity are mediated by β2containing nAChRs in the VTA and NAc.

Our chronic nicotine assessment revealed a significant increase in p603 expression
after 14 days of chronic nicotine exposure. These results suggest that tolerance does not
develop to the acute nicotine-induced increases in p603. In addition to the acute and chronic
nicotine studies, we conducted a withdrawal assessment, which suggests an important role
for β2*, but not α7* nAChRs in nicotine withdrawal. Although studies suggest an important
role for nAChRs in the VTA in mediating nicotine withdrawal behaviors, the DA terminals
that project from the VTA and the presynaptic nAChRs that mediate neurotransmitter
release are located in the NAc; thus, our withdrawal studies focused on the NAc, where the
actual release of neurotransmitter occurs. While MLA did not precipitate any change in
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CaMKII or synpasin I function in the NAc, DHβE precipitated a significant decrease in
CaMKII and synapsin I activity and protein level at doses that precipitated aversion in our
CPA model (Chapter 2). To complement these pharmacological studies, we measured
CaMKII and synapsin I function in the NAc from β2 and α7 KO mice and corresponding
WT littermates after treatment with mecamylamine (2 mg/kg, s.c.) at a dose that precipitated
withdrawal signs in nicotine-dependent mice (Chapters 2 and 3; Damaj et al., 2003). There
was a significant decrease in CaMKII and synapsin I activity after treatment with
mecamylamine in chronic nicotine infused WT mice; however, this decrease was absent in
β2 KO mice. Conversely, a decrease in CaMKII and synapsin I activity was observed in α7
KO mice after mecamylamine precipitated withdrawal. While DHβE precipitated a
significant decrease in CaMKII and synapsin I total protein level, there was no change in the
level of either protein after mecamylamine treatment. The phosphorylated, or activated, state
of the protein is an indication of protein activity, while the protein level reflects the total
expression of protein in the system. Both DHβE and mecamylamine decreased protein
activity; however, the differences in protein level are difficult to interpret. Mecamylamine in
general is a non-selective nAChR antagonist (Papke et al., 2001), and has less selectivity for
α4β2* nAChRs than DHβE; however, we are unable to explain the differences in total
protein level that occurred after treatment with the different antagonists. Regardless, the
results still support our data suggesting a role for β2* nAChRs in nicotine withdrawalinduced decreases in CaMKII and synapsin I activity. Because our chronic nicotine
assessment revealed a significant increase in p603 expression, this rules against the
possibility that our withdrawal data are the result of chronic nicotine exposure rather than
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withdrawal. Although an examination of CaMKII was not provided, because p603 is the site
specifically phosphorylated by CaMKII, we expect that there is also an increase in pCaMKII
expression following chronic nicotine exposure. Together, our biochemical studies using
pharmacological agents and the complementary transgenic mouse approach suggest that β2containing, but not α7* nAChRs are involved in nicotine induced changes in CaMKII and
synapsin I function in the VTA and NAc after acute nicotine, and in the NAc after nicotine
withdrawal.
The α6β2* and α4α6β2* nAChR subtypes are located on presynaptic DA and
GABAergic neurons in the VTA and are involved in nicotine-stimulated DA release in the
striatum (Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 2005). Many studies
support the vital role of the neurotransmitter DA in nicotine dependence. The nicotine
induced increase in VTA DA neuron firing rate (Grenhoff et al., 1986), and subsequent DA
release in the NAc is a process thought to underlie the addictive properties of nicotine
(Ponteiri et al., 1996). Alternatively, studies report decreased DA neuronal activity in the
VTA (Liu and Jin, 2004) and decreased DA output in the NAc after nicotine withdrawal
(Hildebrand et al., 1998; Rada et al., 2001). Indeed, it is hypothesized that this relative
deficiency in DA release following cessation of nicotine exposure accounts for many of the
mood disorders, craving, and anhedonia that persist in many smokers long after quitting
(Benowitz, 2008).

Because CaMKII and synapsin I are essential for neurotransmitter

release, these two proteins are sufficient biochemical markers of neurotransmitter release.
The decrease in CaMKII and synapsin I function in the NAc after nicotine withdrawal may
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correspond to the decrease in DA release observed in the NAc after nicotine withdrawal.
Our behavioral pharmacological assessment in Chapter 5 revealed that the CaMKII
inhibitor, KN-93, significantly enhanced the anxiety-related response and showed a strong
trend for enhancement of nicotine CPA, also suggesting that CaMKII is decreased after
nicotine withdrawal. Further, our behavioral studies in Chapters 2 and 3 revealed a role for
β2-containing receptors, specifically α6β2* and/or α4α6β2* nAChR subtypes in affective
nicotine withdrawal behaviors. Although with the current results, we cannot make a direct
correlation between our behavioral and biochemical studies, these initial results imply that
β2-containing nAChRs, which are critical in affective nicotine withdrawal, also mediate the
nicotine withdrawal induced decreases in CaMKII and synapsin I function in the NAc.
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GENERAL DISCUSSION

A. Rationale and Summary of Overall Hypothesis
In the United States, tobacco dependence is the leading cause of preventable
mortality.

While the positive rewarding and reinforcing effects of nicotine motivate

continued smoking behavior (Kenny and Markou, 2001), many studies suggest that
avoidance of the negative emotional state produced by nicotine withdrawal represents a
motivational component that promotes continued tobacco use and relapse after smoking
cessation. Indeed, the most commonly reported reason for relapsing into smoking during
quit attempts is the desire to relieve the discomforts of smoking withdrawal (US
Department of Health and Human Sciences, 1988). Although there are smoking cessation
therapies available, the success rate is modest, as only 20-25% of smokers remain abstinent
after one year (Gonzales et al., 2006). Because smoking is such a widespread health
problem, it is important to understand the molecular and behavioral mechanisms of
nicotine withdrawal to generate more effective smoking cessation therapies.
Despite the important contribution of withdrawal symptoms to the maintenance of
tobacco use, few studies assess the negative motivational component associated with
nicotine withdrawal. Currently, due to the low selectivity of most available nAChR
antagonists, the identity of nAChR subtypes involved in nicotine withdrawal remains
unclear. Furthermore, studies which address the signaling processes underlying nicotine
withdrawal are lacking; therefore, our studies focused on elucidating the receptor and postreceptor mediated mechanisms involved in nicotine withdrawal. To address this aim, our
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studies focused on three areas of research. First, we identified the major nAChR subtypes
involved in affective and physical nicotine withdrawal behaviors. Because of the
importance of affective signs, we measured two different affective nicotine withdrawal
behaviors; anxiety-related behavior and aversion. Because these signs involve different
brain regions, with the dorsal raphé nucleus being crucial in mediating nicotine’s effects on
anxiety (Cheeta et al., 2001), and the basolateral amygdala being involved in aversion
(Zanoveli et al., 2007), it is possible that they may involve different nAChR subtypes.
Second, we evaluated the role of important Ca2+-dependent mechanisms, such as L-type
VGCCs and CaMKII, in nicotine withdrawal behaviors. Third, we conducted initial
biochemical studies to aid in elucidating the relationship between the altered behavioral
responses in vivo and the in vitro receptor-mediated Ca2+-dependent mechanisms involved
in nicotine withdrawal. Overall, we hypothesized that major nAChR subtypes have
differential roles in the nicotine withdrawal syndrome. Specifically, the α4α6β2* nAChR
subtype is involved in affective nicotine withdrawal behaviors. This subtype also mediates
nicotine-withdrawal induced decreases in CaMKII function in the NAc. The decrease in
CaMKII function leads to decreased phosphorylation of CaMKII substrates, specifically
synapsin I, a protein essential for regulation of neurotransmitter release.
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B. Nicotinic receptor subtypes have differential roles in nicotine withdrawal
The α4α6β2* nAChR subtype is specifically involved in affective nicotine withdrawal
Using spontaneous, precipitated, and CPA models adapted for mouse studies, we
showed that major nAChR subtypes have differential roles in nicotine withdrawal. We
began our study with the α4β2* nAChR subtype, a main nAChR subtype in the brain that
is located on presynaptic dopaminergic and GABAergic neurons in the mesocorticolimbic
drug pathway. In β2 KO mice, there was a loss of anxiety-related behavior and aversion in
the CPA model compared to WT mice, but normal withdrawal-induced somatic signs and
hyperalgesia (Figures 8, 9, and 12). These results were complemented using the β2selective antagonist, DHβE, which precipitated significant aversion in the CPA model (Fig.
3). Previous studies from our lab also showed that DHβE precipitated anxiety-related
behavior, but not somatic signs or hyperalgesia in chronic nicotine infused mice (Damaj et
al., 2003). Immunoprecipitation and ligand-binding studies have also shown that the α5
and 6 subunits are coexpressed with 4 and 2 subunits on midbrain dopaminergic
neurons and terminals (Le Novère et al., 1996; Klink et al., 2001; Champtiaux et al., 2002;
Zoli et al., 2002); therefore, we also evaluated the role of α5 and α6 nAChR subunits in
nicotine

withdrawal.

Central

administration

of

the

α6-selective

antagonist,

MII[H9A;L15A], dose-dependently blocked the expression of the anxiety-related response
and CPA in nicotine withdrawn mice, but had no effect on somatic signs or the
hyperalgesia response (Figures 11 and 13). Additionally, the α6/α3β2* selective
antagonist, MII, blocked the expression of anxiety-related behavior (Fig. 16), but not CPA
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(Fig. 19), suggesting a role for the α6β2* subtype in the anxiety-related response.
Conversely, α5 KO mice displayed significant anxiety-related behavior, CPA, and
hyperalgesia, but a reduction in total somatic signs (Figures 10 and 12). Although α6β2*,
α4α6β2*, and α4α5β2* subtypes are found in the mesocorticolimbic drug pathway and are
involved in striatal DA release (Champtiaux et al., 2003; Salminen et al., 2004; Lai et al.,
2005), the results suggest that the α62* and/or α4α6β2*, but not the α4α5β2* nAChR
subtype, are specifically involved in affective nicotine withdrawal behaviors. Together
with previous studies, these data suggest that α62* and/ or α4α6β2* nAChR subtypes are
critical for affective nicotine withdrawal.
The α7 subtype is involved in the nicotine withdrawal-induced hyperalgesia response
The homomeric 7 nAChR is also a major subtype found on neurons in the
mesocorticolimbic drug pathway and has been implicated in physical withdrawal
behaviors. In fact, in our studies, mice null for the α7 subunit displayed a loss of nicotine
withdrawal-induced hyperalgesia, but significant anxiety-related behavior, CPA, and
somatic signs (Figures 14, 15 and 18). A previous 7 nAChR KO study from our
laboratory using the oral route of chronic nicotine administration and the spontaneous
nicotine withdrawal model produced similar findings, showing a loss of hyperalgesia in α7
KO mice, but otherwise normal somatic signs and anxiety-related response (Grabus et al.,
2005). We also found that MLA, an α7 antagonist, did not precipitate aversion in the CPA
model in chronic nicotine infused mice, thus, complementing our results using transgenic
animals (Fig. 3). MLA was also shown to precipitate a significant hyperalgesia response in
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nicotine dependent mice (Damaj et al., 2003). Overall, these results implicate a role for α7
nAChRs in some aspects of physical withdrawal, but not affective nicotine withdrawal.
The data also suggests that our two physical measures of nicotine withdrawal (somatic
signs and hyperalgesia), are mediated by different nAChR subtype populations. Although
7 KO mice showed a loss of the hyperalgesia response, somatic signs were still present.
Hyperalgesia is measured as a physical sign in the mouse; however, studies have suggested
that spinal and supraspinal nAChR populations mediate the hyperalgesia response
(Schmidt et al., 2001; Damaj et al., 2002). Our hyperalgesia measure was conducted using
the hot plate, which measures supraspinal mechanisms; thus, we cannot rule out the
possibility that the nicotine withdrawal induced hyperalgesia response is mediated by
neuronal 7 nAChRs, which do not contribute to the centrally mediated component of
somatic nicotine withdrawal. It is also noted that MLA precipitated mild somatic signs of
withdrawal in WT mice (Damaj et al., 2003). MLA can antagonize 6, 3, and 3 nAChR
subunits at doses typically used to block 7 nAChRs (Mogg et al., 2002). Indeed, it was
revealed that MLA precipitated significant somatic signs in nicotine dependent α7 KO
mice (Salas et al., 2007). Our studies using α3 nAChR antagonists revealed a role for α3containing nAChRs in somatic nicotine withdrawal signs, as will be discussed in the next
section. Conversely, α6-containing receptors are not involved in somatic nicotine
withdrawal signs; thus, it is possible that the observed behavioral responses were attributed
to effects on other nAChR subunits, such as the α3 and/or β3 subunits.
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α3-containing nAChRs are involved in physical aspects of nicotine withdrawal
The α3 subunit is coexpressed with α5 and β4 nAChRs in the peripheral ganglia,
MHb and IPN (Wada et al., 1990; Zoli et al., 1995; Quick et al., 1999; Whiteaker et al.,
2002). The α3 nAChR subunit is also expressed in brain areas that have been implicated as
having a role in nicotine dependence behaviors, and can coassemble with β2 nAChRs to
form functional receptors on DA neurons and terminals (Le Novère and Changeux, 1995;
Le Novère et al., 1996; Klink et al., 2001). It was shown that 4 KO mice do not display
somatic signs after nicotine withdrawal (Salas et al., 2004), suggesting a role for the β4
subunit in somatic nicotine withdrawal. Additionally, our data suggested a role for the α5
subunit in somatic nicotine withdrawal, as α5 KO mice displayed a significant reduction in
total somatic signs. It was also shown recently that a common haplotype in the
CHRNA5/CHRNA3/CHRNB4 gene cluster, which codes for the α5, α3, and β4 subunits
respectively, predisposes to nicotine dependence (Berrettini et al., 2008); therefore, we
identified a role for α3-containing receptors in nicotine withdrawal behaviors using MII
and AuIB, selective α3β2* and α3β4* nAChR subtype antagonists respectively.
AuIB dose-dependently attenuated somatic nicotine withdrawal signs, but had no
effect on expression of the anxiety-related response, hyperalgesia, or CPA (Figures 17 and
19), suggesting a role for the α3β4* nAChRs in somatic, but not affective nicotine
withdrawal. Results also show that the α3β2* selective antagonist, MII, dose-dependently
blocked expression of the anxiety-related response and attenuated somatic signs (Fig. 16).
MII had no effect on the hyperalgesia response at any dose tested (Fig. 16). Surprisingly,
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MII did not block expression of CPA, even after doubling the dose used to block the
anxiety-related response (Fig. 19). Taken together, these results also stress and important
role for β2*, but not β4* nAChRs, in affective nicotine withdrawal. Studies suggest that
MII may not discriminate well between α3 and α6 nAChRs (Kuryatov et al., 2000), as the
α6 and α3 nAChR subunits share considerable sequence homology (Le Novère and
Changeux, 1995). The MII analog and selective α6 antagonist, MII[H9A;L15A],
effectively discriminates between α3 and α6 nAChR subunits (McIntosh et al., 2004). Our
results from Chapter 3 showed a role for α6-containing nAChRs in nicotine CPA and the
anxiety-related response, but not physical withdrawal, suggesting that α6-containing
nAChRs, and not α3β2* nAChRs, are important for nicotine CPA, while both α6β2* and
α3β2* nAChRs are involved in the withdrawal-induced anxiety-related response. Indeed,
anxiety-related behavior and CPA are mediated by two different brain regions; the dorsal
raphé nucleus (Cheeta et al., 2001) and the basolateral amygdala (Zanoveli et al., 2007)
respectively; thus, it is possible that the two behaviors are mediated by different subtypes.
The dorsal raphé nucleus also receives innervations from the MHb (Morris et al., 1999), a
brain area rich in α3 nAChR expression (Quick et al., 1999); thus, the MHb may also be
involved in anxiety-related behaviors. Conversley, because MII does discriminate well
between α6 and α3 nAChR subunits, we cannot rule out the possibility that the observed
MII effect in the plus maze test are attributed to actions at α6β2* nAChRs rather than
α3β2*.
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These results also implicate the importance of receptor subtype composition. While
our data showed that β2-containing nAChRs were not involved in somatic nicotine
withdrawal, because MII attenuated somatic withdrawal signs, it cannot be ruled out that
the α3β2* subtype is involved in somatic nicotine withdrawal signs. Additionally, it is
noted that α3β2* and α3β4* nAChRs are involved in somatic signs, but not the
hyperalgesia response, whereas the α7 subtype was shown to be involved in the
hyperalgesia response, but not somatic signs. These results are consistent with our proposal
that the physical withdrawal signs measured in our model (somatic signs and hyperalgesia)
are mediated by different nAChR subtypes. It is also possible that the brain regions in
which these nAChR subtypes are expressed can influence their effects.
The α5, α3, and β4 nAChR subunits coassemble in peripheral ganglia, MHb and IPN
(Wada et al., 1990; Zoli et al., 1995; Quick et al., 1999; Whiteaker et al., 2002), and have
all been shown to be involved in somatic nicotine withdrawal. Our studies using central
administration of AuIB, a selective α3β4* antagonist, support a role for central α3β4*
nAChRs in somatic nicotine withdrawal signs. Interestingly, somatic nicotine withdrawal
signs are mediated by both central and peripheral nAChR populations (Watkins et al.,
2000); thus, we propose that α5 and α3β4* nAChRs contribute to expression of somatic
signs through location in the peripheral ganglia, as well as centrally in the MHb and IPN.
The MHb and IPN have been implicated in behaviors associated with drug dependence. A
synthetic derivative of the African shrub ibogaine, 18-Methoxyroconaridine (18-MC), was
shown to be an inhibitor of α3β4* nAChRs in vitro (Glick et al., 2002). When administered
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into the MHb and IPN, 18-MC blocked morphine and nicotine self-administration (Glick et
al., 2000; Glick et al., 2006), somatic morphine withdrawal signs (Panchal et al., 2005),
and dopamine sensitization to morphine (Taraschenko et al., 2007) in rats. Although the
available studies do not provide direct evidence of a α3α5β4* subtype composition in the
brain, studies indicate that α3, α5, and β4 subunit mRNA was present in nearly 100% of
neurons isolated from rat MHb (Sheffield et al., 2000). Overall, the data suggests that
α3α5β4* gene clusters located in the MHb and in peripheral ganglia are important in
somatic nicotine withdrawal.

This extensive investigation of the identity of nAChR subtypes involved in various
aspects of nicotine withdrawal yielded important findings. A pictorial depiction of the
proposed subtypes involved in physical and affective nicotine withdrawal is presented in
Figure 44.
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Figure 44. Overall depiction of the role of major nAChR subtypes in physical and
affective nicotine withdrawal signs as revealed in our studies and others. A.
Represents the two aspects of the nicotine withdrawal syndrome. B. Representation of
the specific signs categorized under each aspect of nicotine withdrawal that were
measured in the current studies. C. The major nAChR subtypes that were found to
be involved in the various aspects of nicotine withdrawal. In addition to the current
studies, citations of studies that support our conclusions for the subtypes’ role in
nicotine withdrawal are listed.
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C. L-type VGCCs and CaMKII differentially regulate nicotine withdrawal

Studies have suggested a role for L-type VGCC and CaMKII in the effects of
several drugs of abuse, including morphine, cocaine, amphetamine, and nicotine (Tan,
2002; Wang Z et al., 2003; Licata et al., 2004; Biala and Weglinska, 2005). Although the
current studies evaluating Ca2+-dependent mechanisms in nicotine dependence provide
evidence of a role for Ca2+ signaling, studies assessing the affective component of nicotine
withdrawal are lacking. There is also no available behavioral correlation for the
biochemical studies which evaluate nicotine-induced Ca2+ mechanisms in vitro; thus, the
relevance of these mechanisms to nicotine withdrawal is unclear. The study by Biala and
Weglinska (2005) found that L-type VGCC blockers attenuated somatic nicotine
withdrawal signs; however, the study utilized high doses of L-type VGCC blockers, which
our studies found significantly reduced locomotor activity (Fig. 20). Furthermore, such
high doses may inhibit α3* and α7* nAChR-mediated currents (Wheeler et al., 2006).

In our study, L-type VGCC blockers attenuated somatic signs and hyperalgesia in
nicotine-withdrawn mice, but there was no effect on anxiety-related behavior or
development of CPA (Figures 21 and 23). Because L-type VGCC blockers have been
shown to inhibit α3* and α7* nAChRs in vitro (Wheeler et al., 2006), we used an L-type
VGCC activator, (±)Bay K8644, to complement our results. (±)Bay K8644 enhanced
somatic nicotine withdrawal signs and the hyperalgesia response (Fig. 22). Taken together,
our studies support a role for L-type VGCCs in physical, but not affective nicotine
withdrawal. Clinically, this may suggest that L-type VGCC blockers would not be very
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successful in alleviating withdrawal symptoms in abstinent smokers. Although somatic
signs do contribute to the discomfort associated with the nicotine withdrawal syndrome,
the affective signs are suggested to be of greater motivational significance in contributing
to relapse (Koob et al., 1993; Markou et al., 1998).

While the L-type VGCC studies yielded clear results, the role of CaMKII in
nicotine withdrawal behaviors appears more complex. While pharmacological blockade of
CaMKII using the inhibitor KN93 dose-dependently attenuated somatic nicotine
withdrawal signs, it enhanced the affective component of nicotine withdrawal (Figures 24
and 28). To examine this effect further, we treated chronic nicotine infused mice with
KN93 and found that the inhibitor precipitated anxiety-related behavior, but had no effect
on somatic signs or hyperalgesia (Fig. 25). These pharmacological results suggest that
CaMKII has opposing roles in nicotine withdrawal. While KN93 enhanced the anxietyrelated response, suggesting that CaMKII activity is decreased after nicotine withdrawal,
KN93 attenuated somatic nicotine withdrawal signs, suggesting that CaMKII activity is
increased after nicotine withdrawal. One explanation for this effect is that CaMKII
function after nicotine withdrawal differs depending on the brain region and nAChR
subtype involved. We proposed that affective withdrawal signs involve α4α6β2* nAChR
subtypes in the VTA, while somatic nicotine withdrawal involves the α3α5β4* subtype in
the MHb. After chronic antidepressant treatment, CaMKII activity differed based on the
brain region and presynaptic compartment (i.e. synaptic vesicles vs. synaptic membranes)
(Schneider et al., 2007). Additionally, our biochemical studies in Chapter 6 showed that
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acute nicotine-induced changes in CaMKII function in the VTA are nicotinic receptor
mediated effect (Fig. 30). Therefore, because we observed attenuation of somatic signs
after KN93 treatment, it is possible that there is an increase in CaMKII function after
nicotine withdrawal in the MHb that is mediated by α3α5β4* nAChRs. The enhanced
anxiety-related response after KN-93 treatment and the trend observed in the CPA model
suggest a decrease in CaMKII function after nicotine withdrawal, which may be mediated
by α4α6β2* nAChR subtypes in the NAc and/or VTA.

Conversely, our transgenic assessment revealed an opposite role for CaMKII than
that observed in our pharmacological assessment. Saline infused CaMKII HT mice had
decreased baseline anxiety levels on the plus maze compared to WT counterparts,
consistent with CaMKII mutants having increased exploratory behavior in the open field
and Y-maze (Silva et al., 1992b), and there was a loss of anxiety-related behavior in
nicotine-infused CaMKII HTs after mecamylamine treatment (Fig. 26). These results
suggest that CaMKII activity is increased after nicotine withdrawal. There was no
significant difference in somatic signs, hyperalgesia, or aversion in the CPA model
between saline and nicotine infused mice (Figures 26 and 28). Several possible
explanations for this discrepancy were discussed in Chapter 5. Overall, the results suggest
that L-type VGCC and CaMKII are differentially regulated in nicotine withdrawal,
although CaMKII, which was shown to be involved in both somatic and affective nicotine
withdrawal, may be a more clinically relevant target.

178
Depression is an affective symptom associated with nicotine withdrawal. Indeed,
the antidepressant, bupropion, is clinically approved for smoking cessation and has been
proposed to act via promoting dopaminergic function (Nestler and Carlezon, 2006).
Changes in synaptic plasticity are involved in the pathophysiology of depression and in the
mechanism of antidepressants (Manji et al., 2001). CaMKII, being a kinase involved in
synaptic plasticity, has been shown to be a target of antidepressants. Reduced α-CaMKII
expression was found in the brains of subjects with bipolar and unipolar depression (Xing
et al., 2002), and antidepressants activate CaMKII in hippocampal neuronal cell bodies by
phosphorylation of Thr286 (Tiraboschi et al., 2004). An inhibitor of CaMKII exacerbated
anxiety-related behavior in our studies, suggesting decreased CaMKII levels after nicotine
withdrawal. Because antidepressants were shown to enhance CaMKII, it is possible that
CaMKII is a relevant target in alleviating the depression and overall negative emotional
state associated with nicotine withdrawal. Additionally, we cannot rule out the possibility
that CaMKIV is involved in these effects, as KN93 also inhibits this kinase (Enslen et al.,
1994). Suppression of CaMKIV in the NAc increased anxiety-related behavior in rats
(Schneider et al., 2007), suggesting that CaMKIV in the NAc is involved in mechanisms
associated with anxiety. The effects of nicotine on CaMKIV to date have not been
assessed; however, CREB, a downstream target of CaMKIV, was shown to be involved in
mechanisms associated with nicotine dependence, including reward (Walters et al., 2005)
and withdrawal (Pandey et al.,2001; Brunzell et al., 2003; Pluzarev and Pandey, 2004).
Further, disruption of CREB function in the NAc is also associated with increased anxiety
responses, while overexpression of CREB was shown to be anxiolytic (Barrot et al., 2002;
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Barrot et al., 2005). Taken together, we propose that intracellular Ca2+-dependent kinases,
such as CaMKII and CaMKIV, are involved in the affective component of nicotine
withdrawal, and are critical targets for the alleviation of affective symptoms associated
with nicotine withdrawal. Additionally, the NAc may be a target brain area involved in
these emotional responses.

D. Nicotine withdrawal-induced decreases in CaMKII and synapsin I function are
mediated through β2-containing nAChRs

Studies suggest a role for CaMKII and synapsin I in various drugs of abuse such as
cocaine, morphine, and amphetamine (Matus-Leibovitch et al., 1995; Iwata et al., 1996;
Iwata et al., 1997a; Iwata et al., 1997b; Tan, 2002; Licata et al., 2004; Wang et al., 2003).
Additionally, our behavioral studies showed that Ca2+-dependent mechanisms, such as Ltype VGCC and CaMKII, are involved in nicotine withdrawal behaviors; therefore, we
wanted to determine the relationship between these nicotine withdrawal-induced
behavioral modifications and the in vitro Ca2+-dependent molecular mechanisms involved
in nicotine withdrawal. We measured CaMKII and synapsin I activity in the VTA and NAc
after acute systemic nicotine administration and found that nicotine induced increases in
the activity of both proteins, and these increases are mediated through β2-containing
nAChRs (Figures 29; 31-34). Further, we measured activity and protein level in the NAc
after chronic nicotine and nicotine withdrawal, as release of neurotransmitter and the
presynaptic nAChRs that mediate neurotransmitter release are located in this brain region.
Synapsin I activity was increased in the NAc after chronic nicotine (Fig. 35), suggesting
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that tolerance does not develop to the acute nicotine-induced increase in this protein.
Results from the nicotine withdrawal assessment show that DHβE, but not MLA,
precipitate significant decreases in CaMKII and synapsin I activity and level at doses that
precipitate significant aversion in the CPA model (Figures 3; 36-39). Our studies using
transgenic animals complemented this data, as the mecamylamine-precipitated decrease in
CaMKII and synapsin I activity in the NAc was present in α7 KO, but not in β KO mice
(Figures 41-43). Taken together, these results suggest that β2*, but not α7*, nAChRs
mediate the acute nicotine-induced increase in CaMKII and synapsin I activity in the VTA
and NAc, as well as the nicotine withdrawal-induced decrease in activity and level in the
NAc.
The α6β2* and α4α6β2* nAChR subtypes are located on presynaptic DA and
GABAergic neurons in the VTA and are involved in nicotine-stimulated DA release in the
striatum (Champtiaux et al., 2003; Salminen et al., 2004; Lai et al., 2005). Indeed, the
nicotine induced increase in VTA DA neuron firing rate (Grenhoff et al., 1986), and
subsequent DA release in the NAc is a process thought to underlie the addictive properties
of nicotine (Ponteiri et al., 1996). Alternatively, studies report decreased DA output in the
NAc after nicotine withdrawal (Hildebrand et al., 1998; Rada et al., 2001). It is
hypothesized that this relative deficiency in DA release following cessation of nicotine
exposure accounts for many of the mood disorders, craving, and anhedonia that persist in
many smokers long after quitting (Benowitz, 2008). CaMKII and synapsin I are sufficient
biochemical markers of neurotransmitter release, as these proteins are essential for
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neurotransmitter release. The decrease in CaMKII and synapsin I function in the NAc after
nicotine withdrawal may correspond to the decrease in DA release observed in the NAc
after nicotine withdrawal. Our behavioral pharmacological assessment in Chapter 5
revealed that the CaMKII inhibitor, KN93, significantly enhanced the anxiety-related
response and showed a strong trend for enhancement of nicotine CPA, which suggests that
CaMKII is decreased after nicotine withdrawal (Figures 24 and 28). Further, our
behavioral studies in Chapters 2 and 3 revealed a role for β2-containing receptors,
specifically α6β2* and/or α4α6β2* nAChR subtypes in affective nicotine withdrawal
behaviors (Figures 3, 8, 9, 11-13).

Overall, these initial results show that CaMKII and synapsin I activity in the NAc are
decreased after nicotine withdrawal, and these decreases are mediated through β2containing nAChRs. Although we did not test the α6 antagonists, MII and MII
[H9A;L15A], or the α3 antagonists, MII and AuIB, in our in vitro studies, we propose that
the α6β2* and /or α4α6β2* subtypes, and not α3* or α7* containing nAChRs, mediate the
nicotine withdrawal-induced decreases in CaMKII and synapsin I function in the NAc. As
mentioned, these subtypes are presynaptically located on DA terminals in the striatum and
are involved in DA release in this brain region. Further, MLA, an α7 antagonist, did not
precipitate a decrease in CaMKII or synapsin I function, and the decrease in activity was
present in α7 KO mice. Our behavioral studies implicate α7 and α3-containing nAChRs in
physical nicotine withdrawal (Chapter 3), yet we saw no effect with MLA at doses that
precipitated withdrawal in mice (Damaj et al., 2003). Based on this data, we propose that
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while α7 and α3-containing nAChRs are involved in physical nicotine withdrawal signs,
they are not relevant to the molecular changes that occur after nicotine withdrawal. It is
noted that the L-type VGCC blocker nimodipine, also blocked the acute nicotine induced
increase in CaMKII activity in the VTA (Fig. 30); however, because we did not evaluate
the role of L-type VGCC in our biochemical assessment after nicotine withdrawal, we
cannot determine if this effect is relevant to the decrease in protein activity after nicotine
withdrawal. Additional studies using behaviorally relevant nimodipine doses (1-2 mg/kg,
i.p.) are necessary to further evaluate this effect.

E. Conclusions and Implications
Overall, our research contributes to the understanding of the behavioral and
molecular mechanisms underlying nicotine withdrawal. These studies identified major
nAChR subtypes, post-receptor Ca2+-dependent mechanisms, and brain regions important
in nicotine withdrawal. Further, by demonstrating that the decreases in CaMKII and
synapsin I function, which may contribute to the decreased DA release observed after
nicotine withdrawal, are mediated through β2-containing nAChRs, which are crucial for
expression of affective nicotine withdrawal signs, this study stresses the importance of
affective nicotine withdrawal as a motivational component of relapse in smoking behavior.
Studies suggest that although somatic signs are an important component of the nicotine
withdrawal syndrome, the affective signs are of greater motivational significance in
contributing to relapse (Koob et al., 1993; Markou et al., 1998). As mentioned, it is also
hypothesized that this relative deficiency in DA release following cessation of nicotine
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exposure accounts for many of the mood disorders, craving, and anhedonia that persist in
many smokers long after quitting (Benowitz, 2008). Indeed, reduced α-CaMKII expression
was found in the brains of subjects with bipolar and unipolar depression (Xing et al.,
2002), and anti-depressants have been shown to increase CaMKII phosphorylation in
hippocampal neuronal cell bodies (Tiraboschi et al., 2004). Further, the anti-depressant,
bupropion, which blocks nAChRs (Slemmer et al., 2000), and inhibits the DA transporter,
thus enhancing DA function (Nestler and Carlezon, 2006), is clinically used as a smoking
cessation therapy. Taken together, these studies suggest that presynaptic β2-containing
nAChRs, specifically α6β2* and/or α4α6β2* subtypes, which mediate striatal DA release,
CaMKII, and synapsin I, are critical components of the affective nicotine withdrawal
syndrome, and may be clinically relevant to smoking cessation; thus, more research should
focus on the role of these targets in development of nicotine dependence. Overall, the
research in this dissertation contributes to the understanding of the behavioral and
molecular mechanisms of nicotine withdrawal, and provides new insight into potential
targets for more effective smoking cessation therapies.
F. Future Studies

A major part of our effort during the Ph.D. work was dedicated to identifying the
major nAChR subtypes involved in nicotine withdrawal. Using pharmacological methods
and genetically modified mice, we showed that the various aspects of nicotine withdrawal
are mediated by different nAChR subtypes. While we were able to identify the major
subtypes involved (Fig. 44), more studies are needed to identify the exact composition of
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these subtypes and important brain regions involved in nicotine withdrawal behaviors. To
support our proposal for a role of the α3α5β4* subtype in somatic nicotine withdrawal
signs, future studies include testing the α3β4* antagonist AuIB in α5 KO mice. Our studies
showed a significant reduction in total somatic signs in α5 KO mice and a dose-dependent
attenuation of somatic signs after central administration of AuIB. We will determine the
role of the α3α54* subtype by determining if we can attenuate somatic signs in α5 KO
mice with AuIB. This would also further implicate the MHb as a brain region involved in
manifestation of somatic signs.
Additionally, our results show that β2-containing nAChRs mediate affective
nicotine withdrawal signs. Because the α4β2* subtype is the most abundant subtype in the
brain, we proposed that this subtype is involved in affective nicotine withdrawal behaviors.
Our pharmacological data using the α6 and α6/α3β2* antagonists, MII[H9A;L15A] and
MII respectively, suggest a role for α6β2* and/or α4α6β2* nAChRs in affective nicotine
withdrawal. To further evaluate these results, we will obtain and breed α4 and α6 KO mice
to test in our nicotine withdrawal models. This complementary approach will allow us to
further differentiate between the importance of α6β2* and α4α6β2* subtypes in affective
nicotine withdrawal.

Another major finding of our work was the involvement of L-type VGCCs and
CaMKII in nicotine withdrawal behaviors. Indeed, results from our second specific aim
clearly showed a role for L-type VGCCs in physical nicotine withdrawal, but not affective
withdrawal. CaMKII results were more difficult to interpret due to differences between our
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pharmacological and transgenic mouse data. We used CaMKII HT mice in our
experiments because of our failed attempts to generate CaMKII KO mice, as CaMKII HT
females do not care for their pups. To alleviate this problem, we will attempt to foster pups
born from CaMKII HT mothers in order to obtain CaMKII KOs. Another option would be
the use of CaMKII conditional KOs, which can be obtained from Jackson Laboratories.
Although our data from specific aim two do suggest a role for Ca2+-dependent
mechanisms in nicotine withdrawal, we used another strategy to explore the involvement
of these mechanisms. We examined the relationship between the altered behavioral
responses in vivo and the in vitro receptor-mediated Ca2+-dependent mechanisms involved
in nicotine withdrawal. For our third specific aim, results showed that there are decreases
in CaMKII and synapsin I activity after nicotine withdrawal, and these decreases are
mediated through β2-containing nAChRs. We propose that the nicotine withdrawalinduced decreases are mediated through α4β2* and/or α4α6β2* nAChR subtypes, which
are involved in affective nicotine withdrawal signs. To further examine this effect, we will
evaluate CaMKII and synapsin I activity and level in the NAc of α4 and α6 KO mice after
nicotine withdrawal. We complement the α6 KO mouse studies using the α6 antagonist,
MII[H9A;L15A], and the α6/α3β2* antagonist, MII. Additionally, we propose that the
α3β4* and/or α3α5β4* nAChR subtypes, which mediate somatic nicotine withdrawal
signs, are not involved in the nicotine withdrawal induced decrease in CaMKII and
synapsin I; therefore, we will also measure CaMKII and synapsin I activity and level in the
NAc in α5 KO mice, and in mice after treatment with the α3β4* antagonist, AuIB. To
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correlate the decrease in CaMKII and synapsin I activity with our behavioral results, we
will complete a time course of the biochemical changes and compare them to our
spontaneous withdrawal assessment. We hypothesize that the decrease in CaMKII and
synapsin I activity is relevant to affective nicotine withdrawal behaviors; therefore, we
expect to see a decrease in CaMKII and synapsin I activity and level in the NAc after
spontaneous nicotine withdrawal that correlates with the increase in severity of affective
withdrawal signs that occurs after the first few days after spontaneous nicotine withdrawal
(Damaj et al., 2003). As the severity of the withdrawal syndrome peaks and subsides over
the course of several days, we expect that activity and protein level of CaMKII and
synapsin I will return to baseline levels.

These proposed studies will further support our hypothesis of the importance of the
α6β2* and/or α4α6β2* subtypes and the decrease in CaMKII and synapsin I function in the
NAc in the manifestation of affective nicotine withdrawal behaviors.
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